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Heart failure is one of the leading causes of death worldwide, and the current 
costs of treatment put a significant economic burden on our societies.  After an infarction, 
fibrotic tissue begins to form as part of the heart failure cascade.  Current options to slow 
this process include a wide range of pharmaceutical agents, and ultimately the patient 
may require a heart transplant.  Innovative treatment approaches are needed to bring 
down costs and improve quality of life.  The possibility of regenerating or replacing 
damaged tissue with healthy cardiomyocytes is generating considerable excitement, but 
there are still many obstacles to overcome.  First, while cell injections into the 
myocardium have demonstrated slight improvements in cardiac function, the actual 
engraftment of transplanted cells is very low.  It is anticipated that improving engraftment 
will boost outcomes.  Second, cellular differentiation and reprogramming protocols have 
not yet produced cells that are identical to adult cardiomyocytes, and immunogenicity 
continues to be a problem despite the advent of autologously derived induced pluripotent 
stem cells.  This dissertation will explore biomaterials approaches to addressing these two 
obstacles.  
 xi 
Tissue engineering scaffolds may improve cell engraftment by providing 
bioactive factors, preventing cell anoikis, and reducing cell washout by blood flow.  
Poly(ethylene glycol) (PEG) is often used as a coating to reduce implant rejection 
because it is highly resistant to protein adsorption.  Because fibrosis of a material in 
contact with the myocardium could cause arrhythmias, PEG materials are highly relevant 
for cardiac tissue engineering applications.  In Chapter 2, we describe a novel method for 
crosslinking PEG microspheres around cells to form a scaffold for tissue engineering.  
We then demonstrate that HL-1 cardiomyocyte viability and phenotype are retained 
throughout the fabrication process and during the first 7 weeks of culture.   
In the third chapter of the dissertation, we demonstrate that the use of PEG cell 
culture substrates can improve efficiency of direct reprogramming from fibroblasts to 
cardiomyocytes for cell transplantation.  Standard tissue culture plastic adsorbs proteins 
from the cell media, increasing experimental variability via non-specific signaling.  
Because of its protein resistant properties, PEG provides cells with highly specific signals.  
In addition to improving the efficiency, we found that presentation of RGD peptides 
stimulated proliferation during reprogramming.  Combined, the improvements enabled us 
to approximately double the number of cardiomyocytes produced by the protocol.   
In Chapter 4, we explore the effects of 3D culture on the direct reprogramming 
protocol described in Chapter 3.  We demonstrate that the variables involved in 3D 
culture, including scaffold material, diffusion, cellular remodeling, and scaffold 
topography, have significant effects on reprogramming efficiency.  This chapter provides 
the groundwork for future studies developing 3D microenvironments for efficient and 
scalable reprogramming to cardiomyocytes.   
 1 
CHAPTER 1 
Introduction 
1.1 The role of biomaterials in cardiac tissue 
engineering 
Nearly a hundred years ago, Ross Harrison, a Yale zoologist who is often 
considered to be the “father of tissue culture” (1), noticed that environmental stimuli were 
commonly reported to affect developing tissues, whether it be fish embryo 
chromatophores responding to circulating blood (2) or nerve guidance by chemotactic 
A
B
Figure 1.1:  Early examples of materials used in cell culture.  A) cells migrating out from embryos onto 
spiderwebs, adapted from Harrison, 1914. B) Stretching fibrin clots was known to induce cell 
elongation (adapted from Weiss, 1952) 
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factors (3).  In his own lab, he had noticed that cells embedded in firmly clotted lymph 
took on a more migratory phenotype than those suspended in unclotted lymph droplets.  
This made him curious about the effects of physical stimuli cell phenotype.  In his 1914 
paper, “The reaction of embryonic cells to solid structures” he describes diligently 
collecting Tegenaria spiders from “old tree stumps” to create webs upon which he could 
culture embryonic cell clusters.  In perhaps the first description of cellular reactions to 
culture materials, Harrison reported that spider webs provided paths for  “cell wandering”, 
or migration along the web (4) (Fig. 1a).  
Tissue culture was founded by growing three-dimensional (3D) explants or 
embryos in lymph or fibrin (5).  However, 2D protocols were widely adopted by the field 
in the 1920s, after Warren and Margaret Lewis developed them in order to investigate the 
morphological details and compartments of single cells (6).  These protocols allowed for 
easier visualization of cellular responses, and also  gave scientists greater control over 
many variables (which will be discussed in Chapter 1.2 and Chapter 4).  Recognizing the 
importance of cellular interactions with the extracellular environment, Paul Weiss re-
introduced the fibrin clot culture protocols in the 1950s .  In a particularly notable 
experiment, he described the tendency of cells to elongate in response to stretching the 
fibrin substrate (Fig. 1b) (7).   
In the 1970s, multiple groups noticed that when dissociated cardiac harvests were 
reaggregated into 3D structures, they bore a closer resemblance to native tissue (8, 9).  In 
1977, Horres, Lieberman and Purdy engineered a 3D preparation with high mechanical 
integrity by culturing the cells onto nylon fibers (10).  This work, which was inspired by 
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a need for easier “experimental manipulation” from 3D preparations, may mark the 
introduction of the “synthetic scaffold” to the field of cardiac tissue engineering (CTE).   
Heart failure is one of the largest public health problems, and will ultimately 
affect 20% of Americans who are currently forty years old (11).  Age-related fibrosis 
around the sinoatrial node is another major health concern (12-16).  Pharmaceutical 
agents are the most common treatment, and in the worst case scenario a patient may be 
placed on a wait list for a heart transplant.  However, the drugs may have serious side 
effects, and mortality rates on the transplant list hover around 10% per year (17).  Over 
the past 30 years, research in the field of CTE has developed with the goal of fully 
repairing or replacing diseased myocardium.  Research in this area usually takes one of 
four forms; 1) injection of cells expected to provide therapeutic benefit to the damaged 
area, 2) implantation of in vitro engineered cardiac tissue (often called a cardiac patch) to 
either replace the infarct zone or support it from the outer surface, 3) in vivo genetic 
alterations to return cells to cardiac phenotypes, or 4) introducing materials to induce 
resident stem cell homing.  Materials engineering principles are being applied in all of 
these research areas.  I will discuss the first and second in some detail.  The third and 
fourth are beyond the scope of this dissertation, but the reader can find thorough reviews 
elsewhere (genetic manipulation: (18-20), stem cell homing: (21, 22)).  For both cell 
injections and engineered tissue implants, a major decision is the type of cell to use. 
 
1.2 Cardiac cell sourcing 
1.2.1 Pluripotent stem cell derived cardiomyocytes 
 4 
The ability to expand mouse embryonic stem cells (mESCs) in vitro (23, 24) was 
the 1981 milestone that ignited the field of regenerative medicine.  It provided a platform 
for researchers to unravel embryonic development mechanisms and a hope of ultimately 
engineering tissue replacements.  Within 4 years, Doetschman et al. described the 
differentiation of mESCs to cardiomyocytes (mESC-CMs) (25).  However, it would be 
nearly 20 years before human ESCs could be expanded in culture (26) and differentiated 
to cardiomyocytes (27), highlighting major differences between the species.  Nonetheless, 
murine stem cell studies continue to provide preliminary research that jump-starts human 
cell research.     
In addition to ethical concerns, a major obstacle for ESC-derived transplants is the 
potential for immune rejection due to their allogenic origin.  In 2006 and 2007, 
Yamanaka and colleagues introduced the induced pluripotent stem cell (iPSC), providing 
a less contentious, autologous, and (presumably) safer alternative.  Human and mouse 
iPSCs are generated by activating a combination of four transcription factors (collectively 
called the Yamanaka factors) (28, 29), which induce epigenetic changes to reset the 
genetic expression profile of the cell (30).  Using the knowledge gained from ESC studies, 
several groups quickly demonstrated that mouse and human iPSCs could be differentiated 
to cardiomyocytes by similar protocols (31-34).  In 2007, LaFlamme et al. described a 
growth factor based protocol that drastically increased efficiency of cardiomyocyte 
derivation to ~30% (35).  More recently, small molecule differentiation has been shown 
to promote cardiogenesis with 98% efficiency (36), providing a cheaper, more efficient, 
and more stable alternative to growth factor based protocols.    
 5 
While iPSCs initially seemed like the perfect alternative to ESCs, recent studies 
have found that the two may not be as similar as originally thought.  Derivatives of both 
cell types carry carcinogenic risk unless they are immaculately purified (37, 38), and at 
least one group has reported that iPSC cells develop into more aggressive tumors than 
ESCs (39).  Unlike ESCs, iPSCs are sourced from adult somatic cells, which may have 
accumulated mutations over time.  The reprogramming process also introduces new 
opportunities for genetic errors.  Mutations resulting in uncontrolled proliferation and 
resistance to apoptosis (tumorogenic qualities) are evolutionarily favorable traits within 
the reprogramming cell population (40, 41), which may explain why mutations at known 
oncogenic genes are more common in iPSCs (42) .  These errors are in addition to genetic 
aberrations that appear with repeat passaging, as is seen with hESCs (43-46).  Errors that 
occur during reprogramming may help to explain a surprising recent study that found 
iPSCs to be immunogenic in syngenic hosts (47).  Another problem with iPSCs is 
“epigenetic memory”, or remnants of epigenetic modifications from the original cell (48-
50).  Cells with epigenetic memory show differentiation biases toward the germ layer of 
the cell source (51).  
A recent study by Newman and Cooper (52) reanalyzed gene expression data 
from seven different laboratories that had previously compared iPSCs to ESCs.  Many of 
these groups had reported distinct differences between the two cell types, but the 
differences found were not consistent between labs.  Newman et al. performed a 
computational meta-analysis of the data.  They determined that gene expression 
signatures were strongly correlated with the laboratory of origin, calling the previous 
conclusions into question.  They wrap up the paper with a call to consider the effects of 
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the microenvironment on reprogramming processes.  In chapter 1.2, I will discuss how 
materials can be used to control microenvironmental variables.   
Despite the obstacles, in vivo studies in small mammals have demonstrated 
modest improvements after injection of pluripotent-cell derived cardiomyocytes (35, 53, 
54) or even undifferentiated pluripotent cells (55, 56).  Actual cell engraftment is quite 
low, suggesting that the benefits are likely related to paracrine effects (35, 57).  Due to 
the hurdles outlined above, the progress of large animal in vivo studies has been slow, 
especially when considering that human trials of adult stem cells injections are well under 
way (58).  However, the potential for unlimited expansion of pluripotent stem cells 
necessitates that we continue to explore this area of research, as the sheer number of cells 
needed for these types of therapies is quite large (59). 
 
1.2.2 Adult stem cell derived cardiomyocytes  
While embryonic and induced pluripotent stem cells have the capacity for greater 
scalability, many groups are studying adult stem cell techniques due to the concerns 
outlined above.  This area of research is quite broad, and generally beyond the scope of 
this dissertation.  However, the field merits some discussion since several human trials 
are already underway, many showing modest improvements in cardiac function (34, 58, 
60).  The majority of groups working with adult derived stem cells are using bone 
marrow derived mesenchymal stem cells (MSCs).  When Orlic et al. (61) and Strauer et 
al. (62) first provided evidence that MSCs induced myocardial regeneration and 
functional improvement in 2001, it was unclear if the benefits were related to true 
differentiation of the MSCs to cardiomyocytes, or to some other effects (63, 64).  This 
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controversy has still not been fully settled (58, 65).  However, since actual stem cell 
engraftment is low (~5%) (66, 67), most groups now agree that increased vascularization 
(68) and paracrine signals from the transplanted MSCs play a much larger role (58, 69) 
than any differentiation.  One such paracrine mechanism may be the activation of resident 
adult cardiac stem cells (CSCs), which normally play only a minor role in cardiac 
regeneration (70).  Interestingly, CSCs themselves can be harvested, expanded in vitro 
(71, 72), and injected back into damaged myocardium.  Cardiac ejection fraction (a 
common and useful functional endpoint, meaning the volumetric fraction that the heart 
pumps out during contraction) has been improved in a number of studies in different 
animal models.  As with MSCs, these improvements appear to be more closely related to 
paracrine signaling since CSC engraftment is low (73).  While studies are promising, the 
clinical adoption of this cell source will likely require functional improvements of a much 
higher magnitude (58).    
 
1.2.3 Direct reprogramming 
Direct reprogramming protocols are a recent addition to the list of potential 
cardiomyocyte sources, and have generated much excitement over the past few years.  
Direct reprogramming (also referred to as direct conversion or transdifferentiation) refers 
to a phenotypical switch that does not involve going through the pluripotent state, and has 
been reported for multiple different lineages (recently reviewed by Morris et al. (74)).  In 
2010, Ieda et al. first reported direct reprogramming of mouse fibroblasts to 
cardiomyocytes using a combination of transcription factors (Gata4, Mef2c, and Tbx5) 
crucial to cardiac development (75), and several variations of that protocol have since 
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been published (76, 77).  The conversion of fibroblasts to iPSC is usually on the range of 
1% (78), and cardiac differentiation efficiency from there is as high as 98% (36), giving 
an overall fibroblast to cardiomyocyte efficiency of about 1%.  Ieda et al. reported higher 
efficiency conversions (~5% troponin-T positive) of fibroblasts directly to 
cardiomyocytes by 4-5 weeks (75), as opposed to ~6-7 weeks for fibroblast to iPSC to 
cardiomyocyte derivations (36, 79).  
 Potentially the most exciting application of this research is the potential to 
reprogram scar tissue fibroblasts to cardiomyocytes in vivo, potentially negating the need 
for cell transplants.  This has been demonstrated in small mammals by multiple groups 
(77, 80-82), one that used micro-RNAs (1, 133, 208, and 499) instead of the transcription 
factors (82).  Up until recently, all research has been performed using mouse somatic 
cells.  In March of 2013, the first article reporting direct reprogramming of adult human 
fibroblasts to cardiomyocytes was published online (83), confirming the potential for 
clinical use.  This protocol used a combination of transcription factors (Gata4, Hand2, 
Tbx5 and Myocardin) in addition to miRNAs-1 and -133.   
Less than a year after the first report of direct reprogramming to cardiomyocytes, 
the Deng group demonstrated that similar results could be achieved using a 
fundamentally different method.  Efe et al. briefly activated the Yamanaka factors 
(normally used to generate iPSCs) to push cells into an epigenetically unstable state, 
while simultaneously inhibiting pluripotentcy pathways (84).  After 9 days, they 
introduced BMP4 to stimulate cardiogenesis.  By day 18, they reported widespread 
beating and ~40% troponin-T positive cells.  During the process, they did note a small 
population of pluripotent cells, but demonstrated that these cells were not the source of 
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the cardiomyocytes.  Instead, the pathway led through a proliferative progenitor state that 
is known to also produce cardiac vasculature (84, 85).   
The protocol described by Efe et al. is faster than the one by Ieda et al., which 
may be clinically important as the cardiac remodeling cascade starts immediately 
following infarction (86, 87).  The possibility of forming the other myocardial cell types 
is a huge advantage, as revascularization will be important to myocardial scar healing.  
Several groups have noted the improvements in cardiomyocyte organization in vitro (88) 
and cardiac function in vivo when a vascular system is also provided within the construct 
at implantation (“prevascularization”) (89, 90).  Further characterization of this protocol 
is needed to quantify endothelial and smooth muscle cells differentiation efficiency.   
Despite the advantages listed above, excitement for the Efe et al. protocol is 
tempered by the formation of pluripotent byproducts (Nanog levels were low but 
detectable by day 18 (84)).  This teratoma risk will have to be eliminated before any 
human trials could take place.  Unlike other protocols, it has not yet been replicated with 
human cells, or shown to work in vivo.  Furthermore, all direct reprogramming protocols 
may encounter the same “epigenetic memory” problems that have plagued iPSC research.  
Nonetheless, this area of research is growing and advancing quickly (91), and these 
hurdles may soon be irrelevant.  Further detail and discussion of direct reprogramming 
can be found in chapter 3 of this dissertation. 
 
1.3 Materials for stem cell microenvironment 
engineering 
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The meta-analysis that found gene expression of reprogrammed cells to correlate 
strongly with the lab of origin (52) elucidated the effects of the microenvironment on 
stem cell research.  The “microenvironment” can encompass a wide range of variables, 
including oxygen levels, temperature, pH, and media components.  However, one that 
often goes unappreciated in stem cell research is the culture surface, which in reality 
should be broken down into several additional variables.  Cell adhesion to the 
extracellular matrix (ECM) is accomplished through cell-surface integrins that link to the 
cytoskeleton (92, 93).  Cytoskeleton-mediated intracellular pathways may then affect cell 
phenotype, making ECM-integrin interactions important to differentiation and 
reprogramming (94-99).  Cellular phenotype can be affected by ECM protein types (100), 
spacing (7, 101) and concentrations (102), as well as substrate topography (103-107) 
mechanical properties (108, 109), and cell shape (110, 111).   
While these factors are known to have profound effects on stem cells (100, 112), 
the majority of differentiation and reprogramming studies still use tissue culture 
polystyrene (TCPS) as the cell culture substrate.  The topographical and mechanical 
features of TCPS (flat and stiff) may be sub-optimal for differentiation to many cell types.  
For example, in Engler et al., mesenchymal stem cells cultured on very hard substrates 
preferred osteogenic differentiation, whereas those cultured on softer substrates preferred 
myogenic or neurogenic pathways (112).  To provide a closer mimic the natural 
environment, ECM proteins are often electrostatically adsorbed to the TCPS prior to cell 
seeding.  However, proteins from serum in the media may also adsorb, and these may 
activate non-specific intracellular pathways that vary by serum batch.  While the 
breakneck speed of stem cell advances makes it inconvenient to question long-established 
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methods, true therapeutic value has not yet been realized.  Innovative approaches are 
needed to increase the value of stem cell research. 
Multiple examples exist in the literature where engineering the stem cell 
microenvironment has changed differentiation patterns.  In 2004, McBeath et al. 
demonstrated that the size of “cell islands” (micropatterned ECM) affected the extent of 
hMSC spreading, which in turn dictated their differentiation to either adipocytes (small 
islands) or osteoblasts (large islands).  They determined that the cytoskeletal shape 
affected the RhoA pathway, which in turn affected the differentiation (110).  Later, Kilian 
et al. demonstrated that cell shape still affected hMSC differentiation even if the 
patterned area (and therefore, number of cell-to-ECM contacts) was held constant (111).  
Nanotopography has shown to dictate differentiation outcomes to neural (104) or 
osteogenic (105) phenotypes, likely by changes in cytoskeletal organization (101, 113).  
In addition to the role of substrate stiffness on hMSC differentiations (112), mESCs may 
also be affected by substrate stiffness, with softer substrates being better suited for the 
maintenance of pluripotency (114).  Studies with hESCs have recently shown that culture 
under biaxial strain helps to maintain pluripotency via the TGFβ-Activin-Nodal pathway 
(99, 115).   
In addition to the effects of ECM composition, stiffness, topography and other 
mechanical factors, natural stem cell niches are 3D environments.  Culture in 2D forces 
cell polarity, changes the membrane-to-cytoplasm ratio, and alters the cell shape (116), 
all of which have physiological repercussions (110, 111, 117, 118).  This might help to 
explain drastic phenotypical differences that are often seen between 2D and 3D cultured 
cells (119-123).  Schenke-Layland et al. recently demonstrated that designing 3D stem 
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cell culture to mimic in vivo CSC niches improved differentiation from mESCs to cardiac 
progenitors (124).  However, variations cannot be attributed solely to differences in 
dimension, since 3D environments incorporate all of the variables mentioned above, as 
well as diffusion limitations not present in 2D culture.  Nonetheless, 3D environments 
more closely mimic natural environments, while simultaneously addressing scalability 
problems encountered with 2D culture (59).  Further discussion on 3D stem cell culture, 
as well as additional examples from the literature, can be found in Chapter 4 of this 
dissertation.   
   
1.4 Using materials to improve cell engraftment in vivo 
As mentioned previously, clinical trials of MSC injections have yielded only 
modest improvements (0-5% increase in ejection fraction) (125-128), and only ~5% of 
cells are actually engrafting into the myocardium (66, 67).  Anoikis, or apoptosis 
resulting from lack of adhesion, is a likely reason for this problem (129).  Laflamme et al. 
found that including Matrigel during injection to prevent anoikis of hESC-CMs helps to 
improve engraftment and functional outcomes (35).  Similarly, Kutschka et al. found that 
delivery of cardiomyocytes to rat infarcts using collagen-Matrigel composites improved 
cell engraftment and ejection fraction over injections alone (130).  Zimmermann et al. 
demonstrated similar effects when suturing a cardiomyocyte-loaded collagen gel on the 
surface of infarcted hearts (131).   
In addition to anoikis, other reasons that transplanted cells are lost are 1) they are 
killed going through the needle, 2) they cannot survive the ischemic environment, 3) they 
are killed by reactive oxygen species (ROS) secreted by inflammatory cells that are 
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responding to the infarction, or 4) they are washed out by circulation.  Materials are being 
developed to address these issues, as well.  For example, Aguado et al. demonstrated that 
cells encapsulated within a highly compliant alginate hydrogel during injection had a 
higher rate of survival (132).  To combat ischemia, many groups have focused on 
“prevascularizing” the graft, or including a ready-made capillary network.  In one 
example, cardiomyocyte sheets were fabricated with or without endothelial cells and 
fibroblasts.  The inclusion of endothelial cells enabled perfusion by the host vasculature 
and improved graft survival (89).  Simultaneous delivery of superoxide dismutase, a 
superoxide scavenger, can reduce cell death due by ROS (133).  Delivery of this unstable 
enzyme can be improved by encapsulating it in polyketal microspheres (134).   
Injection of in situ polymerizing hydrogels alone (without cells) may also 
improve functional outcomes (135-137), possibly by providing structural support, 
releasing bioactive factors, or recruiting endogenous CSCs (138).  Because cells are not 
involved, human clinical trials are farther along (139).  However, the addition of cells 
within materials remains a promising area of research, since they provide functional 
improvements over materials alone in small animal models (130, 137, 140).  The major 
challenges are 1) optimizing cell sourcing, 2) ensuring electrical and mechanical coupling 
with the myocardium, and 3) vascularizing constructs to improve graft viability (141).  
 Another hurdle to this area of research is difficulty in comparing results between 
studies.  Because the field has developed so recently, preparation protocols, delivery 
methods, animal models, and functional endpoints are still highly variable between 
research groups (141).  Also, studies often focus on one specific material instead of 
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comparing several (138), making it difficult to determine which will ultimately perform 
best.   
 
 
1.5 Poly(ethlyene glycol) biomaterials for cardiac tissue 
engineering 
 
Poly(ethylene glycol) (PEG) has been described as a “stealth material” and has 
long been approved by the FDA for clinical use (142).  Because of its resistance to 
protein adsorption and cell adhesion, PEG is a highly favored material for many 
therapeutic applications.  Here, I will discuss its potential in stem cell niche engineering 
and myocardial cell transplantations.   
 
1.5.1 History of PEG materials 
Over long periods of time, most materials adsorb proteins from the blood, 
triggering the foreign body response that walls off the implant in a fibrotic capsule (143).  
PEG was first reported to prevent cell adhesion during coagulation studies in the early 
1970s (144).  Furasawa et al. later demonstrated that including PEG in copolymers 
decreased protein adsorption (145), which was confirmed by Brash, Whicher, and Uniyal 
(146, 147).  A few years later, it was found that platelet adhesion was lower on PEG 
surfaces than on PVP surfaces (148).  Considering results from his own lab (149-151) in 
conjunction with various results from other labs, Merrill composed a convincing 
argument that PEG may be one of the least thrombogenic materials available (152). 	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These findings supporting PEG as a nonthrombogenic material set off a wave of 
research into “PEGylation” of previously studied materials, as well as investigation into 
PEG-copolymers.  In 1994, Hill-West et al. demonstrated that balloon angioplasty-
induced restenosis could be nearly eliminated by coating the surface of the treated artery 
with PEG-diacrylate (153).  In 1993, Hubbell and colleagues developed a PEG-
polylactide surgical sealant to use as a preventative measure against adhesions that 
frequently occur as a result of certain surgical procedures (154).  While these performed 
relatively well in small animals, results in humans were more difficult to assess.  
However, the sealant has been adapted for use in lung (155) and brain (156) surgeries.  
 
1.5.2 PEG for engineering the stem cell niche 
 As mentioned previously, the majority of stem cell research studies have utilized 
tissue culture polystyrene (TCPS) as the culture substrate.  In addition to being a poor 
reproduction of the in vivo environment, TCPS adsorbs proteins from the serum, 
presenting cells with non-specific signals that may vary by serum batch.  Because of its 
protein-resistant properties, PEG is an excellent candidate substrate for stem cell research 
studies (157) because it provides a silent “background” for probing the effects of other 
molecules (158).  In addition, PEG can be tuned to adjust the matrix stiffness (159), 
incorporate bioactive moieties (160-162), and degrade at a controlled pace (163), all of 
which can affect stem cell differentiation outcomes (112, 164).  Recently, Lutolf and 
colleagues have developed a high throughput method to investigate several of these 
variables simultaneously in 2D using a PEG microwell array (165).  The Khademhosseini 
and Hubbell groups have recently published interesting studies of cardiac differentiation 
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from embryoid bodies embedded in PEG gels (159, 166).  Further discussion on using 
PEG materials to engineer the stem cell niche can be found in chapter 3 of this 
dissertation.   
 
1.5.3 PEG for myocardial cell transplantation  
 Of the synthetic materials available, PEG is one of the least likely to cause protein 
adsorption and fibrosis.  For cardiac tissue engineering, this is highly important as 
fibrosis could lead to arrhythmias and death.  Most materials used so far in the cardiac 
setting are degradable to ensure a limited foreign body response.  The Suggs group has 
developed an injectable PEGylated fibrin material for use in cardiac repair (167).  This 
hybrid material provides dual benefits of natural and synthetic materials: the fibrin 
provides topographical cues, degradation, and adhesion sites, while the PEG acts as a 
spacer molecule to enhance cell viability and also provides an inert vehicle for delivering 
growth factors (167).  When delivered via injection, the MSC-loaded PEGylated fibrin 
group had the highest ejection fraction after 4 weeks (as opposed to PEGylated fibrin 
without cells or cells injected alone) (140).   
The Hubbell group has developed injectable matrix metalloproteinase sensitive 
PEG hydrogels for myocardial repair.  In a recent study, these were loaded with hESC-
derived endothelial and smooth muscle cells to provide paracrine benefits and 
vascularization potential, without the complications of electrically and mechanically 
integrating cardiomyocytes (137).  They saw improvements in ejection fraction at 6 
weeks in a rat myocardial infarction model.  The highest performing group had been 
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treated with a cell-loaded gel that also included thymosin β4, a pro-angiogenic survival 
factor.  This was significantly higher than improvements made by the gel alone (168).  
A recent study by Wu et al. reports low cytotoxicity of a supramolecular PEG-
based hydrogel that incorporates poly(caprolactone) for degradation and α-cyclodextrin 
for enhanced drug delivery (169).  Four weeks after injection into a rabbit myocardial 
infarction, control groups (injection of DMEM alone) demonstrated a 30.3% decrease in 
ejection fraction.  MSC injection alone demonstrated a significant improvement over the 
control (17.5% decrease, up 12.8% from control), but injection of MSC loaded gels 
performed the best (6.8% decrease, up 23.5% from control) (170).  The delivery of 
erythropoietin (EPO) from the hydrogels improved outcomes over EPO injections alone 
and hydrogel injections alone (171).   
Several other groups have also recently published in vivo studies analyzing the 
protective effects of PEG hydrogels after myocardial infarction (172-174), and at this 
point the number of potentially useful strategies (biocompatible material X cell source X 
drug to be delivered) seems limitless.  A common theme is that the most improvement 
comes when cells are delivered within a hydrogel.  PEG gels alone do not present the 
same level of improvements in the studies described above or in recent publications by 
Rane et al. (173) and Dobner et al. (174).  The next decade of research in CTE involving 
cell transplantation will need to focus on starting human trials to test these strategies.   
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CHAPTER 2* 
 
Long term culture of HL-1 cardiomyocytes in 
modular poly(ethylene glycol) microsphere-based 
scaffolds crosslinked in the phase separated state 
 
2.1 Abstract 
 
 Poly(ethylene glycol) (PEG) microspheres were assembled around HL-1 
cardiomyocytes to produce highly porous modular scaffolds.  In this study, we took 
advantage of the immiscibility of PEG and dextran to improve upon our previously 
described modular scaffold fabrication methods.  Phase separating the PEG microspheres 
in dextran solutions caused them to deswell and crosslink together rapidly, eliminating 
the need for serum protein-based crosslinking.  This also led to a dramatic increase in the 
stiffness of the scaffolds and greatly improved the handling characteristics.  HL-1 
cardiomyocytes were present during the microsphere crosslinking in the cytocompatible 
dextran solution, exhibiting high cell viability following scaffold formation.  Over the 
course of 2 weeks, a 9-fold expansion in cell number was observed.  The cardiac 
functional markers sarcomeric α-actinin and connexin 43 were expressed at 13 and 24 
days after scaffold formation.  HL-1 cells were spontaneously depolarizing 38 days after 
scaffold formation, which was visualized by confocal microscopy using a calcium-
sensitive dye.  Electrical stimulation resulted in synchronization of activation peaks 
                                                
* Chapter 2 has been adapted from the following manuscript:  
Smith AW, Segar CE, Nguyen PK, MacEwan MR, Efimov IR, Elbert DL.  Long-term 
culture of HL-1 cardiomyocytes in modular poly(ethylene glycol) microsphere-based 
scaffolds crosslinked in the phase-separated state. Acta Biomaterialia. Jan 2012. 8(1):31-
40 
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throughout the scaffolds.  These findings demonstrate that PEG microsphere scaffolds 
fabricated in the presence of dextran can support the long-term three-dimensional culture 
of cells, suggesting applications in cardiovascular tissue engineering. 
 
2.2 Introduction 
 
Advancements in cardiac tissue engineering (CTE) are currently limited by a 
number of engineering challenges.  Engineered myocardium must contain a dense 
population of properly aligned and electrically connected cardiomyocytes.  Scaffold 
materials must be extremely resistant to foreign body reaction because fibrous 
encapsulation might electrically isolate the engineered tissue and cause arrhythmias.  
Cardiomyocytes are highly metabolically active, form a well-coupled electromechanical 
syncytium, and must be in intimate contact with the vascular system (175, 176).   
Scaffolds may also need to be highly porous to allow passage of nutrients so that cells 
survive even at the center of a large construct (177-179).    
Most methods for producing porous scaffolds utilize processing conditions that 
are not compatible with cell survival.  Consequently, cells must be seeded onto the 
exterior of a pre-formed scaffold.  However, this may result in uneven cell distribution 
unless steps are taken to promote deeper cell penetration (180-183).  To achieve well 
distributed cell density, cytocompatible crosslinking and pore formation techniques may 
be needed.  Bulk poly(ethylene glycol) (PEG) hydrogels are easily formed in the presence 
of cells with high cell viability (184-186).  However, the porosity of these scaffolds is at 
the nanoscale and methods to introduce pores are usually not cytocompatible (187-189).  
A different approach is the formation of cell scaffolds by crosslinking hydrogel 
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microparticles in the presence of cells.  This technique introduces pores between the 
microparticles, which may provide greater nutrient diffusion and pathways for cells to 
migrate and proliferate.  Sefton and colleagues have encapsulated cardiomyocytes and 
other cells in collagen-based modules, which were then coated with endothelial cells.  
The modules were stacked together, forming constructs with evenly distributed cells and 
endothelial cell-lined channels (190-192).  Additionally, Khademhosseini and colleagues 
have extensively engineered the self-assembly of cell-laden microgels (166, 193-197).  
Other modular approaches have been recently reviewed (198).  
Modularity is desirable because different microparticles may perform different 
functions in the scaffold.  We have recently developed scalable, aqueous methods for the 
fabrication of stable microspheres from eight arm PEG-amine (PEG8-Am) and PEG8-
vinylsulfone (PEG8-VS), as well as hydrolytically degradable microspheres from PEG8-
Am and PEG8-acrylate (199, 200).  The microspheres were modified with arginine-
glycine-aspartic acid (RGD) peptide to enable cell adhesion (201).   Microspheres had 
unreacted VS groups and aggregated by reaction with free amines in serum proteins, 
enabling assembly of microsphere-based scaffolds.  By including both degradable and 
non-degradable microspheres, scaffolds with porosities on multiple length scales were 
fabricated around HepG2 liver cells.  Some microspheres released sphingosine-1-
phosphate (S1P), which promoted endothelial cell migration into the pores of the scaffold 
(200).  We have also utilized microsphere density differences to incorporate growth 
factor gradients into microsphere-based scaffolds (202). 
We continued to engineer these scaffolds with the goal of developing functional, 
implantable cardiac tissues.  Crosslinking of microspheres via serum proteins is 
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undesirable because it may cause an antigenic response.  Furthermore, the mechanical 
strength of scaffolds crosslinked by the previous method was limited.  We hypothesized 
that by performing microsphere crosslinking in a cytocompatible dextran solution, phase 
separation between dextran in solution and PEG in the microspheres would result in 
microsphere aggregation and more rapid reaction kinetics.  This may enhance the 
strength of the scaffolds and eliminate the need for serum proteins to crosslink the 
microspheres together.  PEG/dextran aqueous two-phase systems have been widely used 
for cellular and molecular partitioning (203-207).  Two-phase dextran/PEG solutions 
have also been used to produce microspheres and alter the porosity of hydrogels (208-
212).  Dextran solutions were therefore seen as an attractive choice for enhancing the 
crosslinking of PEG microspheres in the presence of HL-1 cells (a cardiomyocyte cell 
line), allowing in vitro expansion and long-term culture in the resulting porous 3D 
scaffolds. 
 
2.3 Materials and Methods 
 
2.3.1 Synthesis of PEG derivatives 
Eight arm PEG-vinyl sulfone (PEG8-VS) and eight arm PEG-amine (PEG8-Am) 
were synthesized from eight arm PEG (Creative PEGworks) as previously described (213, 
214).  Stock solutions of polymers (20%) in phosphate buffered saline (PBS) were 
sterilized by filtration (0.22 µm, Millipore).  For fluorescent labeling, 20% PEG8-Am and 
Dylight-633 NHS ester (Pierce) were reacted overnight at 25ºC at a 100:1 molar ratio of 
PEG:dye.  
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2.3.2 Microsphere formation  
 PEG8-VS and PEG8-Am stock solutions (20%) were mixed at a 2:1 volume ratio 
and pre-reacted at 37ºC for 70% of the time needed to reach bulk gelation (5.25 h).  The 
pre-reacted solutions were aliquoted and stored at -80ºC.  RGD cell-adhesion peptide (1 
mM, sequence: GCGYGRGDSPG, Genscript) was added to the pre-reacted solution and 
reacted at 37ºC for 30 min.  For microsphere formation, PBS and 1.5 M Na2SO4 were 
pre-warmed to 37º C.  Pre-reacted solution (50 µL, room temperature) was then diluted 
with pre-warmed solutions in an Eppendorf tube to a final concentration of 2% PEG and 
0.6 M Na2SO4 (500 µL total).  Phase separation occurred upon addition of Na2SO4.  The 
mixture was triturated once and quickly transferred to a 37ºC heating block.  Reaction 
above the cloud point proceeded for 45 min.  Microsphere suspensions were then diluted 
3:1 in PBS, centrifuged at 14,100 g for 2 min, and the supernatant was replaced with an 
equivalent volume of PBS.  This was repeated 2x to ensure all Na2SO4 was removed.  
After the final centrifugation, the pellet was resuspended in 500 µL of PBS.  The post-
swelling microsphere volume was determined by measuring the total volume of solution 
after the addition of 500 µL of PBS.  Microspheres were stored in PBS at 4 ºC and were 
stable for at least 6 months.   
 
2.3.3 Microsphere sizing, swelling and aggregation 
For microsphere sizing, aggregation was minimized by incubating microspheres 
in a 350 µM cysteine solution for 2 hr at 25ºC to cap free VS groups.  Fluorescent 
microspheres (5 µL) were suspended in 45 µL of PBS, then 350 µL of dextran in PBS 
was added just prior to imaging to attain the desired dextran concentration.  Suspensions 
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were vortexed for 30 sec, then samples (10 µL) were imaged on a glass slide by confocal 
microscopy.  Microsphere diameters (n > 40 microspheres per group) were measured 
using ImageJ software (National Institutes of Health) and volumes were calculated 
accordingly.  Reported values are averages from 3 separately made microsphere batches, 
with error bars representing the 95% confidence interval.     
To investigate dextran-induced aggregation, fluorescent microspheres were 
resuspended at a 1:1 volume ratio with 2%(v/v) fetal bovine serum (FBS, Sigma-Aldrich) 
or 20% or 40% dextran (Mr = 100,000, Sigma Aldrich) in PBS.  Suspensions were 
vortexed and incubated at room temperature for 15 min.  Aggregation of microspheres 
was assessed by fluorescence microscopy.  Dextran concentrations are reported 
as %(w/v). 
 
2.3.4 HL-1 culture  
HL-1 cells, a gift from Dr. William Claycomb, are a continuously proliferating 
cardiomyocyte cell line derived from mouse atrial tumors (215, 216).  Cells were 
maintained according to the protocol supplied by the Claycomb lab (217).  Briefly, 
Claycomb Medium (Sigma) was supplemented with 10% FBS, 100 µg/mL 
penicillin/streptomycin, 0.1 mM norepinephrine, and 2 mM L-glutamine.  
Supplementation with norepinephrine is key to maintenance of the contracting cardiac 
phenotype (215-217).   Cells from passages 50-70 were seeded at a density of 105/cm2 
onto gelatin/fibronectin coated plates, supplied daily with 1 mL medium per 5 cm2 
culture area, and split 1:3 every 3.5 days.  HL-1 monolayers were contractile by day 3 
after passage.   
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2.3.5 Scaffold formation 
Scaffolds crosslinked via serum proteins were fabricated as previously described 
(200).   For scaffolds crosslinked without serum proteins, dextran (20% unless otherwise 
noted) was dissolved in serum-free DMEM if cells were present or PBS otherwise.  
Scaffolds were made using 50 µL of RGD-containing microspheres.  HL-1 cells were 
removed from flasks by trypsin dissociation, then rotated in 1.65 mL serum-free DMEM 
in an Eppendorf tube with the RGD-containing microspheres (107 HL-1s/mL 
microspheres) for 1 h at 37ºC to promote cell adhesion (the “adhesion step”).  The cells 
and microspheres were centrifuged at 500 g for 3 min and the supernatant was removed.  
Dextran-containing serum-free DMEM was added at a 1:1 volume ratio with the 
microspheres to resuspend the pellet.  The suspension was centrifuged at 500 g for 3 min, 
then transferred to 37 ºC/5% CO2 for 1 h.  Scaffolds were transferred to 6-well plates (BD 
Falcon) containing either Claycomb medium if cells were present, or PBS otherwise.  
Claycomb medium (4 mL) was replaced daily.  Post-swelling dimensions were 
approximately 8 mm in diameter and 1 mm in thickness.   
 
2.3.6 Microstructural and mechanical analyses of scaffolds  
Confocal microscopy was used to enable measurement of scaffold porosity in the 
hydrated state.  At least 8 confocal images per scaffold (n=3) were taken at randomly 
selected depths and analyzed in Matlab (MathWorks Inc.) to calculate percent porosity 
(area without microspheres/total area).  Scaffolds for oscillatory shear rheometry (RFS3, 
Rheometric Scientific) were made using 100 µL microspheres and were crosslinked in 
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Eppendorf tubes (PDMS was used to fill the conical portion of the tubes such that 
crosslinking occurred in the top of the tube).  PBS-hydrated scaffolds (1 mm thick) were 
die cut to 8 mm and characterized using 8 mm parallel plates, with a normal force of 40 
mN to prevent slipping.  An amplitude sweep (G′ as a function of strain) was performed 
to confirm that measurements were in the linear viscoelastic regime.  Frequency sweeps 
(1-100 radians/second) were then performed at 5% strain.  
 
2.3.7 Characterization of HL-1 response to scaffolds crosslinked in 20% 
dextran  
For cell-viability analysis, scaffolds were incubated in serum-free DMEM 
containing calcein AM (2 µM) and ethidium bromide (4 µM) (Invitrogen) for 30 min.  
Ten images per scaffold (n=3) were taken at randomly selected depths and analyzed in 
Matlab to calculate percent viability.  For measurement of scaffold cell densities, scaffold 
volume was measured prior to storage at -80 ºC.  At the time of the assay, scaffolds were 
thawed, mechanically dissociated by pipetting, and suspended to a final volume of 1 mL 
in dye/cell lysis buffer from a cell quantification kit (CyQUANT®, Invitrogen, 
excitation/emission: 480/520 nm).  Suspensions were vortexed for 2 min, and 5 µL 
samples were diluted in an additional 195 µL of dye/lysis buffer on a 96-well plate.  
Spectrofluorometric measurements were compared to a standard curve of known HL-1 
densities.   
To ensure that cells were well distributed throughout the depth of the scaffold, a 
thicker (~1.65 mm), fluorescently labeled scaffold was fixed (24 hr after scaffold 
crosslinking) in 3.7% formaldehyde for 45 min at room temperature then treated with 
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30% sucrose solution for 3.5 h at room temperature for cryoprotection.  Scaffolds were 
frozen in OCT (Tissue-Tek®, Sakura) at -80º C for 30 min then cryostat sectioned with 
careful attention to depth of sectioning.  Nine evenly spaced serial sections (16 µm 
thickness) were treated with a nuclear stain (Hoescht 33258, Molecular Probes, 1:1000 in 
PBS) for 15 min at room temperature prior to imaging by fluorescence microscopy.  The 
first 3 sections were designated as the top region of the scaffold, the middle three as the 
center, etc., with each region being ~550 µm thick.  Fifteen cell counts were made per 
region, averaged and divided by the average area of microspheres for that region.   
For immunohistochemistry (IHC), non-fluorescent scaffolds were prepared for 
cryostat sectioning as described above.  After sectioning, slides were 
blocked/permeabilized in 10% normal donkey serum/0.1% Triton X-100 in PBS.  
Primary antibodies were goat anti-connexin 43 (cx43, 1:100 dilution, Santa Cruz 
Biotechnologies, SC6560) and rabbit anti α-actinin (1:500, Sigma Aldrich, A2543).  
Alexa Fluor 488-labeled donkey anti-goat (1:1000, Invitrogen, A11055) and Cy5-labeled 
donkey anti-rabbit (1:100, Chemicon, AP1825) secondary antibodies were used to 
visualize the staining.  Coverslips were added with Vectashield® mounting medium 
containing DAPI (Vector Labs) for nuclear detection.   
2.3.8 Microscopy 
For scanning confocal microscopy (Eclipse C1/80i, Nikon), a hydrated scaffold 
was placed on a glass slide and covered with a circular glass coverslip (150 µM thick).  
PBS was pipetted under the coverslip to prevent dehydration.  For scanning electron 
microscopy (SEM, NanoSEM 2300, FEI Nova), hydrated scaffolds were fixed in 3.7% 
formaldehyde for 30 min at room temperature, suspended in diH2O, frozen in liquid 
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nitrogen, and freeze-dried overnight.  Scaffolds were gold-coated (Cressington 108) and 
imaged at 15 kV.  Images of fluorescent microspheres and immunohistochemistry (IHC) 
were acquired by fluorescence microscopy (IX70, Olympus) using a Magnafire camera 
(Optronics).  
 
2.3.9 Detection of HL-1 electrical activity 
Calcium sensitive Fluo-4 AM (10 mM in DMSO, excitation/emission: 494/516 
nm, Invitrogen) was mixed (1:1 volume ratio) with 20% (w/v) Pluronic® F-127 
(Invitrogen), diluted to 10 µM in DMEM, and applied to scaffolds for 30 min at 37ºC/5% 
CO2.  Scaffolds were washed 3x in PBS and incubated 15 min in DMEM + 0.1 mM 
norepinephrine to allow for complete de-esterification of the Fluo-4.   Scaffolds were 
rinsed once in Tyrode’s solution (1.33 mM CaCl2, 1 mM MgCl2, 5.4 mM KCl, 135 mM 
NaCl, 0.33 mM NaH2PO4) containing 0.1 mM norepinephrine, 5 mM glucose, and 5 mM 
HEPES, and this solution was used to keep scaffolds hydrated during imaging.  
Norepinephrine is required in the culture media to maintain the beating phenotype over 
long culture periods, and was similarly added to the Tyrode’s solution (215-217).  
Electrical stimuli were delivered to tissue constructs via a bipolar electrode made of two 
silver microwires (8 mil, A-M systems Inc.) inserted under the glass cover slips and into 
the Tyrode’s solution surrounding the scaffolds.  Sequences of images (sampling rate = 1 
- 2 Hz) were acquired by confocal microscopy at a depth of 100 µm into the scaffold 
while monophasic electrical impulses were applied to the scaffolds (amp = 10 V, duration 
= 200 msec, frequency= 1 Hz, burst width = 10 sec.) using an isolated pulse stimulator 
(Model 2100, A-M systems Inc.).  Resulting images were analyzed using Matlab 
 28 
software for temporal patterns of fluorescence.  Average fluorescence intensity was 
calculated over time for 8x8 pixel regions within the field of view, which were 
normalized to location-specific background intensity values to remove biases associated 
with the variability in cell density across the scaffold.  
 
2.3.10 Statistics  
Comparisons between 2 means were by Student’s T-Test with p < 0.05 considered 
significant.  Three or more means were compared by ANOVA with post hoc Scheffe test 
in Matlab with p < 0.05 considered significant.  Data are mean ± standard deviation or 
95% confidence interval, as specified in the text. 
 
2.4 Results 
 
2.4.1 Effect of dextran on PEG microsphere swelling and aggregation   
Individual microsphere diameters were used to calculate the average individual 
microsphere volume across a range of dextran concentrations. These were normalized to 
average volume of microspheres in PBS (diameter: 20.1 ± 5.3 µm, volume: 2109.8 ± 
1066.1 µm3).  Microsphere volume did not significantly change in the presence of 2% 
serum (1.0 with a 95% CI of 0.8-1.3 as normalized to PBS alone), but decreased upon the 
addition of dextran, becoming more compact as dextran concentration increases (Fig. 2.1 
A).  The wide variation in volume between microsphere batches at 5% dextran was 
because this was close to the critical concentration for phase separation.  PEG 
concentration increases upon deswelling, enabling increased crosslinking between free 
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VS and Am groups.  Phase separation also causes microspheres in dextran solutions to 
aggregate, with increased packing at higher dextran concentrations (Fig. 2.1 B; note that 
the dextran concentration prior to dilution 1:1 (v/v) with PEG microspheres is reported).  
This compaction should increase the local concentration of PEG for microsphere-to-
  
Figure 2.1 Phase separation in dextran increases localized PEG concentration through microsphere 
deswelling and aggregation. (A) The effect of dextran concentration on microsphere size was studied.  
Fluorescent microspheres were suspended in dextran solutions of varying concentrations.  Care was taken to 
diminish microsphere aggregation prior to confocal imaging.  Microsphere volumes () were determined by 
image analysis (n=3 microsphere batches, >40 microspheres per batch) and plotted alongside corresponding 
microsphere PEG concentrations () (both normalized to PBS alone =1).  Microspheres showed a decreasing 
size trend with increasing dexran concentrations.  Error bars correspond to the 95% confidence intervals at 
each point.  (B) Pelleted fluorescent microspheres were resuspended at a 1:1 volume ratio in 2% fetal bovine 
serum, 20% dextran or 40% dextran, vortexed for 1 minute, allowed to aggregate at 25°C for 15 min, and 
imaged by fluorescence microscopy.  Magnified insets highlight the packing of multiple microspheres to form 
large aggregates at higher dextran concentrations.   
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microsphere crosslinking.  
 
2.4.2 Fabrication and swelling of scaffolds crosslinked in 20% dextran 
Due to the higher density of the dextran solutions, centrifugation resulted in 
microspheres rising to the top of the solution (Fig. 2.2 A).  Scaffolds made by our 
previous method (via serum proteins) required overnight immobilization for crosslinking 
into scaffolds that were strong enough to support their weight in solution, but could not 
be removed from the centrifugation container.  Scaffolds fabricated in 20% dextran could 
 
Figure 2.2 Microsphere scaffold formation and swelling.  (A) Microspheres were suspended in medium 
containing either 2% serum or 20% dextran, centrifuged, then crosslinked to form scaffolds. Phase 
separation in dextran allowed microsphere crosslinking in the absence of serum proteins.  Scaffolds 
formed in dextran were much stronger and could be transferred to cell culture plates and cell-specific 
medium after only 1 h at 37°C.  Scaffolds crosslinked in 2% serum had to be kept in the same tubes in 
which they were formed to avoid breakage.  (B) To demonstrate microstructural changes caused by 
swelling upon dextran removal (after crosslinking step), a scaffold crosslinked in 40% dextran was 
imaged by confocal microscopy before and after buffer exchange into PBS. 
 
 31 
be removed from their centrifugation containers after just one hour.  The microsphere 
swelling data (Fig. 2.1 A) helps to explain this phenomenon.  Being a second order 
reaction, the 4-fold increase in PEG concentration in 20% dextran should increase the 
rate of the crosslinking reaction 42 =16 fold.  Sixteen hours approximates the previously 
used overnight crosslinking step.  Scaffolds that were crosslinked in dextran 
demonstrated substantial re-swelling upon transfer to physiological buffer (Fig. 2.2 B).  
                           
2.4.3 Scaffold microstructure and mechanical properties 
  We noted that scaffolds crosslinked in dextran better withstood routine handling, 
 
Figure 2.3 Scaffolds crosslinked in the presence of 20% dextran are stiffer.  Storage moduli (G′) of 
microsphere scaffolds crosslinked in either 20% dextran (n=3) or 2% serum (n=2) in PBS, 1 d after 
scaffold formation.  Error bars = std. dev.  *p < 0.05 for all frequencies 
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possibly due to denser microsphere-to-microsphere crosslinking afforded by the increases 
in local PEG concentration.  Parallel plate rheometry was used to quantify differences in 
stiffness.  The storage moduli of scaffolds crosslinked in 20% dextran was approximately 
3 times higher than the previously published scaffolds crosslinked in 2% serum (Fig. 2.3) 
(200).  However, the nonlinearity of the storage modulus curve is unusual, and further 
characterization is needed to confirm the value.   
Interestingly, confocal microscopy demonstrated larger pores in scaffolds 
crosslinked in dextran compared to scaffolds formed by centrifugation in 2% serum 
without dextran (Fig. 2.4).  Scaffolds crosslinked in 2% serum without dextran were not 
Figure 2.4 Scaffolds crosslinked in the presence of 20% dextran have increased porosity. Hydrated 
scaffolds containing fluorescently labeled PEG8-Am were imaged by scanning confocal microscopy (top 
row).  Fixed and dehydrated scaffolds were also analyzed by scanning electron microscopy (bottom 
row).  Microsphere-based scaffolds were compared to bulk PEG hydrogels made from the same 
precursors by Michael-type reaction (2:1 PEG8-VS:PEG8-Am).  Scaffolds formed in dextran were 
porous without the addition of porogens.  Scaffolds formed in 2% serum appeared to be porous, but 
these are actually large fractures, and the microspheres are otherwise tightly packed.   
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highly porous, thus requiring porogens to enhance porosity (200).  These scaffolds also 
fractured easily, making it impossible to quantify their porosity by image analysis.  
Scaffolds crosslinked in the presence of 20% dextran were porous (42.9 ± 1.2% porosity, 
n=3) even without addition of a porogen.  We suspected that this was due to pre-
crosslinking of the microspheres upon addition of dextran, perhaps around spherical 
dextran-rich droplets, leading to inefficient packing upon centrifugation.  SEM images of 
these scaffolds are in general agreement with the scanning confocal images.  However, it 
is clear that SEM drying artifacts make interpretation of scaffold porosity much more 
tenuous, and that scanning confocal microscopy is clearly superior for characterizing 
porosity (218).  
 
 
                   
Figure 2.5 HL-1 cells retain high cell viability in scaffolds assembled in the presence of 20% 
dextran. (A) Scaffolds (blue) were formed from microspheres with and without RGD peptide.  HL-1 
cells were mixed with the microspheres and rotated for 1 h at 37°C to promote attachment of the 
cells to the microspheres prior to scaffold formation in 20% dextran.  One day after scaffold 
formation, HL-1 cells were labeled with calcein AM (green) and imaged by scanning confocal 
microscopy.   Cells were more spread in scaffolds with RGD peptide.  (B) Live/dead assay of HL-1 
cells in a scaffold 1 d after cross-linking, as imaged by confocal microscopy.  Cell viability was 
81.2 ± 4.7% (n = 3). 
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2.4.4 HL-1 incorporation, viability, and proliferation in microsphere 
scaffolds crosslinked in the presence of 20% dextran 
Scaffold fabrication in dextran solutions was also possible in the presence of 
living cells, giving well distributed cell density throughout the scaffold’s thickness 
(Supplementary Fig. S2.1).  To enable cell adhesion to the microspheres, RGD peptides 
were reacted with PEG8-VS during the pre-reaction stage, as previously described (200).  
Cells in RGD-containing scaffolds had a more spread morphology, as expected (Fig. 2.5 
A).  Cell viability 24 h after scaffold fabrication was 81.2 ± 4.7% (Fig. 2.5 B, n=3).  The 
cell density with 1 mM RGD-containing microspheres, measured 2 h after transfer of the 
                    
Figure 2.6 HL-1 cell proliferation in scaffolds.  (A) HL-1 cell density immediately following scaffold 
formation (day 0) and after 6 and 13 days.  Cell density increased nine-fold by day 13. *p<0.05 
versus day 0 and day 6.  (B) HL-1cells labeled at day 0 with Cell-Tracker dye (green) then 
incorporated into scaffolds (blue) to follow the increase in cell density over time.  Scanning confocal 
images are from the interior of each scaffold. 
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scaffold to cell-specific medium, was 2.2 ± 0.3 million cells/mL scaffold (n=3), and only 
slightly higher by day 6 (Fig. 2.6 A).  However, by day 13, HL-1 cells had proliferated to 
a density of 18.3 ± 1.0 ×106 cells/mL scaffold (Fig. 2.6 A, n=3), and much of the porous 
space in the center of the scaffold was filled with HL-1 cells (Fig. 2.6 B).  Proliferation of 
cells resulted in the formation of large cell clusters in the pores of the scaffold that 
changed the macroscopic appearance of the scaffold (Supplementary Fig. S2.2).   
The experimental design of the proliferation assay originally contained control 
scaffolds that were crosslinked via serum proteins.  However, they broke if removed from 
their centrifugation containers.  In our previous study (200), scaffolds were maintained in 
the centrifugation containers and the latest time point was 108 hr (meaning 2-3 media 
changes).  It is difficult to maintain serum protein-based scaffolds in centrifugation 
 
 
Figure 2.7 HL-1 cells express cardiac functional markers after long term culture in microsphere-based 
scaffolds crosslinked in 20% dextran.  Immunohistochemical staining for connexin 43 (green), 
sarcomeric α-actinin (red), and DAPI (blue) at: (A-C) day 13 and (D-F) day 24 after scaffold 
formation. (A and D) Low magnification view of both sarcomeric α-actinin and connexin 43.  (B and E) 
Magnified staining for connexin 43/DAPI alone and (C and F) sarcomeric α-actinin/DAPI alone.  
Connexin 43 staining was punctuated suggesting substantial cell-cell contacts, while sarcomeric α-
actinin expression indicated that cells had retained the cardiomyocyte phenotype.  Section slices were 
10 µm thick for all images.  Images were acquired by fluorescence microscopy.   
 
 36 
containers much longer than that because frequent media changes cause scaffold 
breakage.  
 
2.4.5 HL-1 expression of cardiac functional markers in microsphere 
scaffolds crosslinked in the presence of 20% dextran 
When cultured on two-dimensional substrates, HL-1 cells are known to express 
both connexin 43 and sarcomeric α-actinin, which are key proteins in excitation and 
contraction of myocytes, respectively (215, 216).  Punctuated expression of the gap 
junction connexin 43 indicates connexon/gap junction assembly and suggests 
intercellular electrical connectivity.  These markers were probed by 
immunohistochemistry at days 13 (Fig. 2.7 A-C) and 24 (Fig. 2.7 D-F) after crosslinking.  
Extensive proliferation (Fig. 2.7 E-F) and cell clustering (Fig. 2.7 D) was further 
confirmed by nuclear staining at day 24.  Both connexin 43 (Fig. 2.7 B and 2.7 E) and 
sarcomeric α-actinin (Fig. 2.7 C and 2.7 F) were expressed at day 13 and continued to be 
expressed through day 24 (Fig. 2.7).  The continued expression of these proteins 
suggested that the cells retained their cardiomyocyte phenotype during culture in the 
microsphere scaffold and were capable of electrical communication via gap junctions.   
 
2.4.6 Detection of HL-1 electrical excitation in microsphere scaffolds 
crosslinked in the presence of 20% dextran 
As a final test of maintenance of cardiac phenotype, we looked at HL-1 excitation 
after over 5 weeks in culture.  Activation of HL-1 cells in day 38 scaffolds was detected 
by confocal microscopy of Fluo-4 stained cells (Fig. 2.8).  Fluorescence intensity traces 
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were collected for multiple pixels in different regions of interest (ROI).  Pixel traces 
shown in a single ROI graph are spaced by a distance of at least 16 µm, such that some of 
the traces were likely from adjacent cells.  Spontaneous excitation was observed 
throughout the scaffolds (Fig. 2.8 A), with pixels from various areas of a single ROI 
peaking simultaneously.  This suggests some degree of electrical connectivity between 
cells of a single cluster.  The duration of the spontaneous transients varied between ROIs, 
possibly due to variation in the activity of Ca2+-ATPase on the surface of the 
sarcoplasmic reticulum.  In paced scaffolds, cells in various ROIs were excited at the 
same frequency (0.5 Hz) for the 10 s duration of the stimulus (Fig. 2.8 B).  Surprisingly 
the excitation frequency of these clusters was only half the stimulation frequency (i.e. a 
2:1 block), suggesting that the cells have a long refractory period (normal murine 
refractory periods are on the range of 50 ms (219)).   
Contraction of cell clusters was not visualized at the microscopic level, but the 
use of an excitation-contraction uncoupler (e.g. blebbistatin) would be necessary to 
absolutely verify that transients were not influenced by contraction-induced motion.  
Although the traces do not appear to represent pure action potential, the presence of 
calcium transients and/or motion indicate that the cells are still electrically active after 5 
weeks in the 3D scaffolds.  This suggests a promising outlook for future work 
investigating HL-1s or other types of cardiomyocytes.  Future studies will focus on 
optimization of materials to support a contractile phenotype. 
 
 
 
 38 
 
 
                        
Figure 2.8  HL-1 cells retain electrical activity after 38 days of culture within microsphere-based scaffolds 
crosslinked in 20% dextran. Day 38 scaffolds containing HL-1 cells were incubated with calcium-sensitive 
Fluo-4 AM to monitor changes in intracellular calcium concentrations.  Activity was imaged by scanning 
confocal microscopy at a depth of 100 µm into the scaffolds. (A) Spontaneous transients were seen in 
various regions of interest (ROI) throughout the scaffold.  (B) Transients from various ROI in response to 
stimulation by monophasic electrical impulses (amplitude = 10 V, duration = 200 msec, frequency= 1 
Hz, burst width = 10 sec).  Traces of transients from different ROI or random pixels are shown.  The 
multiple traces from within each ROI were from pixels spaced at least 16 microns apart. 
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2.5 Discussion 
Phase separations have been utilized to produce porous hydrogel materials for at 
least five decades (220-222).  Crosslinking of a polymer above its LCST results in the 
formation of sponge-like morphologies that sometimes appear to be aggregates of 
microspheres (218, 223-225).  The current method differs from traditional phase 
separation methods because scaffold formation is divided into a microsphere formation 
step and a microsphere assembly step.  Like our previously reported methods (199, 200), 
the microsphere formation step is performed in sodium sulfate solutions rather than 
dextran because the microsphere yield is much higher.  The scaffold formation step is 
then performed in cytocompatible dextran solution, which provides a stiffness increase 
that enables more extensive biological characterization than was possible using the serum 
protein-based protocol.  The two-step method allows the fabrication of large quantities of 
high quality microspheres that may be stored for longer than six months prior to scaffold 
formation.  It is our experience that the complexity of processing materials in the phase-
separated state is mostly captured in the first step.  Thus, if the first step yields high 
quality microspheres, the same microsphere batch may be used over the course of many 
experiments.  
Materials used for cardiac tissue engineering are typically: 1) macroporous 
scaffolds formed apart from cells, or, 2) non-macroporous hydrogels crosslinked around 
cells.  As an example of pre-formed scaffolds, Langer and colleagues produced highly 
porous poly(glycerol sebacate) materials that had mechanical properties similar to 
myocardium (226).  The scaffolds were engineered with intricate, biomimetic pore 
structures that promoted the alignment of cardiomyocytes (227).  As an example of a 
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non-macroporous hydrogel, collagen gels have been extensively characterized by 
Eschenhagen, Zimmermann, Elson and colleagues (131, 179, 228-232).  Primary heart 
cells were added to collagen solutions prior to gelation.  Cardiac fibroblasts contracted 
the gels, which resulted in highly aligned, electrically active tissues (131, 179, 228-232).  
While the lack of porosity may place size limitations on the tissues, researchers have 
circumvented this problem by fusing multiple small collagen gels to create larger cardiac 
patches (131, 231, 232).   
Materials for cardiac tissue engineering must be especially resistant to the 
formation of a fibrous capsule, which may result in electrical isolation of the transplanted 
tissue.  Because of its low protein adsorption properties, PEG is an excellent candidate 
for these types of applications (142, 153, 233).  The PEG-based scaffolds described here 
are macroporous when assembled in the presence of living cells.  Similar to traditional 
macroporous scaffolds, the cells have space within the pores to migrate and proliferate.  
Similar to a collagen gel, the cells are evenly distributed regardless of scaffold thickness 
from the time of scaffold formation.  The storage modulus is also higher than reported 
values for collagen gels (10-100 Pa) (234-237).   
Collagen gels are typically remodeled by cardiac fibroblasts that are present in the 
primary heart cell harvests.  Unfortunately, proliferating fibroblasts may quickly overtake 
the cardiomyocytes, limiting the window of study to a few days and making it difficult to 
analyze cardiomyocyte-specific responses (231, 238).  While patient-derived stem cells 
may be the optimal cell source for cardiac tissue engineering, HL-1 cells are a useful 
model for studying cell responses to biomaterials because they maintain many of the 
characteristics of cardiomyocytes.  HL-1 monolayer cultures have previously been used 
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to probe cardiomyocyte responses to various drugs and other treatments (216, 239-241).  
Several recent studies have used HL-1 cells to study cardiomyocyte responses to 
biomaterials (242-245).  For example, Stupp and colleagues demonstrated HL-1 
alignment and electrical activity at day 10 in nanofibrous amphiphilic peptide gels (242), 
but viability and retention of cardiac phenotype in longer-term cultures were not 
investigated.  Jongpaiboonkit et al. investigated viability over time for HL-1s 
encapsulated in bulk PEG-diacrylate hydrogels, which have negligible porosity (245).  
Viability in non-degrading bulk gels at day 1 was slightly higher than what was seen in 
the PEG microsphere scaffolds (~90% versus ~81%, respectively).  This slight viability 
difference may be a product of the length of the adhesion step used to ensure HL-1 
adhesion to microspheres during centrifugation.  At two weeks, HL-1 viability in the bulk 
PEG hydrogels was low unless RGD density and degradation rate were finely tuned (245).  
In the current study, HL-1 cells expressed functional markers and had a nine-fold 
increase in cell density at two weeks.  While a long-term comparison between the 
systems has not yet been performed, HL-1 cells in PEG microsphere-based scaffolds may 
be at a long-term advantage due to increased porosity and nutrient diffusion.  
However, the current scaffolds still need to be improved to be useful for cardiac 
tissue engineering.  While dense cardiomyocyte packing is important for conduction, 
localized HL-1 proliferation caused clustering within the pores of the scaffold, and the 
cells lacked the alignment and highly organized gap junctions (Figs. 2.6 and 2.7) typical 
of natural myocardium.  Furthermore, the frequency of spontaneous transients in the 
scaffolds was lower than those reported for confluent HL-1 monolayers (246) and seen in 
our own two-dimensional cultures, but similar to what is reported for non-confluent 
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monolayer cultures (239).  The lower frequency and lack of synchronization in 
spontaneous transients probably indicates low electrical conduction between cell clusters 
in the scaffold.  Functionalizing some of the PEG microspheres with enzymatically 
degradable sites may enhance porosity and help the cells to remodel their environment, 
similar to what is seen in collagen gels (161, 229).  Coupling enzymatic degradation with 
mechanical (230) and/or electrical (247) stimulation may further improve cellular 
alignment and electrical conduction.   
Finally, replacing the HL-1 cells with an autologously derived cardiomyocyte 
source will be necessary before the engineered tissue can be used in a clinical setting.  
Recent studies have found that matrix stiffness (159, 164, 248) and topography (101, 107, 
110) have profound influence on cell differentiation and maturation, so it is possible that 
the mechanical differences observed in this study would affect cell phenotype.  However, 
the microstructural differences between PEG microsphere scaffolds and those described 
by other groups limit our ability to hypothesize on the outcome of mechanical and 
topographical changes.  Our future research will likely include variation of microsphere 
size and stiffness and its effects on stem cell differentiation and cardiomyocyte phenotype.   
 
2.6 Conclusions 
In this study, previously published modular scaffold fabrication methods were 
improved, developing stronger, more porous PEG scaffolds by crosslinking microspheres 
in the phase separated state.  Scaffolds were assembled around HL-1 cardiomyocytes, and 
cells were cultured in the scaffolds for over a month.  The HL-1 cells proliferated, 
expressed cardiomyocyte markers, and retained electrical activity. 
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2.8 Supplementary Figures 
 
 
 
 
Supplementary Figure S2.1 HL-1 cells are well distributed throughout the thickness of a 
microsphere scaffold crosslinked in 20% dextran.  Cell nuclei (yellow) in sections from a day 1 
scaffold were counted and the average number per mm2 of microspheres (blue) was calculated for 
three scaffold regions (each representing 550 µm of scaffold thickness).  (A) Images of sections used 
for cell counts. (B) A bar graph presenting the average cell density in the top, center and bottom of 
the scaffold.  Error bars represent standard deviation between 3 sections in one scaffold region.  
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Supplementary Figure S2.2 Macroscopically visible HL-1 clusters are present after 10 days of culture 
in a microsphere scaffold crosslinked in 20% dextran. A phase contrast image of an HL-1 loaded 
scaffold, 10 d after scaffold formation, compared to a scaffold without cells.  White arrows indicate 
visible clusters of HL-1 cells. 
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CHAPTER 3* 
 
Direct reprogramming of mouse fibroblasts to 
cardiomyocyte-like cells using Yamanaka factors 
on engineered poly(ethylene glycol) hydrogels  
 
 
3.1 Abstract 
 
Direct reprogramming strategies enable rapid conversion of somatic cells to 
cardiomyocytes or cardiomyocyte-like cells without going through the pluripotent state.  
A protocol recently described by Efe et al. (Nature Cell Biology, 2011, 13:215) couples 
Yamanaka factor induction with pluripotency inhibition followed by BMP4 treatment to 
achieve rapid reprogramming of mouse fibroblasts to beating cardiomyocyte-like cells.  
The original study was performed using Matrigel-coated tissue culture polystyrene 
(TCPS), a stiff material that also non-specifically adsorbs serum proteins.  Protein 
adsorption-resistant poly(ethylene glycol) (PEG) materials can be covalently modified to 
present precise concentrations of adhesion proteins or peptides without the unintended 
effects of non-specifically adsorbed proteins.  Here, we first reproduced the Efe et al. 
protocol to reprogram adult mouse tail tip mouse fibroblasts (TTF) and mouse embryonic 
fibroblasts (MEF) to cardiomyocyte-like cells that demonstrated striated sarcomeric α-
actinin staining, spontaneous calcium transients, and visible beating on Matrigel-coated 
TCPS.  We then designed poly(ethylene glycol) culture substrates to promote MEF 
                                                
* Chapter 3 is adapted from a manuscript accepted for publication in Biomaterials May 
23rd, 2013. DOI:  10.1016/j.biomaterials.2013.05.050 
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adhesion via laminin and RGD-binding integrins.  PEG hydrogels improved proliferation 
and reprogramming efficiency (evidenced by beating patch number and area, gene 
expression, and flow cytometry), yielding almost twice the number of sarcomeric α-
actinin positive cardiomyocyte-like cells as the originally described substrate.  These 
results illustrate that cellular reprogramming may be enhanced using custom-engineered 
materials. 
 
3.2 Introduction 
 
Heart failure is one of the most common health problems in the United States.  It 
will eventually affect ~20% of all 40-year-old Americans (11).  Innovative solutions are 
necessary to reduce the costs of heart failure, which currently stand at ~$39.2 billion per 
year (11).  Cell-based therapies, or introduction of healthy cells into cardiac scar tissue, 
have modestly improved various measures of cardiac function (60, 249, 250).  The best 
donor cell source is still under debate, with much room for optimization across cell types 
(58).  Current cardiomyocyte derivation strategies include differentiation from embryonic 
stem cells (ESCs), induced pluripotent stem cells (iPSCs), resident cardiac progenitor or 
stem cells, or direct reprogramming, which bypasses the pluripotent state.  ESC and iPSC 
(collectively, PSC)-derived cardiomyocytes are expandable, and iPSC-derived 
cardiomyocytes could be autologously sourced.  However, their populations must be 
carefully purified to avoid risks of teratoma formation, and chromosomal defects arising 
over long periods in culture add to tumorogenic risks (46).  Currently, iPSC derivation is 
relatively inefficient (0.01-1.4%) (78).  The full derivation, expansion, and purification of 
pluripotent stem cell derived cardiomyocytes can take several months (36, 79).   
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Several direct reprogramming strategies (75, 76, 82, 84) have reported bypassing 
the pluripotent state, enabling autologous derivation of cardiomyocyte-like cells in a 
fraction of the time needed for iPS cell production.  This has been achieved by inducing 
transcription factors important for cardiac development (for example; Tbx5, Mef2c, 
Gata4, Myocd and/or Hand2) (75-77) or using microRNAs (82) to control signaling 
pathways.  In addition to implanting cells reprogrammed in vitro, similar techniques have 
been used to reprogram scar tissue to cardiomyocytes in vivo (77, 80-82).  The direct 
reprogramming protocol described by Ding and colleagues (Efe et al. (84)) combines a 
carefully timed induction of Oct4, Sox2, Klf4, and c-Myc (OSKM), inhibition of the 
JAK-STAT (Janus kinase-signal transducer and activator of transcription) pluripotency 
pathway, serum withdrawal, and BMP-4 mediated cardiogenic induction, resulting in 
beating patches of cells in as little as 11 days after OSKM induction (84).  The rapid 
derivation process is especially relevant in cases of myocardial infarction, as the 
inflammatory response begins within 24 hours (86) and scar formation progresses quickly 
from there (87).   
Extracellular matrix (ECM) proteins in the cell microenvironment affect 
pluripotent differentiation via integrin signaling, and are well known to direct 
differentiation down varied pathways (100).  However, the optimal surface density and 
types of proteins are often determined by trial and error.  Efe et al. found that Matrigel 
(~60% laminin-1, ~30% collagen IV, ~8% entactin, ~2% other proteins according to 
product literature) improved cardiac direct reprogramming over Geltrex, gelatin or 
fibronectin coatings, but no mechanism was proposed (84).  In contrast, Thomson and 
colleagues revolutionized PSC culture by measuring ESC growth factor receptor 
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expression and tailoring the media formulation accordingly (251, 252).  Recently, Koche 
et al. analyzed global gene expression of partially reprogrammed mouse embryonic 
fibroblasts (MEFs, 3 days into OSKM induction), reporting upregulation of laminin-
binding integrin subunits α6 (4.0-fold) and β4 (13.3-fold), downregulation of collagen IV 
binding subunits α1 (4.3-fold), and little changes in expression of many RGD motif-
binding integrin subunits (e.g. α5 and αV), with the exception of α8, downregulated 4-
fold (253).  Based on these data, we hypothesized that laminin alone would promote the 
direct reprogramming of MEFs to cardiomyocyte-like cells at least as well as Matrigel.  
The use of laminin also avoids the batch-to-batch variation in protein content seen with 
Matrigel (254, 255). We also hypothesized that the addition of RGD peptide would 
enhance cell adhesion on engineered substrates due to the continued expression of αV 
during the early reprogramming process. 
In the original direct reprogramming protocol, Matrigel was adsorbed to tissue 
culture polystyrene (TCPS) prior to cell seeding (84).  However, adsorption may cause 
unfolding of ECM proteins, resulting in altered cell signaling (256-259).  Serum proteins 
from the media also adsorb to TCPS, competing with the intended ECM proteins (260) 
and activating unintended signaling pathways that may vary by batch of serum.  
Poly(ethylene glycol) (PEG) is resistant to non-specific protein adsorption, but may be 
covalently modified to present bioactive molecules at precise quantities and in their 
native conformations (261, 262).  For this study, we engineered PEG cellular 
microenvironments that potentially provide better control over adhesion molecule 
concentration, conformation, and stability than is possible with TCPS.  We demonstrate 
that these engineered hydrogel substrates lead to higher efficiency of direct 
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reprogramming to cardiomyocyte-like cells than the protocol initially described by Efe et 
al. (84) 
 
3.3 Materials and Methods 
 
3.3.1 Mouse protocols and fibroblast culture   
All animal protocols were approved by Washington University Institutional 
Animal Care Use Committee.  A pair of mice homozygous for doxycycline-inducible 
OSKM factors (Jackson Labs, stock number: 011011) was bred to start a colony for tail 
tip (TTFs) and embryonic fibroblasts (MEFs) (263).  To harvest tail-tip fibroblasts 
(TTFs), adult tails were sterilized in 70% ethanol, skinned, and minced thoroughly.  
Minced pieces were incubated in 3 mL of 0.05% trypsin-EDTA (Invitrogen) at 37ºC for 
30 min then neutralized with 7 mL of fibroblast media (FB media: DMEM+10% fetal 
bovine serum+1% ABAM).  Tail pieces were collected by centrifugation, resuspended in 
3 mL of FB media, and transferred by tweezers to gelatin coated wells (1 mL/well at 0.1 
mg/mL, preincubated 1 h at room temperature) at a ratio of one tail per 2 wells of a 6 well 
plate.  Care was taken to dry the well surfaces by aspiration prior to placing the pieces, 
and to evenly space the pieces in the well.  After allowing 4 h for tails to adhere at 37ºC, 
0.2 mL of FB media was added per well.  The next day, 3 mL/well of FB media were 
added.  Once TTFs became confluent, they were trypsinized, strained through a 70 µm 
cell strainer, and replated (2 wells/T75 flask).  Once confluent, the flask was trypsinized 
and frozen at -80 (1 cryovial per initial mouse tail).   
For preparing mouse embryonic fibroblasts (MEFs), day 13.5 embryos were 
harvested and the visceral organs removed to minimize the presence of cardiac precursor 
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cells.  Embryos were minced, incubated at 37ºC for 30 min in 7 mL of 0.05% trypsin-
EDTA and then triturated using a 10 mL pipet.  Trypsin was neutralized with 23 mL of 
FB media, divided into T75 flasks (2-3 embryos/flask), and cultured in  15 mL of FB 
media.  Once confluent, cells were passaged 1:3 and the passage 2 cells were trypsinized 
and frozen at -80ºC (3 cryovials/confluent flask). 
 
3.3.2 PEG hydrogel fabrication and functionalization of culture surfaces 
All experiments were performed using 24-well plates.  Thirty minutes prior to gel 
fabrication, wells were treated with a plasma cleaner (Harrick Plasma) set to medium 
(350 mTorr for 5 min) to reduce meniscus formation in the wells during gel formation.  
Plates were then UV-sterilized for 30 min and gel precursor solutions were added 
immediately.  PEG derivatives were synthesized as previously described (213, 214, 264).  
For gel fabrication, PEG8-Vs and PEG8-Am solutions (both 20% w/v in PBS, pH 7.4) 
were sterile-filtered (0.22 µm filter) and diluted in 0.03 M NaOH in PBS (pH 8.75, 
NaOH enhanced reaction kinetics and further reduced meniscus formation) for a final 
PEG concentration of 12.43% (w/v).  The precursor mix was aliquoted at 200 µL/well 
and allowed to crosslink in a humidified incubator (37ºC) for 1-2 days.   
Protein and peptide surface concentrations are reported as 1x or 5x.  When 
referring to Matrigel or laminin, 1x is the approximate protein concentration of Matrigel 
used in Efe et al.  The concentration used here may be slightly different than Efe et al. as 
they reported the Matrigel dilution factor (1:40) instead of the coating concentration (84), 
and so their surface concentration will vary by Matrigel batch (265).  Here, we 
standardized the 1x coating protein concentration at 11.4 µg/cm2 (the 1:40 dilution of our 
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first Matrigel stock when used at 200 µL/well).  The 1x concentration of laminin was also 
set to 11.4 µg/cm2.  When referring to the RGD peptide, 1x is the approximate surface 
density of RGD on the PEG microspheres previously tested with HL-1 cardiomyocytes 
(266).   
For functionalization with Matrigel (BD Biosciences, 356234) or laminin-1 
(Sigma, L2020), protein stocks were first diluted to 108.3 (1x) or 541.5 µg/mL (5x) in 
PBS.  If RGD peptide (GCGYGRGDSPG, Genscript) was included, it was diluted in the 
same tube as the protein at 3.36 (1x) or 16.82 (5x) mg/mL.  Each well received 200 µL of 
protein/peptide solution.  For TCPS conditions, (non-plasma treated) 24-well plates were 
incubated at room temperature for 1 h to permit protein adsorption (according to Matrigel 
product literature).  The pre-formed PEG hydrogels were incubated with the 
protein/peptide mixtures overnight at 37ºC to permit the slower, covalent Michael-type 
reaction to occur.  Fibroblast seeding occurred the next day. 
 
3.3.3 Cell culture and reprogramming   
All reagents were purchased from Invitrogen unless otherwise noted.  Passage 3 
fibroblasts were seeded at day -1 (minus one) onto the functionalized 24-well plates at 
3,600 MEFs or 9,700 TTFs/cm2 and incubated overnight in FB media to ensure complete 
adhesion.  Reprogramming commenced the following day (day 0), and media was 
changed every 24-48 hours.  Media formulations and reprogramming timelines were 
adapted from Efe et al. (84).  Reprogramming timeline #4 (Fig. 3.1 a) was the most 
efficient at producing beating in initial testing with MEF, and was used in all experiments 
thereafter.  From days 0-5, cells received knockout DMEM (KO DMEM, 10829018) + 2 
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µg/mL fresh doxycycline (Sigma, D9891) + 0.5 µM JAK inhibitor I (JI1, EMD, 420099) 
+ 15% embryonic stem cell qualified FBS (ES-FBS, 10439-024) + 5% knockout serum 
replacement (KSR, 10828028) + 0.1 mM β-mercaptoethanol (21985-023), + 1% 
Glutamax (35050-061) + 1% non-essential amino acids (11140-050) + 1% embryonic 
stem cell qualified nucleosides (Millipore, ES-008-D).  For days 6-8, doxycycline was 
removed, ES-FBS concentration reduced to 1%, and KSR concentration increased to 14% 
(all other components remained the same).  From days 9-14, cells were given chemically 
defined medium (CDM) with BMP4:  RMPI-1640 (21870-084) + 20 ng/mL BMP4 
(Stemgent, 03-0007) + 0.5x N2 (17502-048) + 1x B27 w/o vitamin A (12587-010) + 
0.05% BSA fraction V (15260-037) + 0.5% Glutamax + 0.1 mM β-mercaptoethanol.  
From day 15 onward, cells were given CDM without BMP4.  RW.4 mouse embryonic 
stem cells (ATCC), a gift from the Sakiyama-Elbert laboratory, were cultured according 
to previously described methods (267). 
 
3.3.4 Cell counts and quantification of beating patches   
Phase contrast microscope images (10x magnification) were taken with a CCD 
camera (Magnifire, Olympus) and used to perform cell counts at days 0 and 3 for analysis 
of initial adhesion and proliferation.  Cell counts for three randomly selected images were 
averaged to determine the cell density of a given well.  For beating patch quantification, 
2x images of the entire well were taken by phase microscopy.  Wells were then carefully 
examined at 4x for beating patches, and these were outlined on the 2x images using 
Microsoft Paint.  Outlined beating patches filled with white using Adobe Photoshop, and 
any bright regions of the image not associated with beating patches were filled with 
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black.  Images were then thresholded and quantified in Matlab (Mathworks) to determine 
the number and size of the beating patches and total beating area of the well.  For late 
stage cell counts, cells were enzymatically dissociated using trypsin at days 15 (n = 3-6) 
and 18 (n = 3-6) and counted using a hemocytometer.  
 
3.3.5 Live-cell calcium imaging  
Calcium-sensitive dye Fluo-2 (medium affinity, 10 mM in dimethyl sulfoxide, 
excitation/emission 488/515 nm, TefLabs) was mixed (1:1 volume ratio) with 20% (w/v) 
Pluronic  F-127 (Invitrogen), diluted to 10 µM in DMEM, and applied to cells for 30 min 
at 37ºC/5% CO2.  Cells were washed three times in PBS and incubated for 15 min in 
DMEM to allow complete de-esterification of the Fluo-2.  Cells were imaged in Tyrode’s 
solution (1.33 mM CaCl2, 1 mM MgCl2, 5.4 mM KCl, 135 mM NaCl, 0.33 mM 
NaH2PO4,, pH 7.4) containing 5 mM glucose and 5 mM HEPES by fluorescence 
microscopy (IX70, Olympus) using a Magnafire camera (Optronics, 10 frames/second).  
The resulting images were analyzed using a custom Matlab script that 
tracked fluorescence localization over different time intervals.  Noise was removed 
through a Prewitt edge detection filter and a series of structuring element filters (2-pixel 
lines at 90, 0, then 45 degrees).  A 10 x 10 pixel averaging filter was then used to remove 
biased pixels that were unrelated to the signal of interest.  Finally, activation events were 
detected in each pixel by setting a fluorescence threshold.  An activation map was formed 
by overlaying temporal data with a gradient color scheme.  
 
3.3.6 Quantification of gene expression   
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Gene expression was evaluated by quantitative real time RT-PCR using an 
Applied Biosystems StepOnePlus or ViiA machine.  On day 18 of reprogramming, 
cellular RNA was purified with TRIzol reagent (Invitrogen, 15596-026) by following the 
manufacturer’s instructions.  RNA concentration and quality (260/280 nm absorbance 
ratio) was verified using a NanoDrop spectrophotometer.  Genomic DNA was removed 
and RNA was reverse transcribed to cDNA (10 ng RNA/µL) using the QuantiTect 
Reverse Transcription Kit (Qiagen, 205313).  Pre-validated primers for mouse GAPDH, 
sarcomeric α-actinin (Actn2), cardiac troponin T (Tnnt2), connexin 43 (Cx43), and 
Nanog (Nanog) transcripts were obtained from Qiagen (Quantitect Primer Assay).  
Forward and reverse primer sequences designed using IDT software and experimentally 
validated were β-actin (ActB), sarcomeric α-actinin (Actn2), myosin light chain-atrial 
isoform (Mlc2a), potassium/sodium hyperpolarization-activated cyclic nucleotide-gated 
channels 1 and 4 (Hcn1, Hcn4), T-box transcription factor Tbx3 (Tbx3), and contactin-2 
(Cntn2).  Primer sequences are in Supplementary Table S3.1.  cDNA was amplified in 
triplicate reactions using Quantitect SYBR Green PCR Kit (Qiagen) following 
manufacturer’s instructions.  Expression levels were normalized to GAPDH or β-actin 
internal control genes, or to sarcomeric α-actinin to exclude effects from non-
cardiomyocytes, using the 2!∆!! method (268).   
 
3.3.7 Immunocytochemistry  
For immunocytochemistry, cells were fixed in 4% paraformaldehyde (500 
µL/well) for 15 min.  Triton-X 100 (Sigma) was diluted 1:1000 in blocking solution 
(10% normal goat serum + 1% BSA in PBS) for permeablization (300 µL/well, 30 min at 
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room temperature).  Sarcomeric α-actinin primary antibody (mouse IgG, Sigma A7811) 
was diluted 1:1600 in the blocking solution and applied to the cells (300 µL/well, 
overnight at 4ºC).  Cells were washed 3x in PBS (5 min each) before incubation in 
secondary antibody diluted 1:1000 in blocking solution (300 µL/well, 1 h at room 
temperature, Alexa Fluor 594 goat anti-mouse, Invitrogen, A-11005).  Cells were washed 
3x more in PBS before application of DAPI as a nuclear counterstain (100 ng/mL, 300 
µL/well, 30 min at room temperature).  Wells were washed once in PBS then imaged in 
PBS.   
 
3.3.8 Flow cytometry   
At day 18, cells were enzymatically dissociated into a single-cell suspension using 
0.25% trypsin-EDTA (Invitrogen), fixed in 1% paraformaldehyde in PBS at 4ºC with 
agitation for 20 min, permeablized with 1% saponin (Sigma, S4521) in PBS at 4ºC with 
agitation for 20 min, and blocked with 5% normal goat serum (NGS) + 0.5% saponin in 
PBS at 4ºC with agitation for 20 min.  Sarcomeric α-actinin primary antibody (mouse 
IgG, Sigma A7811) was applied to the cells for 30 min at 4ºC with agitation (1:1600 in 
2% NGS + 0.5% saponin in PBS).  Negative controls had no primary antibody at this step.  
AlexaFluor 647 goat anti-mouse secondary IgG (Invitrogen, A21235) was applied to the 
cells for 30 min at 4ºC with agitation (1:200 in 2% NGS + 1% saponin in PBS).  DAPI 
(1:125 in PBS) was applied as a nuclear counterstain.  Data were acquired on a 
FACSCanto II (BD Biosciences), with at least 10,000 counts per condition.  Data were 
analyzed using FlowJo software (Tree Star).  Negative controls were used to determine 
gating parameters. 
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3.3.9 Statistics  
Two-condition comparisons were made using student’s t-test, whereas multiple 
comparisons were made using ANOVA with post-hoc Tukey HSD.  In figures, data are 
presented as mean ± standard error of the mean.  Text references to data are mean ± 1 
standard deviation 
 
3.4 Results 
 
3.4.1  Replicating direct reprogramming to cardiomyocyte-like cells on 
Matrigel-coated TCPS 
To verify that direct reprogramming using OSKM could be replicated in our 
hands, we first used adult mouse TTFs to test three possible interpretations of the 
published protocol (84) (Fig. 3.1 a).  Cells from all groups demonstrated noticeable 
morphological changes, notably a decrease in cytoplasm/nucleus ratio by day 6.  By day 
12, large cell clusters had formed, and were most prevalent in wells from timeline 4 (Fig. 
3.1 b).  By day 14, beating patches were noted under timelines 3 and 4 only.  Timelines 3 
& 4 gave similar numbers of beating patches by day 18, with timeline 4 having a slightly 
higher number.  Given that timeline 4 was also shorter and less complex, it was used in 
all subsequent experiments.   
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Figure 3.1: Effects of varied induction timelines on adult tail tip fibroblasts. A) Multiple 
reprogramming media timelines were tested to clarify the protocols described by Efe et al.  Media 
with doxycycline (dox) promoted expression of the Yamanaka factors Oct4-Sox2-Klf4-c-Myc 
(OSKM) in tail tip fibroblasts (TTFs) derived from transgenic mice.  Timeline 4 produced the most 
beating clusters.  In timeline 4, six days of dox-induced OSKM were coupled with pluripotency 
inhibition by Jak-Stat Inhibitor (JI1) in high serum medium.  This was followed by three days of 
recovery in low serum medium also containing JI1, and then six days of induction of cardiomyocyte 
differentiation in chemically defined (no serum) medium containing bone morphogenetic protein 4 
(BMP4).  Abbreviations: Fibroblast (FB) medium, Knockout (KO) medium, Chemically Defined 
(CD) medium, ES-qualified fetal bovine serum (FBS).  B) TTFs became smaller and more rounded 
under the influence of OSKM, and cells in timeline 4 produced clusters of very small cells by day 
12 that ultimately began beating.   
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The beating patches demonstrated spontaneously oscillating calcium transients, 
which were most prevalent at the outer edges of differentiated clusters or in patches of 
cells surrounding the clusters (Fig. 3.2 a-c).  Beating patches derived from TTFs stained 
positively for striated sarcomeric α-actinin, a cardiac-specific marker (Fig. 3.2 d-e).  In 
agreement with the location of calcium transients, the most intense α-actinin staining was 
 
            
Figure 3.2: Characterization of cardiomyocytes directly reprogrammed from adult tail-tip fibroblasts.  
Reprogrammed cells formed beating patches visible by phase contrast microscopy (A, day 19).  (B) A 
time-based map of an activation wavefront from the beating patch in (A) was made using the calcium-
sensitive dye Fluo-2.   The wavefront starts at the right side of the cluster (dark red) and travels through 
the perimeter of the cluster (demonstrated by color changes to orange and then yellow).  Calcium traces 
from individual regions of interest (ROIs) are shown in (C).  (D and E)  Immunocytochemistry of day 18 
TTF-derived cardiomyocytes revealed expression of sarcomeric α-actinin (red) within the beating patches 
and in cells attached to the adjacent substrate.   
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found in cells surrounding the differentiated clusters.   
After demonstrating that the protocol is effective with adult somatic cells, MEFs 
harvested from the same mice containing the doxycycline-inducible OSKM cassette were 
utilized because they could be expanded to greater numbers in culture and 
reprogramming efficiency could be directly compared to the results of Efe et al.  At day 
21, the number of beating patches generated with MEFs on Matrigel-coated TCPS was 
similar to the number previously reported by Efe et al. (245 ± 83 in this study, versus 257 
± 17 beating patches per initial 100,000 MEFs seeded).    
 
3.4.2  Adhesion and proliferation of MEFs undergoing reprogramming 
on PEG hydrogels 
To verify that direct reprogramming could be performed on PEG hydrogels, 
MEFs were cultured on surfaces presenting covalently immobilized Matrigel, laminin or 
RGD at varied concentrations (referred to as 1x or 5x: for detailed explanations of the 
surface concentrations see the methods section or Supplementary Table S3.2).  As noted 
in previous studies (264), cells did not adhere to PEG surfaces without adhesion 
molecules.  It is well known that the protein content of Matrigel varies by batch  (~60% 
laminin, ~30% collagen IV, ~8% entactin and ~2% various growth factors and other 
proteins according to product literature) (265).  Consistent with this, we found that the 
ability of cells to adhere to Matrigel-functionalized PEG was Matrigel batch-dependent 
(data not shown).  However, cells consistently adhered to laminin-functionalized PEG.  
By 24 hours after seeding (day 0 of reprogramming), cell densities were similar on PEG-
RGD(5x) and TCPS coated with Matrigel or laminin.  The densities were statistically 
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higher than all other PEG groups and uncoated TCPS (Fig. 3a), indicating higher rates of 
initial adhesion and/or proliferation on these surfaces.   
Early proliferation dictates the ultimate number of cells available for cardiac 
differentiation.  To analyze the role of the adhesion molecules on proliferation of cells on 
PEG conditions during the first 3 days of OSKM induction, we quantified cell densities at 
day 3 and applied the following equation to determine the number of doublings per day:  
𝑑   =    𝑙𝑜𝑔!(!!!!)𝑡  
 
where d = doublings/day, N0 = number of cells at day 0, Nt = number of cells after t days, 
and t = number of days (Fig. 3.3 b).   Day 3 was chosen as the endpoint because cells on 
PEG conditions reached confluency by days 4-5 and thus could not be readily counted.  
Rates could not be determined for TCPS conditions as they had reached confluency by 
day 3.  For PEG conditions presenting RGD alone, the RGD concentration had an effect 
on cell proliferation (0.84 ± 0.07 doublings/day for 1x RGD versus 1.14 ± 0.15 for 5x 
RGD, p = 0.01 by t-test).  PEG conditions presenting laminin alone at 1x or 5x 
concentration exhibited proliferation rates similar to the 5x RGD condition.   
Over the course of reprogramming, cells on PEG-RGD(5x) continued to 
proliferate rapidly compared to other PEG groups, resulting in an extremely high cell 
density by day 9 (Fig. 3.3 c).  Interestingly, when laminin was added to PEG hydrogels 
that also contained 5x RGD, cell densities were noticeably lower.  By day 12, the dense 
cell layer on PEG-RGD(5x) began peeling off the gel forming compact aggregates at the 
edges of the wells (Fig. 3.4 b), and could not be analyzed further.  Other conditions 
enabled better long-term adhesion, but by day 18, cells of the 1x laminin, 1x RGD and, to  
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Figure 3.3: Substrate effects on early stage cell adhesion and proliferation. The culture substrate had 
dramatic effects on cell adhesion and proliferation during the first 9 days of the protocol.  A) Although 
surfaces were seeded equally, the efficiency of cell adhesion and/or proliferation was not the same.  
One day after MEF seeding (day 0 of reprogramming), similar cell densities were seen on TCPS 
surfaces (red bars) coated with Matrigel or laminin.  Cell densities on PEG surfaces did not vary with 
low (blue bars) versus high (green bars) concentrations of adhesion molecules (#not statistically 
different at α=0.95 by Tukey’s HSD test), but some conditions were lower than the coated TCPS groups 
(* p<0.05 versus TCPS-Mat(1x) and TCPS-lam(1x)) B) Cell counts from PEG hydrogels containing 
only RGD or only laminin were used to calculate proliferation rates over days 0-3.  The proliferation 
rate was positively influenced by RGD concentration (*p<0.05 by t-test), but not laminin-1 
concentration.  C) When RGD was used alone at 5x (lower left), an exceptionally high cell density was 
noticeable by phase microscopy by day 9.  Densities were not as high on PEG-RGD(1x) or any PEG 
group where laminin was included. 
 62 
 
a lesser degree, 5x laminin conditions had also begun peeling off the gel in isolated areas.  
Long-term adhesion problems were completely resolved by using both laminin and RGD.  
No long-term adhesion issues were noted on any TCPS conditions.   
Cells were counted by hemocytometer on days 15 and 18 for TCPS-Mat(1x), 
PEG-lam(5x), PEG-lam(5x)-RGD(1x), and PEG-lam(5x)-RGD(5x) to assess 
proliferation at a later stage of the reprogramming timeline.  The cell density between the 
two days was not different for any condition, suggesting a decrease in proliferation.  This 
finding is consistent with the decrease in progenitor marker (Mesp1 and Isl1) expression 
reported by Efe et al. for that time frame, which suggests a transition from a proliferative 
progenitor to a less proliferative immature cardiomyocyte (84).  Counts also did not vary 
between PEG-lam(5x) with 1x versus 5x RGD.  Counts were therefore pooled to increase 
the number of samples for a statistical analysis of late stage cell density (n=6-12).  PEG-
lam(5x)-RGD(1x or 5x) gels had a ~25% increase in cell density compared to the original 
condition used in Efe et al., or PEG-lam(5x) without RGD (Fig. 3.4 a, p<0.05 by 
ANOVA with post-hoc Tukey HSD).  Cell density on PEG-lam(5x) with RGD increased 
by a factor of 136.2 ± 23.7 compared to initial MEF seeding density.  Densities on PEG-
lam(5x) without RGD and TCPS-Mat(1x) increased by factors of 109.1 ± 20.5 and 108.3 
± 16.7, respectively.   
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Figure 3.4: Cell density and morphology at late stages of reprogramming protocol.  Addition of RGD to 
PEG hydrogels boosted cell proliferation.  A) Cells were trypsinized and counted by hemacytometer at 
days 15 and 18.  Within the same condition, the cell density did not vary by day.  Counts also did not vary 
between PEG-lam(5x) with 1x or 5x RGD.  Counts from these conditions were therefore pooled to 
increase the number of samples for statistical analysis (n = 6-12).  PEG-lam(5x) gels with RGD yielded 
~25% more cells per square centimeter than TCPS-Mat(1x) or PEG-lam(5x) without RGD (*p<0.05 by 
ANOVA with post-hoc Tukey HSD test). B) Phase contrast images were stitched together to give a 
macroscopic view of the individual wells.  Without laminin, cells on the RGD(5x) gel rolled off the plate 
forming a large clump at the edge of the well (white arrow).  On gels with laminin, more clusters were 
seen on gels that also presented RGD at 5x.  Clusters on gels with 5x laminin but no RGD had a more 
spread morphology than those on gels presenting RGD (bottom image).   
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3.4.3  Functional assessment of direct reprogramming to 
cardiomyocyte-like cells on PEG surfaces 
Many of the laminin receptors are upregulated during the first 3 days of OSKM 
reprogramming, whereas collagen receptors are downregulated (253).  Thus, we 
hypothesized that reprogramming would be equally as efficient on laminin versus 
Matrigel.  Numbers of differentiated clusters were visibly increased on PEG-lam(5x)-
RGD(5x) compared to PEG-RGD(1x), PEG-lam(1x)-RGD(1x) and PEG-lam(5x)-
RGD(1x) (Fig. 3.4 b).  
Beating assays provide a simple yet well-accepted method for initially estimating 
cardiac reprogramming efficiency (32, 84, 269-272).  On TCPS (Fig. 3.5 a, red columns, 
 
                                           
Figure 3.5: Effects of culture substrate on cell beating at day 18 of reprogramming.  The extent of cell 
beating, quantified manually by phase contrast microscopy, was influenced by the culture substrate. A) 
Beating patches are defined as synchronously contracting.  PEG hydrogels with high surface densities of 
adhesion molecules (green bars) had greater numbers of beating patches than gels with low surface 
densities (blue bars) or any TCPS surface (red bars)   (*p<0.05 versus PEG-lam(5x)-RGD(5x); #p<0.05 
against PEG-lam(5x) by Tukey’s HSD test).  The numbers of beating patches on TCPS surfaces (red bars) 
were similar regardless of adhesion molecule type or concentration.  Unlike the PEG gels, it was not 
possible to increase beating on TCPS by increasing the laminin concentration.  B) PEG conditions 
presenting laminin at 5x (with or without 5x RGD) also had greater coverage of beating cells than all 
TCPS conditions or PEG-lam(1x) (*p<0.05 by Tukey’s HSD test). 
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Matrigel and laminin-1 coatings led to similar numbers of beating patches per cm2 at day 
18 (9.04 ± 3.05 versus 9.44 ± 2.42 respectively; p = 0.71 by t-test).  When PEG was 
functionalized with 1x RGD, 1x laminin, or both (Fig. 3.5 a, blue columns), beating patch 
numbers were similar to the TCPS conditions.  A non-significant increase was noted 
when PEG-lam(1x) gels also presented 5x RGD.  This trend was also seen on PEG-
lam(5x) gels presenting 1x or 5x RGD (Fig. 3.5 a, green columns).  PEG-lam(5x)-
RGD(5x) had more beating patches than all TCPS conditions and PEG with lower 
adhesion molecule concentrations.  PEG-lam(5x) (no RGD) also promoted more beating 
than several of these groups, including the PEG-lam(1x) (no RGD) condition.  Increasing 
laminin concentration from 1x to 5x on TCPS did not result in more beating, suggesting 
that adsorbed amounts of laminin were already near maximal at 1x solution concentration.  
On TCPS, laminin saturates around 850 ng/cm2 (273), which is 13.4 and 67.1 times lower 
than our 1x and 5x concentrations.  Therefore, the actual density of the laminin layer 
adsorbed on TCPS is likely similar for our 1x and 5x concentrations.  Similar trends were 
noted when considering the total beating area instead of the number of beating patches 
(Fig. 3.5 b).  Reprogramming efficiency on Matrigel-functionalized PEG was difficult to 
assess given the aforementioned adhesion inconsistencies, and Matrigel-functionalized 
PEG gels were not studied further.   
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3.4.4 Gene and protein expression of directly reprogrammed cultures  
 Gene expression in day 18 reprogrammed cells was evaluated by reverse 
transcription quantitative real-time PCR (qRT-PCR) (Fig. 3.6 a-b).   Similar to what was 
seen in the beating patch counts, gene expression levels from PEG hydrogels with 5x 
laminin and 1x, 5x, or no RGD were statistically similar.  Likewise, no differences were 
 
                                                                         
 
Figure 3.6: Effects of culture substrate on gene expression at day 18 of reprogramming.  A) Levels of 
cardiac (Actn2, Tnnt2, Cx43) and pluripotency (Nanog) markers were analyzed by quantitative real time 
RT-PCR.  Markers were normalized to the GAPDH internal control gene.  TCPS condition levels are scaled 
to 1 to present fold induction.  Levels of Actn2 were higher on PEG-lam(5x) substrates (all RGD levels, 
green bars) than TCPS (all laminin levels, red bars) (*p <0.05 by t-test).  Nanog levels were decreased 
(*p<0.05 by t-test).  N = 9-18 wells.  Samples were pooled to increase the number of samples, with 
measurements for individual substrates presented as supplementary materials. No statistical differences or 
trends were found between any of the pooled conditions.  B) Expression levels of cardiac sub-type genes 
were normalized to sarcomeric α-actinin (Actn2) to exclude effects from non-cardiomyocytes.  Expression 
level of the atrial marker Mlc2a stays constant, while markers for cardiac nodal and conduction cell 
phenotypes (Hcn1, Hcn4, Tbx3, Cntn2) are generally downregulated on PEG-lam(5x) conditions when 
compared to TCPS-Mat(1x)  (the condition in Efe et al.).  TCPS+Mat(1x) (n=3) is normalized to 1 to 
present fold change of the PEG-lam(5x) conditions.  No statistical differences or trends were seen in PEG-
lam(5x) gels presenting 5x RGD (n=3) or no RGD (n=3), so the conditions were pooled for the purpose of 
statistical testing (n=6).  (*p<0.05 by Student’s t-test.) 
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seen in expression levels on TCPS with 1x or 5x laminin (supplementary Fig. S3.1).  Due 
to inherent high variability in qRT-PCR, data from similar conditions were pooled to 
increase sample numbers for statistical analysis.  Results for each surface are presented 
individually as supplementary materials (Fig. S3.1).  
Cells reprogrammed on PEG hydrogels presenting 5x laminin (with varied levels 
of RGD) had higher sarcomeric α-actinin (Actn2, 1.7-fold, p =0.03) levels than those 
reprogrammed on TCPS conditions (with varied levels of laminin) (Fig. 3.6 a).  Levels 
were also higher for cardiac troponin T (Tnnt2, 1.3-fold, p =0.08) and connexin 43 (Cx43, 
1.6-fold, p= 0.06), although these changes were not statistically significant.  Nanog 
expression was lower on 5x laminin PEG groups (with all levels of RGD) than on TCPS 
groups with all laminin concentrations (2.4-fold decrease, p= 0.0001), and the pooled 5x 
laminin PEG groups were ~700 fold lower than Nanog levels of RW.4 mouse embryonic 
stem cells.   
Cardiomyocyte-like cells resulting from direct reprogramming strategies have not 
been well characterized with regard to the cardiomyocyte subtype generated, however, 
the ability to generate different types of cardiomyocytes will likely have important 
therapeutic consequences.   We compared expression of atrial and conduction-enriched 
genes on PEG-lam(5x) (with and without 5x RGD) to the original condition described in 
Efe et al. (TCPS-Mat(1x)).  Markers for conduction and nodal cell phenotypes (Hcn1, 
Hcn4, Tbx3, and Cntn2) were normalized to α-actinin to take into the account the  
differences we see in reprogramming efficiency in these conditions (Fig. 3.6 b).  
Interestingly, expression of conduction and nodal genes was generally higher on the 
TCPS-Mat(1x) condition, suggesting that there may be subtle but important roles that the 
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microenvironment plays in the reprogramming processes to generate these different 
subtypes of cells.    
Immunocytochemistry was used to quantitatively compare cardiac marker 
sarcomeric α-actinin expression on PEG conditions.  Actinin/DAPI-positive pixel ratios 
for PEG hydrogels presenting 5x laminin with varied RGD concentration were double 
those presenting 1x laminin with varied RGD concentration (0.02 ± 0.01 versus 0.01 ± 
0.01, respectively. p <0.05 by t-test) (Fig. 3.7 a-c).  Data for individual conditions can be 
found in supplementary Fig. S3.2.  
                                               
 
Figure 3.7: Immunocytochemical comparison of cardiac marker expression on PEG conditions with 1x 
versus 5x laminin.  Wells were stained for the cardiomyocyte marker sarcomeric α-actinin, with DAPI 
as a nuclear counterstain.  A) The number of α-actinin positive pixels was normalized to the number of 
DAPI positive pixels for each well.  PEG conditions presenting laminin at 5x had a higher α-
actinin/DAPI ratio than conditions presenting laminin at 1x (*p<0.05 by t-test). (B and C) sample 
images from the quantitative analysis performed in (A). Samples were pooled to increase the number of 
samples, with measurements for individual substrates presented as supplementary materials.  
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Reprogramming efficiency was measured by flow cytometry for sarcomeric α-
actinin (Fig. 3.8 a).  No significant differences were found between any of the PEG-
lam(5x) groups, though averages for groups containing RGD were slightly higher.  The 
percentage of sarcomeric α-actinin-positive cells was 1.72-fold higher on PEG-lam(5x)-
RGD(1x or 5x) compared to TCPS-Mat(1x) (Fig. 3.8 b, 6.35 ± 0.69% versus 3.70 ± 
1.03%, p<0.05 against TCPS-Mat(1x) by ANOVA with post-hoc Tukey HSD test).  
 
 
Figure 3.8: Quantification of α-actinin expression by flow cytometry.  PEG-lam(5x) gels with RGD 
promoted higher efficiency reprogramming.  A) Histograms for fluorescence intensity of sarcomeric 
α-actinin IgG negative controls (black) versus stained cells (grey) demonstrated well-separated peaks 
between stained cells and the negative control.  At least 10,000 events are presented per condition. B) 
The average percentage of α-actinin positive cardiomyocytes in PEG-lam(5x) gels containing RGD 
was ~1.72-fold higher than the condition originally described in Efe et al. (*p<0.05 against TCPS-
Mat(1x) condition by ANOVA with post-hoc Tukey-HSD). C) Combined with the proliferation data, 
the increased efficiency gave greater numbers of cardiomyocyte on PEG-lam(5x) gels containing 
RGD than PEG-lam(5x) gels without RGD or TCPS-Mat(1x) controls (*p<0.05 by ANOVA with post-
hoc Tukey HSD).  
 
 70 
Coupled with the late-stage cell density data (Fig. 3.4 a), the PEG-lam(5x) conditions 
containing RGD yielded 7.73 ± 0.78 cardiomyocyte-like cells per originally seeded MEF, 
which is ~2-fold higher than TCPS-Mat(1x) and ~1.5-fold higher than PEG-lam(5x) 
without RGD (Fig. 3.8 c, p<0.05 against both conditions by ANOVA with post-hoc 
Tukey HSD).  
 
3.5 Discussion 
 
In this study, we demonstrated that the efficiency of direct reprogramming to 
cardiomyocyte-like cells can be nearly doubled by using custom-tailored PEG culture 
substrates.  By using protein-resistant PEG, we were able to specifically probe the effects 
of covalently bound ligands on direct reprogramming without the confounding effects of 
adsorbed serum proteins.  Ultimately, this led to the development of a culture surface that 
produced about twice as many cardiomyocyte-like cells as the originally described 
substrate.  This type of precise control over microenvironment definition is a promising 
frontier in the field of undifferentiated PSC expansion (274).  Global gene expression 
analyses have also allowed researchers to specifically tailor media to meet the needs of 
pluripotent stem cells (251, 252), and this strategy should have a similar impact on the 
design of materials to control cell microevironment.  To date, many laboratories still use 
Matrigel to trigger integrin signaling pathways and define the cell microenvironment.  
Replacement of Matrigel with synthetic surfaces (275, 276), biologically inspired 
peptides (277-279) or purified whole proteins has allowed or enhanced PSC expansion in 
multiple studies.  When ECM components are analyzed individually, laminin (100, 280), 
vitronectin (102), and E-cadherin (281) have shown to promote undifferentiated human 
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PSC expansion on TCPS, while fibronectin and collagen IV have been reported to cause 
their differentiation (100).  Interestingly, while the laminin-111 isoform (used in this 
study) allows undifferentiated expansion of human PSCs (280), it has also caused 
differentiation of mouse PSCs (282), suggesting differences in integrin 
expression/signaling/ligand interactions between species.   
While many groups are studying substrate designs for differentiating PSCs to 
cardiomyocytes, the cells of this protocol start as “pre-iPSCs”, which are phenotypically 
different from iPSCs (283).   The cardiac direct reprogramming literature has not yet 
examined the importance of ECM signaling, making comparisons between various 
protocols rather complicated.  As mentioned earlier, we began with the insight that Koche 
et al. (253) provided into pre-iPSC integrin expression 3 days after OSKM induction.  
Taking that study into account, we designed the PEG substrates to have a high 
concentration of laminin (without the collagen IV that is present in Matrigel).  However, 
laminin alone was not sufficient to support cell adhesion to PEG during the full 18 days 
of our protocol, possibly due to matrix metalloproteinase degradation.  Because RGD-
binding integrins were not strongly affected by OSKM induction (253), we incorporated 
RGD to promote long-term cell adhesion.  While the presence of RGD positively affected 
cell proliferation on PEG hydrogels, its effects on cardiac gene or protein expression 
were not significant. 
Recently, MacLellan and colleagues demonstrated that the timing of ECM protein 
presentation is important for cardiac maturation.  First, they performed an 
immunohistochemical analysis of developing mouse and human hearts.  This showed 
distinct ECM differences between stem cell niches (mostly collagen IV and laminin) and 
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the surrounding myocardium (mostly collagen I and fibronectin) into which the maturing 
cells migrate (124).   Using this information, they differentiated mouse ESCs on TCPS 
and found upregulation of Flk1 (a VEGF receptor but also a cardiac progenitor marker) 
and ultimately higher expression of the α-MHC (cardiomyocyte marker) on collagen IV 
and laminin coatings (as compared to collagen I or fibronectin).  By isolating Flk1+ 
progenitor cells and re-plating them onto new ECM protein coatings, they showed that 
fibronectin was better at promoting cell cardiomyocyte maturation than collagen IV or 
laminin.  Interestingly, Kamp and colleagues have demonstrated that cardiogenesis from 
iPSCs is robustly increased by providing “Matrigel overlays” at several timepoints during 
differentiation (284), further indicating the importance of timing in ECM presentation.  
We expect that by providing ECM proteins to match the timing of integrin expression 
during direct reprogramming, we could further improve cardiac cell differentiation 
efficiency.  
Hydrogel substrates allow manipulation of multiple variables beyond what was 
examined in this study.  In addition to ligand type and density, one could also study 
effects of hydrogel chemistry, nanotopography, degradation/remodeling, and elastic 
modulus.  Here, we compared effects of two substrates that differ drastically in stiffness.  
The storage modulus of this type of gel is ~7 kPa (200), which is similar to developing 
heart tissue (164) and has been shown to support embryonic cardiomyocytes (109) and 
ESC differentiation to cardiac progenitors (159) better than substrates of drastically 
different stiffnesses.   While the adhesion protein density dependence (seen only on PEG) 
confirmed that integrin-dependent pathways are in some part responsible for the 
improvement, it is possible that the heart-like elastic modulus also played a role.  Further 
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studies should be undertaken to examine the interplay of these two factors in greater 
detail.   
To compare our data to Efe et al., we terminated our studies at day 18.  However, 
many factors are known to affect the maturation of PSC-derived cardiomyocytes, 
including duration in culture (34) embryoid body size and culture condition (285, 286), 
and growth factor signaling (287).  Electrophysiological analysis and global gene 
expression analyses could be used to assess the maturity at timepoint and later time points 
(288).  Based on the aforementioned studies, we expect that the mechanical and integrin-
activation properties and could be adjusted to fine-tune specific cardiac phenotypes 
yielded by the protocol.  
Of the currently reported cardiac direct reprogramming strategies, we chose to 
work with the Efe et al. protocol for several reasons, many of which are also outlined in a 
recent review by Morris and Daley (74).  The ability to expand cells in culture is 
important for treating large myocardial injuries.  In the Ieda et al. method, cells are 
converted directly to non-proliferating cardiomyocytes.  In the Efe et al. protocol, the 
cells travel through a proliferative progenitor state, yielding greater numbers of 
cardiomyocytes (84).  Indeed, in this study we were able to double the number of 
cardiomyocytes produced, in part due to enhanced proliferation on the PEG-lam(5x) gels 
containing RGD.  The progenitors formed by this protocol may also have vascularization 
potential (84, 85).  Indeed, brief OSKM induction combined with VEGF stimulation has 
separately been shown to directly reprogram human pre-iPSCs to endothelial cells (289).  
Finally, the Efe et al. method reduces the time to beating (~2 weeks versus 4-5 weeks) 
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compared to the Ieda et al. method, which may be important clinically as the cardiac 
remodeling cascade starts immediately following infarction (86, 87).   
On the other hand, several groups have reported in vivo infarction scar 
reprogramming since their original in vitro paper (77, 80-82).  This feat has not yet been 
performed using the Efe et al. protocol, and it can be argued that teratoma risks are higher 
for the Efe protocol because the cells are more likely to revert to a pluripotent state.  
However, the OSKM induction in this protocol is transient, and further studies may allow 
development of methods that ameliorate the risk of teratoma formation (290).  In this 
study, we were able to reduce the already low Nanog expression 2.3-fold by using 
defined substrates.  This leads us to believe that it will ultimately be possible to prevent 
the formation of pluripotent cells.  However, it will also be important to demonstrate the 
effects of cell microenvironment on the efficiency of the Ieda protocol.  
Some groups have reported difficulties reproducing the Ieda et al. protocol (291), 
and to our knowledge no studies have yet been published using the Efe et al. protocol.  
Robust induction and proper stoichiometry of the reprogramming factors are highly 
important for achieving reprogramming using the Ieda et al. protocol (292) and 
presumably the Efe et al. protocol as well.  This can be difficult to achieve using viral 
induction methods.  The availability of mice carrying a doxycycline-inducible 
polycistronic OSKM cassette (263) eliminated variability between experiments, 
providing an excellent cell source for probing cell-material interactions in direct 
reprogramming.  While demonstration of direct reprogramming in human cells is more 
clinically relevant, the genetic homogeneity of cells from transgenic mice is a powerful 
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advantage, especially when differences in microenvironments may change a number of 
measures by less than two-fold. 
The original publication also reported ~40% cTnT-positive cells, which was an 
additional reason we initially selected this protocol over the others.  However, we found 
cells cultured on TCPS-Mat(1x) to be only ~4% α-actinin-positive.  This discrepancy 
may be attributed to one or several of the following: 1) temporal variations in the 
expression of cTnT versus α-actinin during reprogramming, 2) differences in the 
robustness of the cTnT antibody versus the α-actinin antibody, 3) subtle differences in 
culture protocols between laboratories, or 4) variations in flow cytometry analysis 
between laboratories.   
 The field of cellular reprogramming has progressed at lightning speed since the 
discovery of induced pluripotency in 2006 (28).  Unlike traditional PSC differentiation 
strategies, direct reprogramming has the potential to eliminate the need for in vitro cell 
expansion, differentiation, and cell transplantation.  Biomaterials that control the cellular 
microenvironment and eliminate confounding signals caused by adsorbed serum proteins 
have the potential to enhance our understanding of the requirements for both in vitro and 
in vivo direct reprogramming.   
 
3.6 Conclusions 
PEG culture substrates were designed to match integrin expression during the 
initial stages of OSKM-mediated direct reprogramming of fibroblasts to cardiomyocyte-
like cells.  Through a combination of increased reprogramming efficiency and increased 
proliferation, PEG hydrogels presenting high concentrations of laminin and RGD peptide 
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yielded twice as many cardiomyocyte-like cells as the originally reported substrate 
(Matrigel-coated TCPS).  RGD peptides enabled better cell adhesion, stimulated 
proliferation, and did not impede reprogramming.  The general methodology, using gene 
expression to guide materials design, may be applicable to a wide variety of 
reprogramming strategies.  
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3.8 Supplementary Tables and Figures  
 
 
Table S3.1:  Primer sequences.  Primer sequences used in the analysis of cardiac sub-types. 
   
                                       
Table S3.2: Substrate conditions table.  Surface densities and method of binding for adhesion 
molecules on various substrates.  *Matrigel and laminin-1 surface densities (1x) are based on 
approximate Matrigel surface protein concentration reported in Efe et al.  **RGD surface density (1x) 
based on the approximate RGD surface density of PEG hydrogel microspheres in Smith et al. 
 
 
 78 
 
 
 
 
 
 
 
 
 
 
Figure S3.1: Expanded gene expression data. Sarcomeric α-actinin (Actn2), Cardiac troponin T 
(Tnnt2), Connexin 43 (Cx43), and Nanog (Nanog) gene expression levels were were acquired by 
quantitative real-time RT-PCR and normalized to those of the internal control gene GAPDH.  *p<0.05 
by Tukey’s HSD test against the undifferentiated MEF control.  
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Figure S3.2: Immunocytochemical comparison of cardiac marker expression on PEG gels 
Wells were stained for cardiomyocyte marker sarcomeric α-actinin and DAPI as a nuclear 
counterstain.  The number of α-actinin positive pixels was normalized to the number of DAPI positive 
pixels for each well. *p<0.05 against PEG-RGD(1x) by Tukey’s HSD test. 
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CHAPTER 4 
 
Effects of 3D microenvironmental variables on 
direct reprogramming of mouse fibroblasts to 
cardiomyocyte-like cells 
 
4.1 Abstract 
 
 Direct reprogramming to cardiomyocytes, or conversion of somatic cells to 
cardiomyocytes without going through the pluripotent state, has so far only been 
investigated using two-dimensional culture substrates.  However, optimizing three-
dimensional culture protocols will bolster the scalability for clinical use.  In this study, 
we analyze the effects of materials, topography, diffusion, and remodeling on a 3D direct 
reprogramming protocol adapted from Efe, et al. (Nature Cell Biology, 2011, 13:215).  
Compared to 2D culture, cardiac gene expression (Actn2 and Tnnt2) was downregulated 
when cells were reprogrammed within 3D PEG microsphere scaffolds and 3D collagen 
scaffolds but was not statistically different for 3D collagen-PEG microsphere hybrid 
scaffolds.  Sarcomeric α-actinin expression was lowest within PEG microsphere scaffold 
interiors, suggesting that diffusion and remodeling restrictions may be at play.  Cardiac 
gene expression was also downregulated when cells were cultured on 2D layers of PEG 
microspheres as compared to flat 2D PEG surfaces, suggesting that the topography of the 
microspheres may be inhibiting efficient cardiac reprogramming.  These analyses provide 
the groundwork for designing 3D scaffolds to permit high efficiency direct 
reprogramming to cardiomyocytes, particularly with regards to substrate topography and 
cellular remodeling capacity.  
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4.2 Introduction 
Two-dimensional (2D) cell culture models have led to countless medical 
breakthroughs.  However, the clinical transition of autologous cell transplantation 
research will demand a scalability that 2D culture cannot easily provide.  For example, if 
all of the cells of the average human heart were to be cultured in 2D, it would require 
~3,5002 feet of culture area.  Three-dimensional (3D) culture techniques address 
scalability, but many differentiation protocols are still being optimized for 2D culture, 
including those related to the new and rapidly growing field of direct reprogramming to 
cardiomyocytes (75, 76, 82, 84).  Direct reprogramming is the process by which a fully 
differentiated cell (i.e. a skin fibroblast) can be converted to another cell type without 
entering a pluripotent state.  In this study, we focus on the protocol initially described by 
Efe et al., which is faster and more efficient than taking somatic cells through induced 
pluripotency before reaching cardiomyocytes (84).  Like other direct reprogramming 
protocols (75, 76, 82), it has only been optimized for 2D culture.   
Cells adhered to 3D materials exhibit dramatic differences compared to their 2D 
counterparts (119-123).  Adhesion-mediated processes begin at integrin receptors in focal 
adhesions, and are transmitted through the cell via mechanically-sensitive cytoskeletal 
networks (293-296).  DeSimone (297), Guilak and colleagues have recently provided 
thorough reviews on adhesion mediated processes, which are well known to affect cell 
division, apoptosis, migration, and differentiation.  Various groups have demonstrated the 
importance of substrate mechanical properties (108, 109, 159), substrate topography (101, 
107), and the shape of adhesive areas (110, 298, 299) on cytoskeletal morphology and 
cell behavior.  Recently, Schenke-Layland et al. investigated specific properties of the 
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natural cardiac stem cell niche, and designed culture substrates accordingly.  They found 
that differentiation of mouse embryonic stem cells (ESCs) to cardiac progenitors was 
enhanced in a 3D electrospun scaffold compared to routine, flat 2D culture (124). 
Differentiation to cardiac progenitors was further enhanced when the scaffolds were 
coated with type IV collagen and gelatin as opposed to gelatin alone.    
We have previously demonstrated that direct reprogramming efficiency can be 
increased using 2D poly(ethylene glycol) (PEG) substrates that present precise 
concentrations of adhesion molecules instead of 2D tissue culture polystyrene (TCPS) 
substrates (300).  Separately, we have also demonstrated that modular PEG microsphere-
based scaffolds enable HL-1 cells to retain certain aspects of their cardiomyocyte 
phenotype for long periods in culture (266).  In this study, we encapsulate cells in PEG 
microsphere scaffolds, collagen scaffolds, or collagen-PEG microsphere hybrid scaffolds, 
and compare the 3D materials in terms of direct reprogramming efficiency.  We also 
examine the effects of dimension (2D vs. 3D), diffusion into the 3D scaffold, and 
topography of the culture substrates using PEG materials. 
 
 
 
 
 
 
 
 
 83 
4.3 Materials and Methods: 
4.3.1 Cell culture and direct reprogramming   
The direct reprogramming protocol used to generate cardiomyocytes is adapted 
from Efe et al. (84).  Extended versions of this protocol, including validation with adult 
somatic cells, are published elsewhere (84, 266).  All experiments in this study used 
mouse embryonic fibroblasts (MEFs) homozygous for doxycycline-inducible Yamanaka 
factors (Oct4, Sox2, Klf4 and c-Myc) (28, 263).  Animal protocols were approved by 
Washington University Institutional Animal Care Use Committee.  A schematic of the 
culture timeline is shown in Fig. 4.1.  MEFs were plated onto 2-dimensional substrates 
(3,600/cm2) or seeded into 3-dimensional scaffolds one day prior to beginning the 
 
         
 
Figure 4.1: Direct reprogramming media and supplements timeline. The direct reprogramming 
protocol was adapted from Efe et al.  (and verified in Smith et al.).  Six days of dox-induced OSKM 
were coupled with pluripotency inhibition by Jak-Stat Inhibitor (JI1) in high serum medium.  This 
was followed by three days of recovery in low serum medium also containing JI1, and then six days of 
induction of cardiomyocyte differentiation in chemically defined (no serum) medium containing bone 
morphogenetic protein 4 (BMP4).  Abbreviations: Fibroblast (FB) medium, Knockout (KO) medium, 
Chemically Defined (CD) medium, ES-qualified fetal bovine serum (FBS). 
 
 84 
protocol (day -1).  Seeding densities were 10 million/mL for PEG scaffolds (unless 
otherwise noted) and 1 million/mL for collagen-containing scaffolds (lowered to account 
for cell density increases upon collagen gel compaction (301)).  Reprogramming 
commenced the following day (day 0), and media was changed every 24-48 hours.  From 
days 0-5, cells received knockout DMEM (KO DMEM, 10829018) + 2 µg/mL 
doxycycline (made fresh for each experiment, Sigma, D9891) + 0.5 µM JAK inhibitor I 
(JI1, EMD, 420099) + 15% embryonic stem cell qualified FBS (ES-FBS, 10439-024) + 
5% knockout serum replacement (KSR, 10828028) + 0.1 mM β-mercaptoethanol (21985-
023), + 1% Glutamax (35050-061) + 1% non-essential amino acids (11140-050) + 1% 
embryonic stem cell qualified nucleosides (Millipore, ES-008-D).  For days 6-8, 
doxycycline was removed, ES-FBS concentration reduced to 1%, and KSR concentration 
increased to 14% (all other components remained the same).  From days 9-14, cells were 
given chemically defined medium (CDM) with BMP4:  RMPI-1640 (21870-084) + 20 
ng/mL BMP4 (Stemgent, 03-0007) + 0.5x N2 (17502-048) + 1x B27 w/o vitamin A 
(12587-010) + 0.05% BSA fraction V (15260-037) + 0.5% Glutamax + 0.1 mM β-
mercaptoethanol.  From day 15 onward, cells were given CDM without BMP4.  Cells in 
scaffolds received 3 mL of media/day, while 2D cultures were given 1 mL/well.  RW.4 
mouse embryonic stem cells (ATCC), a gift from the Sakiyama-Elbert laboratory, were 
cultured according to previously described methods (267). 
 
4.3.2 Materials  
For 2D control conditions, experiments were performed in 24-well plates.  For 
PEG substrates, plates were first treated with a plasma cleaner (Harrick Plasma) set to 
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medium (350 mTorr for 5 min) to reduce meniscus formation in the wells during gel 
formation.  Plates were then UV-sterilized for 30 min and gel precursor solutions were 
added immediately.  PEG derivatives were synthesized as previously described (213, 214, 
264).  For gel fabrication, PEG8-Vs and PEG8-Am solutions (both 20% w/v in PBS, pH 
7.4) were sterile-filtered (0.22 µm filter) and diluted in 0.03 M NaOH in PBS (pH 8.75; 
NaOH enhanced reaction kinetics and further reduced meniscus formation) for a final 
PEG concentration of 12.43% (w/v).  The precursor mix was aliquoted at 200 µL/well 
and allowed to crosslink in a humidified incubator (37ºC) for 1-2 days.   
On 2D surfaces, protein and peptide surface concentrations are given as 1x or 5x 
as previously reported (300).  When referring to Matrigel (BD Biosciences, 356234) or 
laminin-1 (Sigma, L2020), 1x is the approximate protein concentration of Matrigel used 
in Efe et al. (11.4 µg/cm2).  The 1x concentration of laminin was also set to 11.4 µg/cm2.  
When referring to the RGD peptide, 1x (354 µg/cm2) was empirically determined to 
promote robust cell adhesion and reprogramming on 2D substrates (300).  For 
functionalization with Matrigel or laminin-1, protein stocks were first diluted to 108.3 
(1x) or 541.5 µg/mL (5x) in PBS.  If RGD peptide (GCGYGRGDSPG, Genscript) was 
included, it was diluted in the same tube as the protein at 3.36 (1x) or 16.82 (5x) mg/mL.  
Each well received 200 µL of protein/peptide solution.  The pre-formed PEG hydrogels 
were incubated with the protein/peptide mixtures overnight at 37ºC to permit the covalent 
Michael-type reaction to occur.  For TCPS conditions, (non-plasma treated) 24-well 
plates were incubated at room temperature for 1 h to permit protein adsorption (according 
to Matrigel product literature). 
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Microspheres were fabricated as previously described (199, 200, 266).  Briefly, 
20% (w/v) PEG8-VS and PEG8-Am were mixed (either 2:1 or 1:1 PEG8-Vs:PEG8-Am) 
and pre-reacted for 70% of the total gel time needed to reach gel point.  RGD (1 or 5 mM, 
sequence GCGYGRGDSPG, Genscript) was added to the prereacted solution and reacted 
at 37ºC for an additional 30 min.  The pre-reacted solution was diluted to a final 
concentration of 2% PEG and ~0.5 M Na2SO4 and brought to 37ºC to induce phase 
separation.  The Na2SO4 concentration needed to achieve cloud point is sensitive to 
fluctuations in pH, temperature, Na2SO4 and PEG stock concentrations (199), and should 
be empirically verified any time a new stock solution is introduced.  PEG was reacted in 
the phase-separated state for 45 min (for 1:1 OVs:OAm microspheres) or 55 min (for 2:1 
OVs:OAm) to form microspheres, Na2SO4 solution was replaced with PBS via 
centrifugation (14,000 RCF for 2 min), and microspheres were washed once more then 
resuspended in PBS.  Post-swelling microsphere diameters were 10.2 µm for 1:1 
OVs:OAm and 20.1 µm for 2:1 OVs:OAm.  Microsphere volumes were determined by 
measuring the total volume of solution after the addition of 500 µL of PBS.   
For reaction of adhesion proteins to remaining OVs groups on microsphere 
surfaces, microspheres were incubated overnight at 37ºC on a slow, horizontal rocker 
with laminin in PBS at a 2:5 microsphere:laminin solution volume ratio.  The 
concentration of laminin reacted to the microspheres was adjusted to approximate the 
equivalent protein spacing as the cells experienced in 2D:  [𝑙𝑎𝑚]!! =    [𝑙𝑎𝑚]!! ! 
So 1x (11.4 µg/cm2) in 2D becomes 38.5 µg/mL microspheres in 3D.  To fluorescently 
label microspheres, 1 µL of Dylight-633 NHS Ester (10 mg/mL, Thermo Scientific, 
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46414) was added per microliter of pre-formed 2:1 OVs:OAm microspheres.   To create 
2D microsphere layers on TCPS, 20 µL of pre-functionalized microspheres in PBS were 
suspended per well of a 24 well plate, and centrifuged at 300 RCF for 15 min.  
Microspheres remained adhered to the plate by electrostatic interactions throughout the 
18 day protocol, forming a continuous layer upon which cells could be cultured.   
 Encapsulation of cells during the crosslinking of PEG microsphere scaffolds has 
also been described elsewhere (266).  Pelleted MEFs were resuspended in 50 µL of 
warmed 20% dextran (Mr = 100,000, Sigma Aldrich, 09184) in DMEM, and this solution 
was used to resuspend a microsphere pellet of equal volume (50 µL) in a 1.5 mL 
Eppendorf tube.  The tube was centrifuged (500g for 3 min) to promote separation of the 
PEG and the dextran, and incubated at 37ºC for 1 hr to allow microsphere-to-microsphere 
crosslinking around the MEFs.  Cylindrical, crosslinked scaffolds (~5.9 µm in diameter, 
1.8 µm in height) were then transferred to 35 mm diameter non-tissue culture treated 
plastic petri dishes and routine cell culture techniques commenced (3 mL media/day).  
 For collagen-based scaffolds, 60 µL of collagen (5 mg/mL, Cultrex Rat Tail 
Tendon Collagen I, R&D Systems, 3447-020-01) was diluted on ice in 73.6 µL sterile 
double distilled water, 15 µL of 10X concentrated DMEM, and 1.4 µL of 0.34 M NaOH.  
Pelleted MEFs were quickly resuspended in 50 µL of serum free DMEM and added to 
the collagen mixture for a final collagen concentration of 1.5 mg/mL.  For collagen-PEG 
hybrid gels, 20 µL of pre-functionalized microspheres were added with the cells.  
Collagen was then carefully pipetted onto a 35 mm non-tissue culture treated plastic petri 
dishes.  After crosslinking at 37ºC for 1 hr, gels were carefully detached from the surface 
and routine cell culture techniques commenced (3 mL media/day).  
 88 
 
4.3.3 Quantification of gene expression   
Gene expression was evaluated by quantitative real time RT-PCR using an 
Applied Biosystems StepOnePlus machine.  On day 18 of reprogramming, cellular RNA 
(n=6 samples per condition) from 2D samples was purified with TRIzol reagent 
(Invitrogen, 15596-026) by following the manufacturer’s instructions.  For 3D samples, 
each scaffold was homogenized (Tissue Miser, Fisher Scientific) on ice in a 50 mL 
centrifuge tube containing 2.6 mL of ice cold TRIzol and 137 µL of glycogen (5 mg/mL, 
Invitrogen, AM9510) for 1 min.  The suspension was divided into two 1.5 mL Eppendorf 
tubes and centrifuged at 4ºC for 2 min at 12,000 RCF to remove solid material.  The 
supernatant was transferred to two new 1.5 mL Eppendorf tubes, and routine TRIzol 
extraction methods ensued.  The final RNA pellet was resuspended in 12 µL of 1 mM 
sodium citrate buffer (pH 6.4, Invitrogen, AM7000).  RNA concentration and quality 
(260/280 nm absorbance ratio) were verified using a NanoDrop 2000 or Implen 
Nanophotometer P-Class.  Genomic DNA was removed and RNA was reverse 
transcribed to cDNA (10 ng RNA/µL) using the QuantiTect Reverse Transcription Kit 
(Qiagen, 205313).  Pre-validated primers for mouse GAPDH (Gapdh), sarcomeric α-
actinin (Actn2), cardiac troponin T (Tnnt2), connexin 43 (Cx43), Nanog (Nanog), and 
CD31 (Cd31) transcripts were obtained from Qiagen (Quantitect Primer Assay).  cDNA 
was amplified in triplicate reactions using Quantitect SYBR Green PCR Kit (Qiagen) 
following manufacturer’s instructions.  Expression levels were normalized to GAPDH 
and then to the 2D PEG control condition by the 2!∆∆!! method (268).   
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4.3.4 Scaffold remodeling assay   
Images of scaffolds were taken by brightfield microscopy (2x objective, IX70, 
Olympus) using a Magnafire camera (Optronics).  For scaffolds larger than the field of 
view, multiple images were stitched using Adobe Photoshop.  Scaffold diameters were 
measured using ImageJ (National Institutes of Health) (4 equally spaced diameters were 
averaged for each scaffold).  Average diameters for each day were then normalized to the 
diameter from the day of seeding.   
 
4.3.5 Immunofluorescence and image processing   
Sarcomeric α-actinin expression within reprogrammed scaffolds was analyzed by 
quantitative immunofluorescence.  Day 18 scaffolds were fixed in 3.7% formaldehyde for 
45 min at room temperature, treated with 30% sucrose solution for 3.5 h at room 
temperature for cryoprotection, then frozen in OCT (Tissue-Tek®, Sakura) at -80º C for 
30 min (or more for storage).  Scaffolds were cryostat sectioned with careful attention to 
depth of sectioning.  After sectioning, slides were blocked for 30 min at room 
temperature using 10% normal goat serum/1% bovine serum albumin in PBS (also 
containing 0.1% Triton-X 100 for permeabilization).  Sarcomeric α-actinin primary 
antibody (mouse IgG, Sigma A7811) was diluted 1:1600 in the blocking solution and 
applied to the slides overnight at 4ºC.  Slides were washed 3x in PBS (5 min each) before 
incubation in secondary antibody diluted 1:1000 in blocking solution (1 h at room 
temperature, Alexa Fluor 594 goat anti-mouse, Invitrogen, A-11005).  Slides were 
washed 3x in PBS before application of DAPI as a nuclear counterstain (100 ng/mL, 30 
min at room temperature).  Slides were washed once more and coverslips were applied. 
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For quantification of sarcomeric α-actinin expression, images were acquired by 
fluorescence microscopy (IX70, Olympus) using a Magnafire camera (Optronics).  Each 
section was imaged in its entirety using a 10x objective.  Images were analyzed in Matlab, 
with the number of α-actinin positive pixels normalized to the number of DAPI positive 
pixels for each image to create an α-actinin-DAPI ratio.  Ratios were then averaged with 
respect to condition or depth within the scaffold.  For the cell density analysis, at least 20 
images were averaged per scaffold.  For the depth analysis, at least 6 images were 
averaged per depth region, per scaffold.  
 
4.3.6 Statistics   
Two-condition comparisons were made using student’s t-test, whereas multiple 
comparisons were made using ANOVA with post-hoc Tukey HSD.  Data are presented as 
mean ± standard error of the mean.  
 
 
4.4 Results 
4.4.1 Effects of dimension and 3D scaffold material on gene expression 
of directly reprogrammed cells   
To assess the effects of dimension and 3D scaffold material on the phenotype of 
reprogrammed cells, we tested three 3D conditions and normalized gene expression to 
cells cultured on 2D PEG-lam(5x)-RGD(5x) substrates (300).  Microspheres used in 
scaffolds within this experiment were also PEG-lam(5x)-RGD(5x) (2:1 OVs:OAm).  
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Cardiac troponin T (Tnnt2) and sarcomeric α-actinin (Actn2) are well-established 
cardiomyocyte markers, while connexin 43 (Cx43) is a gap junction protein that is 
present in ventricular cardiomyocytes and many other cell types (including ESCs (302)).  
Nanog (Nanog) is a pluripotent cell marker, which is minimally expressed by cells 
directly reprogrammed on 2D PEG-lam(5x)substrates (~700-fold lower than RW.4 
      
 
Figure 4.2: Effects of dimension and 3D scaffold material on gene expression. Expression of cardiac 
markers Actn2, Tnnt2, and Cx43, pluripotency marker Nanog, and endothelial cell marker Cd31 was 
assessed for various 3D materials (100% PEG- green columns, collagen/PEG hybrid- red columns, 
100% collagen I- blue columns) and normalized to levels from 2D PEG culture substrates (with 
laminin and 5 mM RGD) by the 2-ΔΔCt method.  PEG microspheres used in 3D materials were also 
functionalized with laminin and 5 mM RGD.  Gene expression was compared using a nonparametric 
Kruskal-Wallis test with post-hoc Tukey HSD.  The collagen/PEG hybrid material presented no 
statistical differences for any gene compared to the 2D control.  However, expression of cardiac 
markers Actn2 and Tnnt2 was downregulated for the 3D 100% PEG microsphere and 100% collagen 
I scaffold conditions (*p<0.05).  Cx43 expression was slightly upregulated for all conditions, 
possibly due to the presence of other cell types (#p<0.05 between 100% PEG-microsphere and 100% 
collagen I).  Nanog expression was not significantly different for any of the tested conditions.  Cd31 
expression was downregulated in the 100% PEG microsphere scaffolds compared to the 2D control 
(*p<0.05), but changes in the collagen and collagen/PEG hybrid were not significant.  
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mouse ESCs (300)).  Since the originally described protocol reported a progenitor that 
may have potential to form vascular cell types as well as cardiomyocytes (84), we also 
looked at the endothelial cell marker CD31 (Cd31).  
Compared to the 2D PEG control, cardiac markers Actn2 and Tnnt2 were 
downregulated for the 100% PEG-microsphere and 100% collagen 3D scaffold 
conditions (Fig. 6).  Cardiac gene expression from the 3D PEG/collagen hybrid scaffold 
did not differ statistically from the 2D control (though a 9.3-fold decrease in the mean 
was observed).  Cx43 levels were slightly higher in 3D materials than in 2D, but this was 
not statistically significant.  Cx43 upregulation in conjunction of downregulation of the 
more specific cardiac genes may reflect reprogramming into other cell types (for example, 
Cx43 is also expressed in ESCs (302)).  For all 3D materials, Nanog expression remained 
similar to the 2D control.  Cd31 was significantly downregulated for 100% PEG 
microsphere scaffolds but not for the 100% collagen or the collagen/PEG hybrid scaffold, 
suggesting these materials may be better suited for endothelial cell differentiation or 
certain hematopoietically derived cell types (neutrophils, platelets, monocytes, and some 
T-cells) that also express Cd31 (303). 
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4.4.2 Effects of cellular remodeling on 3D direct reprogramming to 
cardiomyocytes 
In two dimensions, reprogramming cells begin to form clusters around day 10, 
and many of these begin beating by day 18.  These clusters are often macroscopically 
visible, and can grow to be several millimeters wide (Fig. 4.3 a, (84, 300)).  In 3D culture, 
 
                                     
Figure 4.3: Morphology of reprogrammed cells at scaffold surfaces compared to cells embedded 
within microspheres.  Scaffolds were fixed at day 18, sectioned, and stained for sarcomeric α-actinin.  
A) On 2D substrates, reprogrammed cells form large clusters that may be several millimeters wide 
and sometimes beat spontaneously.  B) Densely packed, large, beating clusters were occasionally 
seen on the surfaces of scaffolds.  Sarcomeric α-actinin within these surface clusters had a striated 
appearance, indicating a mature contractile apparatus (white arrow in magnified inset).  C) The 
largest cluster of α-actinin positive cells embedded within microspheres at a depth greater than 100 
µm.  α-actinin positive clusters within microspheres were rare and smallerthan those on the surface.  
Most often, α-actinin positive cells occurred in groups of 1-3 cells if embedded within microspheres.   
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beating clusters were occasionally observed at scaffold edges, and these stained positive 
for large areas of striated sarcomeric α-actinin (Fig. 4.3 b).  However, at greater depths, 
α-actinin positive cells almost always appeared in small groups of 1-3 cells (not shown).  
The largest α-actinin positive cluster observed surrounded by microspheres was ~100 µm 
wide (Fig. 4.3 c), but this was unusual and very small compared to beating clusters seen 
on 2D substrates.  The decrease in reprogramming efficiency seen in the PEG materials 
may be partially attributed to the inability to form large clusters, as is seen in studies on 
embryoid bodies (285, 304-307).  This would impact paracrine signaling and possibly 
interfere with reprogramming. 
Cells release matrix metalloproteinases (MMPs) that cleave and remodel collagen 
 
            
 
Figure 4.4:  Cellular remodeling of 3D scaffolds.  Decreasing scaffold diameter indicates ECM 
cleavage and remodeling.  Scaffolds were fabricated 1 day prior to initiating reprogramming and 
their diameters were measured over the first 5 reprogramming days.  Diameters were normalized 
to their diameter at day 0.  All groups decreased in diameter, with collagen-containing scaffolds 
decreasing to a greater extent than 100% PEG microsphere scaffolds (*p<0.05 by ANOVA with 
post-hoc Tukey HSD).  This indicates that cells are better able to remodel the collagen materials 
than the PEG microspheres.   
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gels, causing a decrease in the scaffold size over time (301, 308, 309).  To highlight the 
differences in how reprogramming cells may react with scaffold materials, we took 
scaffold diameter measurements during the early stage of direct reprogramming (Fig. 4.4).  
Microspheres used in this experiment were PEG-lam(5x)-RGD(5x) (2:1 OVs:OAm).  All 
scaffolds showed decreases in diameter, but the collagen-based scaffolds shrank much 
more than PEG microsphere scaffolds.  This could be due in part to the greater 
susceptibility to MMP cleavage (p<0.05 by ANOVA with post-hoc Tukey HSD test at 
every day following seeding).  
PEG microsphere morphology was retained throughout reprogramming in 100% 
PEG scaffolds, but few sphere-like PEG structures were found in collagen-PEG hybrid 
scaffolds after 18 days of reprogramming (Fig. 4.5).  In Fig. 4.5, PEG in collagen-hybrid 
scaffolds was fluorescently labeled (red), whereas the PEG microspheres in 100% 
microsphere scaffolds were visible by phase microscopy. In the collagen/PEG hybrid 
scaffold, embedding PEG microspheres in the collagen gel enables a reaction between 
free PEG-VS groups and the surrounding collagen fibrils, such that the PEG microsphere 
becomes part of the polymer network.  The cells, which use focal adhesions to reshape 
the collagen, are also pulling on the collagen-linked PEG.  In the 100% PEG microsphere 
scaffolds, cells interact only with laminin or RGD-functionalized VS groups, which 
likely provides far fewer focal adhesions than the collagen/PEG hybrid scaffold.  This 
may explain why the 100% PEG microsphere scaffolds decrease to a lesser extent than 
the collagen based materials.  In addition to differences in the chemical structure of the 
scaffold materials, the differences in cellular interactions with the materials may help to 
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explain the trend towards more efficient cardiac reprogramming seen in the in collagen-
based scaffolds (Fig. 4.2).   
 
4.4.3 Effects of cell density and cell depth on 3D direct reprogramming 
to cardiomyocytes 
To assess the possible effects of nutrient diffusion and cell density within the 
 
 
 
Figure 4.5: Morphology of PEG in scaffolds with or without collagen after 18 days of reprogramming.  
Collagen-PEG hybrid scaffolds were fabricated with fluorescent PEG microspheres (red, left side).  
Microspheres in 100% PEG scaffolds (right side) were not fluorescent, but are clearly visible by phase 
contrast.  Scaffolds were fixed on day 18, sectioned and imaged by either fluorescence or phase 
microscopy.  By day 18, the PEG in collagen-PEG hybrid scaffolds no longer resembled microspheres, 
indicating that it had been remodeled by cells.  Microspheres were still clearly defined in 100% PEG 
scaffold (lower right, white arrows).   
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scaffold, we assessed sarcomeric α-actinin expression by immunohistochemistry at 
various depths from the surface of PEG-RGD(1x) microsphere scaffolds (1:1 OVs:OAm).   
Scaffolds were seeded at either 5 million (low density) or 25 million (high 
density) MEFs/mL.  The seeding density had an inverse effect on reprogramming 
efficiency, with α-actinin:DAPI ratios for low cell density scaffolds 18.7-fold higher than 
high cell density scaffolds (p<0.05 by t-test) (Fig. 4.6 a).  Similar results have been noted 
in iPSC derivation from MEFs using the inducible transgene system (310), and may 
reflect: 1) differences in paracrine signaling intensity, or 2) nutrient depletion at high cell 
densities.  The effect of depth into the scaffold was less pronounced, but a decreasing 
trend in reprogramming efficiency was noted as depth increased (Fig. 4.6 b).  When 
depths were normalized to the outermost region, the innermost region had a 1.62 fold 
decrease in the α-actinin/DAPI ratio as compared to the outermost region (Fig. 4.6 c) 
(p<0.05 by t-test).  This could be attributed to multiple effects: 1) limitations in cluster 
size as mentioned above, or 2) lowered diffusion of nutrients.  
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Figure 4.6: Effects of cell density and cell depth on direct reprogramming.  A quantitative 
immunohistochemical analysis of sarcomeric α-actinin expression was performed to analyze 
expression at various depths within PEG microsphere scaffolds initially seeded at two different cell 
densities (5 million/mL- light green columns and 25 million/mL- dark green columns).  Scaffolds were 
fixed on day 18, sectioned and stained for the α-actinin and DAPI.  Fluorescent images were 
analyzed in Matlab, with the number of α-actinin positive pixels normalized to the number of DAPI 
positive pixels for each image.  A) Cell seeding density was inversely related to reprogramming 
efficiency (*p<0.05 by t-test), with a 5-fold increase in cell density resulting in an 18.7-fold decrease 
in α-actinin/DAPI ratio (n=3, >20 images analyzed per condition).  B) Reprogramming was 
generally higher in the outer regions of the scaffold, though no statistical differences were seen (n = 
2-3, >6 images analyzed per condition).  C)  Data from scaffolds of both cell densities were 
combined and the 151-300 and 301-450 depths were normalized to the outermost region to present 
the fold decrease in α-actinin/DAPI ratio.  The ratio of the innermost region was 1.62-fold lower 
than the outermost region (*p<0.05 by t-test, n = 4-5, >12 images analyzed per condition).   
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4.4.4 Effects of substrate topography on direct reprogramming to 
cardiomyocytes  
 To investigate the effects of substrate topography while eliminating the variable 
of diffusion, we reprogrammed cells on a 2D layer of PEG-Mat(1x)-RGD(1x) 
microspheres (1:1 OVs:OAm), and normalized their gene expression to flat 2D PEG-
lam(1x).  In our previous study, reprogramming efficiency remained similar between 
these adhesion molecules at these concentrations (300), so we expect any changes to be 
more influenced by the variation in topography.  Changes in mechanical stiffness of the 
culture substrate can have dramatic effects on cellular phenotype (108, 109).  The flat, 
hydrated PEG gel is estimated to be 1.1 millimeters thick, while the microspheres are 
about 10.2 ± 0.2 µm thick (~100-fold thinner).  Therefore, the relative stiffness 
experienced by the cells is likely much higher on the microsphere layer (closer to that of 
the TCPS substrate underneath).  To demonstrate that variations from the flat PEG 
surface are not solely attributed to these mechanical differences, we also have included 
the gene expression data for TCPS-lam(1x).  Culture on the PEG-microsphere layer 
caused dramatic decreases in Actn2 (21.2 ± 11.2-fold), Tnnt2 (5.0 ± 2.4-fold), and Cd31 
(27.0 ± 4.4-fold) expression as compared to the 2D PEG gel surface (p<0.05 by t-test) 
(Fig. 4.7).  These changes were more pronounced than variations between PEG-lam(1x) 
and TCPS-lam(1x), indicating that they were not solely attributable to mechanical 
variation.  This finding also suggests that, in addition to diffusion limitations, the 
microsphere topography is not optimal for direct reprogramming to the cardiomyocyte 
phenotype as markers were downregulated despite unrestricted access to the media.  
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Figure 4.7:  Effects of 2D PEG topography on gene expression of directly reprogrammed cells.  In 
order to analyze responses to microsphere topography without the confounding effects of diffusion 
limitations seen in 3D, cells were reprogrammed on a thin layer of PEG microspheres at the bottom 
of a 2D well, and expression levels were normalized to a flat 2D PEG gel control condition.  Cells on 
the thin layer of microspheres experience higher stiffness than those on the thicker flat PEG gel due 
to closer proximity to the TCPS surface underneath (~100 fold difference in gel thickness).  Because 
of this, expression levels from TCPS were also included to help delineate effects of topography and 
mechanical properties.  Expression of cardiac markers Actn2 and Tnnt2 were downregulated on the 
microsphere layer as compared to the 2D PEG gel (*p<0.05 compared to the 2D PEG control by t-
test).  Nanog was upregulated (*p<0.05), but still low in comparison to RW.4 mouse embryonic stem 
cells (not shown).  Cd31 was also downregulated on the microsphere layer, indicating that the 
topography may be disruptive for formation of endothelial cells.  Regulation patterns between the 
microsphere layer and the TCPS substrate varied (#p<0.05 for 2D microsphere layer versus TCPS), 
suggesting that expression differences between the thin layer of microspheres and the thick flat PEG 
gel cannot be solely attributed to mechanical differences. 
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4.5 Discussion 
The role of the microenvironment on embryonic cells has been under 
investigation for nearly a century, when their orientation along a fiber was first described 
(4).  Since then, we have become increasingly aware of the roles of cellular remodeling, 
diffusion, intercellular contacts, topography, and mechanical properties in embryonic 
development and stem cell differentiation protocols.  Differentiating cells in 3D culture is 
an increasingly important goal for the field of regenerative medicine, as cell 
transplantation techniques will require vastly higher numbers of cells than 2D culture can 
practically provide.   
The improved scalability of 3D culture systems can be leveraged to meet this 
demand.  For example, in this study we cultured 200,000 cells in one collagen-based 
scaffold, using 3 mL of media per day.  Culturing the equivalent number of cells in 2D 
required 28 mL/day (~10 times as many cells in 3D versus 2D per mL of media).  While 
our initial studies show a modest decrease in cardiac gene expression in 3D for the 
collagen-based scaffolds (Fig. 4.2), the 3D culture may still yield more cardiomyocytes 
per mL of media.  Furthermore, various modifications to the material could foreseeably 
improve efficiency, and they will be discussed herein.  A review of the current cardiac 
direct reprogramming literature is beyond the scope of this discussion, but can be found 
elsewhere (300).   
 Our study highlights differences in ECM remodeling between collagen-based and 
100% PEG-microsphere scaffolds.  Collagen allows the cells to arrange their 
microenvironment, as demonstrated by the scaffold size changes (Fig. 4.4) and the 
differences in the day 18 PEG morphology when microspheres were embedded in 
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collagen versus part of a 100% microsphere scaffold (Fig. 4.5).  Other studies have also 
highlighted the importance of remodeling in 3D environments.  Recently, our 
collaborators showed greater PC12 cell aggregation in collagen-PEG microsphere hybrid 
scaffolds compared to 100% PEG microsphere scaffolds (311).  The Seliktar group has 
studied neonatal rat cardiomyocytes cultured in PEG-fibrinogen hybrid materials and 
found that increasing the ratio of PEG to fibrinogen limited cellular remodeling (312) and 
resulted in a decrease in beating scaffolds (313).  Similarly, the Hubbell group has found 
that inhibiting remodeling activity within a bulk PEG hydrogel caused P19 cells 
undergoing cardiac differentiation to stall at a progenitor state, whereas their uninhibited 
counterparts expressed markers of fully mature cardiomyocytes (159).  It is therefore 
likely that remodeling constrictions within our 100% PEG microsphere scaffolds were 
partially responsible for the dramatic downregulation of cardiac gene expression 
compared to 2D surfaces.   
 Though they rarely exhibit a pluripotent phenotype (84), reprogramming cells on 
2D surfaces form large clusters that morphologically resemble embryoid bodies (EBs).  
These clusters are macroscopically visible and can sometimes be several millimeters 
wide (Fig. 4.3 a).  Several groups have demonstrated profound effects of EB size on 
cardiac differentiation efficiency (304-307).  In 1987, Smith et al. noted that cardiac 
differentiation from P19 embryonic carcinoma cells was dependent on the initial size of 
the cell aggregates.  They suggested a relationship between paracrine signals from an 
endodermal layer on the aggregate surface and ultimate cardiac differentiation efficiency 
(304).  More recently, the Zandstra group has also noted that the optimal EB size for 
cardiac differentiation is 400 µm (as compared to 200 or 800) (285, 305).  They 
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confirmed the relationship between cardiac differentiation and the endodermal surface 
layer, linking EB size to the relative strength of paracrine signaling (314).  Taking these 
studies into account, it is possible that the relatively small pore size in our 100% PEG 
microsphere scaffolds (266) inhibited the large cluster formation seen in 2D and 
interfered with cardiac direct reprogramming processes.   
We investigated the impact of topography on direct reprogramming by comparing 
gene expression from cells cultured on a 2D layer of PEG microspheres, a flat 2D PEG 
substrate, or a 2D TCPS substrate (Fig. 4.7).  Substrate topographies are well known to 
have effects on cellular behaviors (103).  For 2D cardiomyocyte culture, particular 
research emphasis has been placed on topographies that induce cellular alignment, as is 
seen in vivo.  In natural myocardium, action potential propagation occurs fastest along the 
longitudinal axis of the rod shaped cardiomyocytes (315).  The largest collagen fibrils run 
parallel to the long axis (316), likely helping cells to maintain their orientation (106).  In 
2D cardiac culture, elongated topographical features, such as physical fibers (10), 
grooves (9), or patterned lines of ECM molecules (317, 318), help to induce cellular 
alignment and conduction anisotropy (319).  Recently, Levchenko and colleagues 
demonstrated that nanoscale variations in elongated 2D surface patterns influence 
cytoskeletal architecture and the resulting conduction speed and anisotropy (106).  This 
research has also been translated to 3D, resulting in greater cellular alignment (227, 320), 
anisotropic conduction (321), and higher instances of beating within scaffolds (322).  In 
contrast to elongated contact cues, the rounded surface of the microspheres does not 
appear to be favorable for efficient direct reprogramming to cardiomyocytes.  This may 
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also further help to explain the better performance of the fibrillar collagen-based 
materials as compared to the 100% PEG-microsphere scaffolds (Fig. 4.2).   
Many groups have noted a decrease in cell viability and differences in phenotype 
at scaffold depths greater than 200 µm due to decreased diffusion of nutrients (177-179).  
Depth within EBs also affects cardiac differentiation and cell necrosis (304).  Future 
studies will need to address this facet of 3D reprogramming, possibly by using smaller 
scaffolds or improving nutrient transport using perfusion or hydrodynamic mixing.  PEG 
microspheres may also improve diffusion within scaffolds made of more fibrous 
materials (like collagen or other naturally derived ECM).  In a study comparing 
chondrogenic differentiation in ECM pellet cultures with and without microspheres, our 
collaborators found that inclusion of PEG microspheres reduced the incidence of a 
fibrous layer surrounding the pellet culture, and noted several variations in gene 
expression patterns (323).  Since inclusion of PEG microspheres did not significantly 
hinder ECM remodeling in collagen scaffolds (Figs. 4.4 and 4.5) or alter gene expression 
(Fig. 4.2), they may be useful for delivering morphogen from within the scaffold.  This 
has been shown to improve differentiation within EBs by more evenly distributing the 
delivery profile (324).  
 
 
4.6 Conclusion 
Future cell transplantation procedures will require more scalable approaches to 
stem cell differentiation and direct reprogramming.  In this study, we investigated the 
effects of several factors on direct reprogramming to cardiomyocytes in 3D cultures.  We 
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confirmed that material topography, diffusion, and cell density directly impact 
reprogramming efficiency in 3D.  Our results also suggest that ECM remodeling must be 
taken into consideration when designing these 3D scaffolds.  The results presented here 
lay the groundwork for development of materials that will promote efficient 3D direct 
reprogramming.  
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CHAPTER 5 
 
Conclusions and Future Directions 
 
In this dissertation, I have explored PEG materials as they relate to cardiac tissue 
engineering, first as scaffolds for engineering a cardiac construct (Chapter 2), then as a 
base material for designing the stem cell niche (Chapters 3 and 4).  In chapter 2, I 
designed a novel method for crosslinking PEG microspheres around cells to form a 
scaffold that could be easily handled and subjected to robust analyses.  To verify that 
cardiac cell types would respond well to this material, we encapsulated HL-1 
cardiomyocytes, which proliferated and maintained their phenotype over several weeks in 
culture.  While the gap junction staining suggested that HL-1 cells were connected in 
small clusters, large-scale electrical synchrony was not observed within the scaffold.  
Certain improvements to the design and protocol may help to promote better organization 
and cellular alignment within the scaffold.  Primarily, providing matrix-metalloproteinase 
degradable sites within the PEG mesh may enable better remodeling and allow for more 
cell-to-cell contact (159).  Alternatively, the microspheres could be embedded around 
cells in a naturally derived hydrogel such as collagen or fibrin, similar to the collagen-
PEG hybrids described in Chapter 4.  This would retain the potential for drug release 
from PEG (200) and potentially improve diffusion within the natural hydrogel (167).  
Finally, electrical and mechanical stimulation might be helpful for coaxing cells into 
cardiac-like organization (230, 247).   
The third chapter focused on a new cell type.  The HL-1s provided an excellent 
model for preliminary biomaterial testing because they skirt many technical issues 
encountered with stem cell derived cardiomyocytes.  However, their clinical relevance is 
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limited because they are a permanently dividing line.  We were finishing the HL-1 
studies when a new way of considering cell sourcing was emerging.  Of the direct 
reprogramming strategies published, neither had yet considered the effects of the culture 
substrate on efficiency (75, 84).  However, from pluripotent cell studies, we know this to 
be an important variable that can be engineered to our advantage (100, 124).  The protein 
resistant properties of PEG ensure a clean slate for delivering the desired bioactive 
molecules while inhibiting non-specific adsorption (325, 326).  An advantage of one of 
the direct reprogramming strategies was the potential to form vascular cells alongside 
cardiomyocytes (84, 85).  Many in vitro and in vivo studies have also reported the 
positive influence of vascular cell types on cardiomyocyte viability (88) and cardiac 
function (89, 90) after implantation.  
Using custom-engineered 2D PEG substrates, we demonstrated that 
reprogramming efficiency could be improved in ways that TCPS substrates would not 
allow.  We also found RGD to promote proliferation during reprogramming, which 
ultimately provided more cardiomyocytes without diminishing efficiency.  Interestingly, 
the Matrigel proteins that had been used with TCPS in the original publication were 
found to have high batch-to-batch variation in the ability to promote cell adhesion to PEG.  
Laminin was chosen as a potential alternative because its receptors are known to be 
upregulated during the first few days of reprogramming (253), and it makes up ~60% of 
the proteins in Matrigel (according to product literature).  Because laminin can be 
recombinantly synthesized, this also represents a move away from animal derived 
materials and toward fully synthetic materials (though for our purposes we did use 
purified mouse-derived laminin-1).   
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While many questions could still be addressed using the 2D PEG substrates 
(differentiation to vascular cells, the effects of substrate elastic modulus, etc.), we were 
equally eager to analyze the effects of 3D culture during the direct reprogramming 
protocol (Chapter 4).  This area of research has 2 main motivations.  The first is 
scalability; 2D differentiation methods cannot reasonably provide enough cells.  For 
example, in a recent clinical trial of human MSC injections, the authors injected 205 x 
106 bone marrow cells (125).  At a typical MSC culture density of 10,000 cells/cm2 (327), 
that would require 20,500 cm2, or ~270 typical T75 tissue culture flasks (for just one 
patient).  While researchers may opt for large, thin, stackable 2D surfaces (“Cell 
Factories” with 636 cm2 surface area per plate can be purchased from Thermo 
Scientific®) (328), the sheer media volume necessary brings up costs and routine upkeep 
becomes labor intensive.  As discussed in Chapter 4, optimization of 3D differentiation 
methods could help with scalability issues.   
The second motivation for Chapter 4 was to determine the effects of 3D culture 
on reprogramming efficiency.  Since cells typically reside in a 3D environment, they are 
accustomed to receiving signals from three dimensions (116).  In many cases, they take 
on different phenotypes in 2D versus 3D (119, 120), sometimes resulting in improved 
differentiation (121-124).  Unfortunately, in our study we did not see an improvement in 
reprogramming efficiency.  However, we did learn important details about how the 
reprogramming cells react to microsphere topography, encapsulation between 
microspheres, diffusion limitations, and variations in materials (collagen to PEG) that can 
help us to design better scaffolds for future studies.      
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In a broader sense, there are many future directions to this project.  First, the 
direct reprogramming field moves at a rapid pace.  Very recently (March of 2013), the 
first group published a protocol for directly reprogramming human cells to 
cardiomyocytes (83).  We will need to consider the clinical relevance of continuing to 
work with mouse cell types in future materials studies.  Secondly, a study of 
simultaneous reprogramming to vascular cells would be highly desirable as it may help 
with cardiomyocyte organization within the scaffold (88).  For the 3D approaches, 
designing enzymatically degradable PEG microspheres may improve remodeling and 
organization within the scaffold, which may in turn improve reprogramming efficiency.  
The collagen gels containing PEG microspheres may be the most promising of the 
three materials investigated in Chapter 4, based on the gene expression studies. Loading 
microspheres with bioactive factors may counteract diffusion limitations to improve 
reprogramming efficiency.  Using microspheres to deliver retinoic acid from within EBs 
has shown to advance differentiation, likely by ensuring an even delivery profile instead 
of relying on diffusion from the outer surfaces (324).  In the Efe et al. protocol, the 
pluripotency inhibitor is delivered for 9 days immediately following cell seeding.  If we 
were to continue using this reprogramming protocol, one might design microspheres to 
incorporate controlled release of this or other factors.  
Ultimately, diffusion limitations will need to be addressed by either incorporating 
perfusion or rotary culture into the methods, or making much smaller 3D constructs 
(~200-400 µm wide to completely avoid diffusion issues (177-179)).  One such way 
would be to fabricate the scaffold as described, then to break it into smaller pieces such 
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that the cells were still encapsulated.  In fact, such a strategy might lend itself well to in 
vivo injections that deliver cells, bioactive factors and surfaces to prevent cell anoikis.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 111 
REFERENCES 
 
1. S. P. Langdon, in Cancer Cell Culture: methods and protocols S. P. Langdon, Ed. 
(Springer, 2004), vol. 88, pp. 3-15. 
2. J. Loeb, A contribution to the physiology of coloration in animals. Journal of 
Morphology 8, 161 (1893). 
3. S. Ramón y Cajal, La rétine des vertébrés. La Cellule 9, 121 (1892). 
4. R. G. Harrison, The reaction of embryonic cells to solid structures. Journal of 
Experimental Zoology 17, 521 (1914). 
5. R. G. Harrison, The outgrowth of the nerve fiber as a mode of protoplasmic 
movement. Journal of Experimental Zoology 9, 787 (1910). 
6. W. H. Lewis, M. R. Lewis, in General Cytology, E. V. Cowdry, Ed. (University 
of Chicago Press, Chicago, 1924),  pp. 384-447. 
7. P. Weiss, B. Garber, Shape and Movement of Mesenchyme Cells as Functions of 
the Physical Structure of the Medium: Contributions to a Quantitative 
Morphology. Proceedings of the National Academy of Sciences of the United 
States of America 38, 264 (Mar, 1952). 
8. T. F. McDonald, H. G. Sachs, R. L. DeHaan, Development of sensitivity to 
tetrodotoxin in beating chick embryo hearts, single cells, and aggregates. Science 
176, 1248 (Jun 16, 1972). 
9. M. Lieberman, A. E. Roggeveen, J. E. Purdy, E. A. Johnson, Synthetic strands of 
cardiac muscle: growth and physiological implication. Science 175, 909 (Feb 25, 
1972). 
10. C. R. Horres, M. Lieberman, J. E. Purdy, Growth orientation of heart cells on 
nylon monofilament. Determination of the volume-to-surface area ratio and 
intracellular potassium concentration. J Membr Biol 34, 313 (Jun 15, 1977). 
11. D. Lloyd-Jones et al., Heart disease and stroke statistics--2010 update: a report 
from the American Heart Association. Circulation 121, e46 (Feb 23, 2010). 
12. Y. Song, Q. Yao, J. Zhu, B. Luo, S. Liang, Age-related variation in the interstitial 
tissues of the cardiac conduction system; and autopsy study of 230 Han Chinese. 
Forensic Sci Int 104, 133 (Oct 11, 1999). 
13. I. Shiraishi, T. Takamatsu, T. Minamikawa, Z. Onouchi, S. Fujita, Quantitative 
histological analysis of the human sinoatrial node during growth and aging. 
Circulation 85, 2176 (Jun, 1992). 
14. V. V. Fedorov et al., Structural and functional evidence for discrete exit pathways 
that connect the canine sinoatrial node and atria. Circ Res 104, 915 (Apr 10, 
2009). 
15. W. J. Mandel, J. L. Jordan, H. S. Karagueuzian, Disorders of Sinus Function. 
Curr Treat Options Cardiovasc Med 1, 179 (Aug, 1999). 
16. R. Evans, D. B. Shaw, Pathological studies in sinoatrial disorder (sick sinus 
syndrome). Br Heart J 39, 778 (Jul, 1977). 
17. . (U.S. Organ Procurement and Transplantation Network and the Scientific 
Registry of Transplant Recipients, 2009), vol. 2013. 
18. H. Zhu, G. C. Fan, Role of microRNAs in the reperfused myocardium towards 
post-infarct remodelling. Cardiovascular research 94, 284 (May 1, 2012). 
 112 
19. V. Divakaran, D. L. Mann, The emerging role of microRNAs in cardiac 
remodeling and heart failure. Circulation research 103, 1072 (Nov 7, 2008). 
20. P. Kesharwani, V. Gajbhiye, N. K. Jain, A review of nanocarriers for the delivery 
of small interfering RNA. Biomaterials 33, 7138 (Oct, 2012). 
21. Y. Wu, R. C. Zhao, The role of chemokines in mesenchymal stem cell homing to 
myocardium. Stem Cell Rev 8, 243 (Mar, 2012). 
22. S. K. Ghadge, S. Muhlstedt, C. Ozcelik, M. Bader, SDF-1alpha as a therapeutic 
stem cell homing factor in myocardial infarction. Pharmacol Ther 129, 97 (Jan, 
2011). 
23. M. J. Evans, M. H. Kaufman, Establishment in culture of pluripotential cells from 
mouse embryos. Nature 292, 154 (Jul 9, 1981). 
24. G. R. Martin, Isolation of a pluripotent cell line from early mouse embryos 
cultured in medium conditioned by teratocarcinoma stem cells. Proceedings of the 
National Academy of Sciences of the United States of America 78, 7634 (Dec, 
1981). 
25. T. C. Doetschman, H. Eistetter, M. Katz, W. Schmidt, R. Kemler, The in vitro 
development of blastocyst-derived embryonic stem cell lines: formation of 
visceral yolk sac, blood islands and myocardium. J Embryol Exp Morphol 87, 27 
(Jun, 1985). 
26. J. A. Thomson et al., Embryonic stem cell lines derived from human blastocysts. 
Science 282, 1145 (Nov 6, 1998). 
27. I. Kehat et al., Human embryonic stem cells can differentiate into myocytes with 
structural and functional properties of cardiomyocytes. The Journal of clinical 
investigation 108, 407 (Aug, 2001). 
28. K. Takahashi, S. Yamanaka, Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell 126, 663 (Aug 25, 
2006). 
29. K. Takahashi et al., Induction of pluripotent stem cells from adult human 
fibroblasts by defined factors. Cell 131, 861 (Nov 30, 2007). 
30. N. Maherali et al., Directly reprogrammed fibroblasts show global epigenetic 
remodeling and widespread tissue contribution. Cell Stem Cell 1, 55 (Jun 7, 2007). 
31. G. Narazaki et al., Directed and systematic differentiation of cardiovascular cells 
from mouse induced pluripotent stem cells. Circulation 118, 498 (Jul 29, 2008). 
32. C. Mauritz et al., Generation of functional murine cardiac myocytes from induced 
pluripotent stem cells. Circulation 118, 507 (Jul 29, 2008). 
33. K. Schenke-Layland et al., Reprogrammed mouse fibroblasts differentiate into 
cells of the cardiovascular and hematopoietic lineages. Stem Cells 26, 1537 (Jun, 
2008). 
34. J. Zhang et al., Functional cardiomyocytes derived from human induced 
pluripotent stem cells. Circulation research 104, e30 (Feb 27, 2009). 
35. M. A. Laflamme et al., Cardiomyocytes derived from human embryonic stem 
cells in pro-survival factors enhance function of infarcted rat hearts. Nature 
biotechnology 25, 1015 (Sep, 2007). 
36. X. Lian et al., Robust cardiomyocyte differentiation from human pluripotent stem 
cells via temporal modulation of canonical Wnt signaling. Proceedings of the 
 113 
National Academy of Sciences of the United States of America 109, E1848 (Jul 3, 
2012). 
37. L. M. Bjorklund et al., Embryonic stem cells develop into functional 
dopaminergic neurons after transplantation in a Parkinson rat model. Proceedings 
of the National Academy of Sciences of the United States of America 99, 2344 
(Feb 19, 2002). 
38. J. Nussbaum et al., Transplantation of undifferentiated murine embryonic stem 
cells in the heart: teratoma formation and immune response. FASEB journal : 
official publication of the Federation of American Societies for Experimental 
Biology 21, 1345 (May, 2007). 
39. I. Gutierrez-Aranda et al., Human induced pluripotent stem cells develop 
teratoma more efficiently and faster than human embryonic stem cells regardless 
the site of injection. Stem Cells 28, 1568 (Sep, 2010). 
40. Y. Mayshar et al., Identification and classification of chromosomal aberrations in 
human induced pluripotent stem cells. Cell Stem Cell 7, 521 (Oct 8, 2010). 
41. U. Ben-David, N. Benvenisty, The tumorigenicity of human embryonic and 
induced pluripotent stem cells. Nature reviews. Cancer 11, 268 (Apr, 2011). 
42. L. C. Laurent et al., Dynamic changes in the copy number of pluripotency and 
cell proliferation genes in human ESCs and iPSCs during reprogramming and 
time in culture. Cell Stem Cell 8, 106 (Jan 7, 2011). 
43. J. S. Draper et al., Recurrent gain of chromosomes 17q and 12 in cultured human 
embryonic stem cells. Nature biotechnology 22, 53 (Jan, 2004). 
44. D. E. Baker et al., Adaptation to culture of human embryonic stem cells and 
oncogenesis in vivo. Nature biotechnology 25, 207 (Feb, 2007). 
45. N. Lefort et al., Human embryonic stem cells reveal recurrent genomic instability 
at 20q11.21. Nature biotechnology 26, 1364 (Dec, 2008). 
46. C. Spits et al., Recurrent chromosomal abnormalities in human embryonic stem 
cells. Nature biotechnology 26, 1361 (Dec, 2008). 
47. T. Zhao, Z. N. Zhang, Z. Rong, Y. Xu, Immunogenicity of induced pluripotent 
stem cells. Nature 474, 212 (Jun 9, 2011). 
48. K. Kim et al., Epigenetic memory in induced pluripotent stem cells. Nature 467, 
285 (Sep 16, 2010). 
49. J. M. Polo et al., Cell type of origin influences the molecular and functional 
properties of mouse induced pluripotent stem cells. Nature biotechnology 28, 848 
(Aug, 2010). 
50. Z. Ghosh et al., Persistent donor cell gene expression among human induced 
pluripotent stem cells contributes to differences with human embryonic stem cells. 
PLoS One 5, e8975 (2010). 
51. O. Bar-Nur, H. A. Russ, S. Efrat, N. Benvenisty, Epigenetic memory and 
preferential lineage-specific differentiation in induced pluripotent stem cells 
derived from human pancreatic islet beta cells. Cell Stem Cell 9, 17 (Jul 8, 2011). 
52. A. M. Newman, J. B. Cooper, Lab-specific gene expression signatures in 
pluripotent stem cells. Cell Stem Cell 7, 258 (Aug 6, 2010). 
53. O. Caspi et al., Transplantation of human embryonic stem cell-derived 
cardiomyocytes improves myocardial performance in infarcted rat hearts. Journal 
of the American College of Cardiology 50, 1884 (Nov 6, 2007). 
 114 
54. L. Carpenter et al., Efficient differentiation of human induced pluripotent stem 
cells generates cardiac cells that provide protection following myocardial 
infarction in the rat. Stem Cells Dev 21, 977 (Apr 10, 2012). 
55. J. Y. Min et al., Transplantation of embryonic stem cells improves cardiac 
function in postinfarcted rats. J Appl Physiol 92, 288 (Jan, 2002). 
56. T. J. Nelson et al., Repair of acute myocardial infarction by human stemness 
factors induced pluripotent stem cells. Circulation 120, 408 (Aug 4, 2009). 
57. H. Masumoto et al., Pluripotent stem cell-engineered cell sheets reassembled with 
defined cardiovascular populations ameliorate reduction in infarct heart function 
through cardiomyocyte-mediated neovascularization. Stem Cells 30, 1196 (Jun, 
2012). 
58. K. Malliaras, E. Marban, Cardiac cell therapy: where we've been, where we are, 
and where we should be headed. British medical bulletin 98, 161 (2011). 
59. T. E. Robey, M. K. Saiget, H. Reinecke, C. E. Murry, Systems approaches to 
preventing transplanted cell death in cardiac repair. Journal of molecular and 
cellular cardiology 45, 567 (Oct, 2008). 
60. E. Martin-Rendon et al., Autologous bone marrow stem cells to treat acute 
myocardial infarction: a systematic review. Eur Heart J 29, 1807 (Aug, 2008). 
61. D. Orlic et al., Bone marrow cells regenerate infarcted myocardium. Nature 410, 
701 (Apr 5, 2001). 
62. B. E. Strauer et al., [Intracoronary, human autologous stem cell transplantation for 
myocardial regeneration following myocardial infarction]. Dtsch Med 
Wochenschr 126, 932 (Aug 24, 2001). 
63. C. E. Murry et al., Haematopoietic stem cells do not transdifferentiate into cardiac 
myocytes in myocardial infarcts. Nature 428, 664 (Apr 8, 2004). 
64. L. B. Balsam et al., Haematopoietic stem cells adopt mature haematopoietic fates 
in ischaemic myocardium. Nature 428, 668 (Apr 8, 2004). 
65. M. A. Sussman, C. E. Murry, Bones of contention: marrow-derived cells in 
myocardial regeneration. Journal of molecular and cellular cardiology 44, 950 
(Jun, 2008). 
66. M. Hayashi, T. S. Li, H. Ito, A. Mikamo, K. Hamano, Comparison of 
intramyocardial and intravenous routes of delivering bone marrow cells for the 
treatment of ischemic heart disease: an experimental study. Cell transplantation 
13, 639 (2004). 
67. T. Freyman et al., A quantitative, randomized study evaluating three methods of 
mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 27, 
1114 (May, 2006). 
68. K. A. Jackson et al., Regeneration of ischemic cardiac muscle and vascular 
endothelium by adult stem cells. The Journal of clinical investigation 107, 1395 
(Jun, 2001). 
69. M. Gnecchi et al., Evidence supporting paracrine hypothesis for Akt-modified 
mesenchymal stem cell-mediated cardiac protection and functional improvement. 
FASEB journal : official publication of the Federation of American Societies for 
Experimental Biology 20, 661 (Apr, 2006). 
 115 
70. K. E. Hatzistergos et al., Bone marrow mesenchymal stem cells stimulate cardiac 
stem cell proliferation and differentiation. Circulation research 107, 913 (Oct 1, 
2010). 
71. E. Messina et al., Isolation and expansion of adult cardiac stem cells from human 
and murine heart. Circulation research 95, 911 (Oct 29, 2004). 
72. R. R. Smith et al., Regenerative potential of cardiosphere-derived cells expanded 
from percutaneous endomyocardial biopsy specimens. Circulation 115, 896 (Feb 
20, 2007). 
73. P. V. Johnston et al., Engraftment, differentiation, and functional benefits of 
autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. 
Circulation 120, 1075 (Sep 22, 2009). 
74. S. A. Morris, G. Q. Daley, A blueprint for engineering cell fate: current 
technologies to reprogram cell identity. Cell research 23, 33 (Jan, 2013). 
75. M. Ieda et al., Direct reprogramming of fibroblasts into functional 
cardiomyocytes by defined factors. Cell 142, 375 (Aug 6, 2010). 
76. S. Protze et al., A new approach to transcription factor screening for 
reprogramming of fibroblasts to cardiomyocyte-like cells. Journal of molecular 
and cellular cardiology 53, 323 (Sep, 2012). 
77. K. Song et al., Heart repair by reprogramming non-myocytes with cardiac 
transcription factors. Nature 485, 599 (May 31, 2012). 
78. Y. Zhang et al., A poor imitation of a natural process: A call to reconsider the 
iPSC engineering technique. Cell cycle 11, 4536 (Dec 15, 2012). 
79. J. Sterneckert, S. Hoing, H. R. Scholer, Concise review: Oct4 and more: the 
reprogramming expressway. Stem Cells 30, 15 (Jan, 2012). 
80. L. Qian et al., In vivo reprogramming of murine cardiac fibroblasts into induced 
cardiomyocytes. Nature 485, 593 (May 31, 2012). 
81. K. Inagawa et al., Induction of cardiomyocyte-like cells in infarct hearts by gene 
transfer of Gata4, Mef2c, and Tbx5. Circulation research 111, 1147 (Oct 12, 
2012). 
82. T. M. Jayawardena et al., MicroRNA-mediated in vitro and in vivo direct 
reprogramming of cardiac fibroblasts to cardiomyocytes. Circulation research 
110, 1465 (May 25, 2012). 
83. Y. J. Nam et al., Reprogramming of human fibroblasts toward a cardiac fate.  
DOI: 10.1073/pnas.1301019110. Proceedings of the National Academy of 
Sciences of the United States of America,  (Mar 4, 2013). 
84. J. A. Efe et al., Conversion of mouse fibroblasts into cardiomyocytes using a 
direct reprogramming strategy. Nature cell biology 13, 215 (Mar, 2011). 
85. A. Moretti et al., Multipotent embryonic isl1+ progenitor cells lead to cardiac, 
smooth muscle, and endothelial cell diversification. Cell 127, 1151 (Dec 15, 
2006). 
86. J. H. Hill, P. A. Ward, The phlogistic role of C3 leukotactic fragments in 
myocardial infarcts of rats. J Exp Med 133, 885 (Apr 1, 1971). 
87. B. I. Jugdutt, Ventricular remodeling after infarction and the extracellular 
collagen matrix: when is enough enough? Circulation 108, 1395 (Sep 16, 2003). 
 116 
88. D. A. Narmoneva, R. Vukmirovic, M. E. Davis, R. D. Kamm, R. T. Lee, 
Endothelial cells promote cardiac myocyte survival and spatial reorganization: 
implications for cardiac regeneration. Circulation 110, 962 (Aug 24, 2004). 
89. K. R. Stevens et al., Physiological function and transplantation of scaffold-free 
and vascularized human cardiac muscle tissue. Proceedings of the National 
Academy of Sciences of the United States of America 106, 16568 (Sep 29, 2009). 
90. T. Dvir et al., Prevascularization of cardiac patch on the omentum improves its 
therapeutic outcome. Proc Natl Acad Sci U S A 106, 14990 (Sep 1, 2009). 
91. R. Bolli, The 10 Most Read Articles Published in Circulation Research in 2012. 
Circulation Research 112, 586 (2013). 
92. C. S. Izzard, L. R. Lochner, Cell-to-substrate contacts in living fibroblasts: an 
interference reflexion study with an evaluation of the technique. Journal of cell 
science 21, 129 (Jun, 1976). 
93. R. O. Hynes, A. T. Destree, Relationships between fibronectin (LETS protein) 
and actin. Cell 15, 875 (Nov, 1978). 
94. S. D. Hauschka, I. R. Konigsberg, The influence of collagen on the development 
of muscle clones. Proceedings of the National Academy of Sciences of the United 
States of America 55, 119 (Jan, 1966). 
95. S. Meier, E. D. Hay, Control of corneal differentiation by extracellular materials. 
Collagen as a promoter and stabilizer of epithelial stroma production. Dev Biol 38, 
249 (Jun, 1974). 
96. R. A. Kosher, J. W. Lash, R. R. Minor, Environmental enhancement of in vitro 
chondrogenesis. IV. Stimulation of somite chondrogenesis by exogenous 
chondromucoprotein. Dev Biol 35, 210 (Dec, 1973). 
97. A. J. Zhu, I. Haase, F. M. Watt, Signaling via beta1 integrins and mitogen-
activated protein kinase determines human epidermal stem cell fate in vitro. 
Proceedings of the National Academy of Sciences of the United States of America 
96, 6728 (Jun 8, 1999). 
98. L. S. Campos et al., Beta1 integrins activate a MAPK signalling pathway in 
neural stem cells that contributes to their maintenance. Development 131, 3433 
(Jul, 2004). 
99. S. Saha, L. Ji, J. J. de Pablo, S. P. Palecek, TGFbeta/Activin/Nodal pathway in 
inhibition of human embryonic stem cell differentiation by mechanical strain. 
Biophysical journal 94, 4123 (May 15, 2008). 
100. C. Xu et al., Feeder-free growth of undifferentiated human embryonic stem cells. 
Nature biotechnology 19, 971 (Oct, 2001). 
101. M. Arnold et al., Activation of integrin function by nanopatterned adhesive 
interfaces. Chemphyschem 5, 383 (Mar 19, 2004). 
102. S. R. Braam et al., Recombinant vitronectin is a functionally defined substrate 
that supports human embryonic stem cell self-renewal via alphavbeta5 integrin. 
Stem Cells 26, 2257 (Sep, 2008). 
103. A. S. Curtis, M. Varde, Control of Cell Behavior: Topological Factors. J Natl 
Cancer Inst 33, 15 (Jul, 1964). 
104. E. K. Yim, S. W. Pang, K. W. Leong, Synthetic nanostructures inducing 
differentiation of human mesenchymal stem cells into neuronal lineage. Exp Cell 
Res 313, 1820 (May 15, 2007). 
 117 
105. M. J. Dalby et al., The control of human mesenchymal cell differentiation using 
nanoscale symmetry and disorder. Nature materials 6, 997 (Dec, 2007). 
106. D. H. Kim et al., Nanoscale cues regulate the structure and function of 
macroscopic cardiac tissue constructs. Proceedings of the National Academy of 
Sciences of the United States of America 107, 565 (Jan 12, 2010). 
107. S. Gerecht et al., The effect of actin disrupting agents on contact guidance of 
human embryonic stem cells. Biomaterials 28, 4068 (Oct, 2007). 
108. A. J. Engler, F. Rehfeldt, S. Sen, D. E. Discher, Microtissue elasticity: 
measurements by atomic force microscopy and its influence on cell differentiation. 
Methods in cell biology 83, 521 (2007). 
109. A. J. Engler et al., Embryonic cardiomyocytes beat best on a matrix with heart-
like elasticity: scar-like rigidity inhibits beating. Journal of cell science 121, 3794 
(Nov 15, 2008). 
110. R. McBeath, D. M. Pirone, C. M. Nelson, K. Bhadriraju, C. S. Chen, Cell shape, 
cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev Cell 
6, 483 (Apr, 2004). 
111. K. A. Kilian, B. Bugarija, B. T. Lahn, M. Mrksich, Geometric cues for directing 
the differentiation of mesenchymal stem cells. Proceedings of the National 
Academy of Sciences of the United States of America 107, 4872 (Mar 16, 2010). 
112. A. J. Engler, S. Sen, H. L. Sweeney, D. E. Discher, Matrix elasticity directs stem 
cell lineage specification. Cell 126, 677 (Aug 25, 2006). 
113. M. Schvartzman et al., Nanolithographic control of the spatial organization of 
cellular adhesion receptors at the single-molecule level. Nano Lett 11, 1306 (Mar 
9, 2011). 
114. F. Chowdhury et al., Soft substrates promote homogeneous self-renewal of 
embryonic stem cells via downregulating cell-matrix tractions. PLoS One 5, 
e15655 (2010). 
115. S. Saha, L. Ji, J. J. de Pablo, S. P. Palecek, Inhibition of human embryonic stem 
cell differentiation by mechanical strain. Journal of cellular physiology 206, 126 
(Jan, 2006). 
116. B. M. Baker, C. S. Chen, Deconstructing the third dimension: how 3D culture 
microenvironments alter cellular cues. Journal of cell science 125, 3015 (Jul 1, 
2012). 
117. V. M. Weaver et al., beta4 integrin-dependent formation of polarized three-
dimensional architecture confers resistance to apoptosis in normal and malignant 
mammary epithelium. Cancer Cell 2, 205 (Sep, 2002). 
118. J. Meyers, J. Craig, D. J. Odde, Potential for control of signaling pathways via 
cell size and shape. Curr Biol 16, 1685 (Sep 5, 2006). 
119. K. von der Mark, V. Gauss, H. von der Mark, P. Muller, Relationship between 
cell shape and type of collagen synthesised as chondrocytes lose their cartilage 
phenotype in culture. Nature 267, 531 (Jun 9, 1977). 
120. J. T. Emerman, D. R. Pitelka, Maintenance and induction of morphological 
differentiation in dissociated mammary epithelium on floating collagen 
membranes. In Vitro 13, 316 (May, 1977). 
 118 
121. P. D. Benya, J. D. Shaffer, Dedifferentiated chondrocytes reexpress the 
differentiated collagen phenotype when cultured in agarose gels. Cell 30, 215 
(Aug, 1982). 
122. J. C. Dunn, M. L. Yarmush, H. G. Koebe, R. G. Tompkins, Hepatocyte function 
and extracellular matrix geometry: long-term culture in a sandwich configuration. 
FASEB journal : official publication of the Federation of American Societies for 
Experimental Biology 3, 174 (Feb, 1989). 
123. M. A. Hadley, S. W. Byers, C. A. Suarez-Quian, H. K. Kleinman, M. Dym, 
Extracellular matrix regulates Sertoli cell differentiation, testicular cord formation, 
and germ cell development in vitro. The Journal of cell biology 101, 1511 (Oct, 
1985). 
124. K. Schenke-Layland et al., Recapitulation of the embryonic cardiovascular 
progenitor cell niche. Biomaterials 32, 2748 (Apr, 2011). 
125. B. Assmus et al., Transcoronary transplantation of progenitor cells after 
myocardial infarction. N Engl J Med 355, 1222 (Sep 21, 2006). 
126. S. Janssens et al., Autologous bone marrow-derived stem-cell transfer in patients 
with ST-segment elevation myocardial infarction: double-blind, randomised 
controlled trial. Lancet 367, 113 (Jan 14, 2006). 
127. K. Lunde et al., Intracoronary injection of mononuclear bone marrow cells in 
acute myocardial infarction. N Engl J Med 355, 1199 (Sep 21, 2006). 
128. V. Schachinger et al., Intracoronary bone marrow-derived progenitor cells in 
acute myocardial infarction. N Engl J Med 355, 1210 (Sep 21, 2006). 
129. I. Zvibel, F. Smets, H. Soriano, Anoikis: roadblock to cell transplantation? Cell 
transplantation 11, 621 (2002). 
130. I. Kutschka et al., Collagen matrices enhance survival of transplanted 
cardiomyoblasts and contribute to functional improvement of ischemic rat hearts. 
Circulation 114, I167 (Jul 4, 2006). 
131. W. H. Zimmermann et al., Engineered heart tissue grafts improve systolic and 
diastolic function in infarcted rat hearts. Nat Med 12, 452 (Apr, 2006). 
132. B. A. Aguado, W. Mulyasasmita, J. Su, K. J. Lampe, S. C. Heilshorn, Improving 
viability of stem cells during syringe needle flow through the design of hydrogel 
cell carriers. Tissue engineering. Part A 18, 806 (Apr, 2012). 
133. K. Suzuki et al., Dynamics and mediators of acute graft attrition after myoblast 
transplantation to the heart. FASEB journal : official publication of the Federation 
of American Societies for Experimental Biology 18, 1153 (Jul, 2004). 
134. G. Seshadri et al., The delivery of superoxide dismutase encapsulated in polyketal 
microparticles to rat myocardium and protection from myocardial ischemia-
reperfusion injury. Biomaterials 31, 1372 (Feb, 2010). 
135. K. L. Christman, H. H. Fok, R. E. Sievers, Q. Fang, R. J. Lee, Fibrin glue alone 
and skeletal myoblasts in a fibrin scaffold preserve cardiac function after 
myocardial infarction. Tissue engineering 10, 403 (Mar-Apr, 2004). 
136. J. Leor et al., Intracoronary injection of in situ forming alginate hydrogel reverses 
left ventricular remodeling after myocardial infarction in Swine. Journal of the 
American College of Cardiology 54, 1014 (Sep 8, 2009). 
 119 
137. T. P. Kraehenbuehl et al., Human embryonic stem cell-derived microvascular 
grafts for cardiac tissue preservation after myocardial infarction. Biomaterials 32, 
1102 (Feb, 2011). 
138. T. D. Johnson, K. L. Christman, Injectable hydrogel therapies and their delivery 
strategies for treating myocardial infarction. Expert Opin Drug Deliv 10, 59 (Jan, 
2013). 
139. M. T. Lam, J. C. Wu, Biomaterial applications in cardiovascular tissue repair and 
regeneration. Expert Rev Cardiovasc Ther 10, 1039 (Aug, 2012). 
140. G. Zhang, Q. Hu, E. A. Braunlin, L. J. Suggs, J. Zhang, Enhancing efficacy of 
stem cell transplantation to the heart with a PEGylated fibrin biomatrix. Tissue 
engineering. Part A 14, 1025 (Jun, 2008). 
141. G. Vunjak-Novakovic et al., Challenges in cardiac tissue engineering. Tissue Eng 
Part B Rev 16, 169 (Apr, 2010). 
142. N. A. Peppas, J. Z. Hilt, A. Khademhosseini, R. Langer, Hydrogels in Biology 
and Medicine: From Molecular Principles to Bionanotechnology. Advanced 
Materials 18, 1345 (2006). 
143. B. D. Ratner, A. S. Hoffman, F. J. Schoen, J. E. Lemons, Eds., Biomaterials 
Science,  (Elsevier Academic Press, San Diego, ed. 2, 2004), 2. 
144. J. N. George, Direct assessment of platelet adhesion to glass: a study of the forces 
of interaction and the effects of plasma and serum factors, platelet function, and 
modification of the glass surface. Blood 40, 862 (Dec, 1972). 
145. K. Furasawa, Y. Shimura, K. Otobe, K. Atsumi, K. Tasuda, Blood compatibility 
of polyether-polyurethanes. Ronbushi Kobushu 4,  (1977). 
146. S. J. Whicher, J. L. Brash, Platelet-foreign surface interactions: release of granule 
constituents from adherent platelets. Journal of biomedical materials research 12, 
181 (Mar, 1978). 
147. J. L. Brash, S. Uniyal, Dependence of albumin–fibrinogen simple and competitive 
adsorption on surface properties of biomaterials. Journal of Polymer Science: 
Polymer Symposia 66, 377 (1979). 
148. Y. Mori et al., A new antithrombogenic material with long polyethyleneoxide 
chains. Trans Am Soc Artif Intern Organs 28, 459 (1982). 
149. V. Sa Da Costa et al., Polyether—polyurethane surfaces: Thrombin adsorption, 
platelet adsorption, and ESCA scanning. Journal of Colloid and Interface Science 
76, 594 (1980). 
150. V. Sa Da Costa, D. Brier-Russell, E. W. Salzman, E. W. Merrill, Esca studies of 
polyurethanes: blood platelet activation in relation to surface composition. 
Journal of Colloid and Interface Science 80, 445 (1981). 
151. E. W. Merrill et al., Platelet-compatible hydrophilic segmented polyurethanes 
from polyethylene glycols and cyclohexane diisocyanate. Trans Am Soc Artif 
Intern Organs 28, 482 (1982). 
152. E. W. Merrill, E. W. Salzman, Polyethylene oxide as a biomaterial. American 
Society for Artificial Internal Organs Journal 6, 60 (1983). 
153. J. L. Hill-West, S. M. Chowdhury, M. J. Slepian, J. A. Hubbell, Inhibition of 
thrombosis and intimal thickening by in situ photopolymerization of thin hydrogel 
barriers. Proc Natl Acad Sci U S A 91, 5967 (Jun 21, 1994). 
 120 
154. A. S. Sawhney, C. P. Pathak, J. A. Hubbell, Interfacial photopolymerization of 
poly(ethylene glycol)-based hydrogels upon alginate-poly(l-lysine) microcapsules 
for enhanced biocompatibility. Biomaterials 14, 1008 (Oct, 1993). 
155. H. L. Porte et al., Randomized controlled trial of a synthetic sealant for 
preventing alveolar air leaks after lobectomy. The Annals of thoracic surgery 71, 
1618 (May, 2001). 
156. M. C. Preul, P. K. Campbell, W. D. Bichard, R. F. Spetzler, Application of a 
hydrogel sealant improves watertight closures of duraplasty onlay grafts in a 
canine craniotomy model. J Neurosurg 107, 642 (Sep, 2007). 
157. C. C. Lin, K. S. Anseth, PEG hydrogels for the controlled release of biomolecules 
in regenerative medicine. Pharmaceutical research 26, 631 (Mar, 2009). 
158. D. S. Benoit, M. P. Schwartz, A. R. Durney, K. S. Anseth, Small functional 
groups for controlled differentiation of hydrogel-encapsulated human 
mesenchymal stem cells. Nature materials 7, 816 (Oct, 2008). 
159. T. P. Kraehenbuehl et al., Three-dimensional extracellular matrix-directed 
cardioprogenitor differentiation: systematic modulation of a synthetic cell-
responsive PEG-hydrogel. Biomaterials 29, 2757 (Jun, 2008). 
160. J. Heller, R. F. Helwing, R. W. Baker, M. E. Tuttle, Controlled release of water-
soluble macromolecules from bioerodible hydrogels. Biomaterials 4, 262 (Oct, 
1983). 
161. M. P. Lutolf et al., Repair of bone defects using synthetic mimetics of 
collagenous extracellular matrices. Nat Biotechnol 21, 513 (May, 2003). 
162. N. S. Hwang, S. Varghese, Z. Zhang, J. Elisseeff, Chondrogenic differentiation of 
human embryonic stem cell-derived cells in arginine-glycine-aspartate-modified 
hydrogels. Tissue engineering 12, 2695 (Sep, 2006). 
163. J. West, J. Hubbell, Polymeric Biomaterials with Degradation Sites for Proteases 
Involved in Cell Migration. Macromolecules 32, 241 (1999). 
164. J. L. Young, A. J. Engler, Hydrogels with time-dependent material properties 
enhance cardiomyocyte differentiation in vitro. Biomaterials 32, 1002 (Feb, 2011). 
165. S. Gobaa et al., Artificial niche microarrays for probing single stem cell fate in 
high throughput. Nat Methods 8, 949 (Nov, 2011). 
166. H. Qi et al., Patterned differentiation of individual embryoid bodies in spatially 
organized 3D hybrid microgels. Advanced Materials 22, 5276 (Dec 7, 2010). 
167. G. Zhang, X. Wang, Z. Wang, J. Zhang, L. Suggs, A PEGylated fibrin patch for 
mesenchymal stem cell delivery. Tissue engineering 12, 9 (Jan, 2006). 
168. N. Smart et al., Thymosin beta4 induces adult epicardial progenitor mobilization 
and neovascularization. Nature 445, 177 (Jan 11, 2007). 
169. D. Q. Wu et al., Fabrication of supramolecular hydrogels for drug delivery and 
stem cell encapsulation. Langmuir 24, 10306 (Sep 16, 2008). 
170. T. Wang et al., Bone marrow stem cells implantation with alpha-
cyclodextrin/MPEG-PCL-MPEG hydrogel improves cardiac function after 
myocardial infarction. Acta biomaterialia 5, 2939 (Oct, 2009). 
171. T. Wang et al., The inhibition of postinfarct ventricle remodeling without 
polycythaemia following local sustained intramyocardial delivery of 
erythropoietin within a supramolecular hydrogel. Biomaterials 30, 4161 (Sep, 
2009). 
 121 
172. J. Wu et al., Infarct stabilization and cardiac repair with a VEGF-conjugated, 
injectable hydrogel. Biomaterials 32, 579 (Jan, 2011). 
173. A. A. Rane et al., Increased infarct wall thickness by a bio-inert material is 
insufficient to prevent negative left ventricular remodeling after myocardial 
infarction. PLoS One 6, e21571 (2011). 
174. S. Dobner, D. Bezuidenhout, P. Govender, P. Zilla, N. Davies, A synthetic non-
degradable polyethylene glycol hydrogel retards adverse post-infarct left 
ventricular remodeling. J Card Fail 15, 629 (Sep, 2009). 
175. D. L. Brutsaert, Cardiac endothelial-myocardial signaling: its role in cardiac 
growth, contractile performance, and rhythmicity. Physiol Rev 83, 59 (Jan, 2003). 
176. K. Rakusan, B. Korecky, The effect of growth and aging on functional capillary 
supply of the rat heart. Growth 46, 275 (Autumn, 1982). 
177. R. L. Carrier et al., Cardiac tissue engineering: cell seeding, cultivation 
parameters, and tissue construct characterization. Biotechnol Bioeng 64, 580 (Sep 
5, 1999). 
178. M. Papadaki et al., Tissue engineering of functional cardiac muscle: molecular, 
structural, and electrophysiological studies. Am J Physiol Heart Circ Physiol 280, 
H168 (Jan, 2001). 
179. W. H. Zimmermann et al., Three-dimensional engineered heart tissue from 
neonatal rat cardiac myocytes. Biotechnol Bioeng 68, 106 (Apr 5, 2000). 
180. C. E. Holy, M. S. Shoichet, J. E. Davies, Engineering three-dimensional bone 
tissue in vitro using biodegradable scaffolds: investigating initial cell-seeding 
density and culture period. J Biomed Mater Res 51, 376 (Sep 5, 2000). 
181. B. S. Kim, A. J. Putnam, T. J. Kulik, D. J. Mooney, Optimizing seeding and 
culture methods to engineer smooth muscle tissue on biodegradable polymer 
matrices. Biotechnol Bioeng 57, 46 (Jan 5, 1998). 
182. M. Radisic, A. Marsano, R. Maidhof, Y. Wang, G. Vunjak-Novakovic, Cardiac 
tissue engineering using perfusion bioreactor systems. Nat Protoc 3, 719 (2008). 
183. L. A. Solchaga et al., A rapid seeding technique for the assembly of large 
cell/scaffold composite constructs. Tissue Eng 12, 1851 (Jul, 2006). 
184. M. P. Lutolf et al., Synthetic matrix metalloproteinase-sensitive hydrogels for the 
conduction of tissue regeneration: engineering cell-invasion characteristics. Proc 
Natl Acad Sci U S A 100, 5413 (Apr 29, 2003). 
185. S. J. Bryant, K. S. Anseth, The effects of scaffold thickness on tissue engineered 
cartilage in photocrosslinked poly(ethylene oxide) hydrogels. Biomaterials 22, 
619 (Mar, 2001). 
186. C. A. DeForest, B. D. Polizzotti, K. S. Anseth, Sequential click reactions for 
synthesizing and patterning three-dimensional cell microenvironments. Nat Mater 
8, 659 (Aug, 2009). 
187. V. Keskar, N. W. Marion, J. J. Mao, R. A. Gemeinhart, In vitro evaluation of 
macroporous hydrogels to facilitate stem cell infiltration, growth, and 
mineralization. Tissue engineering. Part A 15, 1695 (Jul, 2009). 
188. M. C. Ford et al., A macroporous hydrogel for the coculture of neural progenitor 
and endothelial cells to form functional vascular networks in vivo. Proceedings of 
the National Academy of Sciences of the United States of America 103, 2512 (Feb 
21, 2006). 
 122 
189. A. N. Stachowiak, A. Bershteyn, E. Tzatzalos, D. J. Irvine, Bioactive Hydrogels 
with an Ordered Cellular Structure Combine Interconnected Macroporosity and 
Robust Mechanical Properties. Advanced Materials 17, 399 (2005). 
190. A. P. McGuigan, B. Leung, M. V. Sefton, Fabrication of cell-containing gel 
modules to assemble modular tissue-engineered constructs [corrected]. Nat 
Protoc 1, 2963 (2007). 
191. B. M. Leung, M. V. Sefton, A Modular Approach to Cardiac Tissue Engineering. 
Tissue Eng Part A,  (Jun 29). 
192. B. M. Leung, M. V. Sefton, A modular tissue engineering construct containing 
smooth muscle cells and endothelial cells. Ann Biomed Eng 35, 2039 (Dec, 2007). 
193. J. Yeh et al., Micromolding of shape-controlled, harvestable cell-laden hydrogels. 
Biomaterials 27, 5391 (Nov, 2006). 
194. Z. Shi, N. Chen, Y. Du, A. Khademhosseini, M. Alber, Stochastic model of self-
assembly of cell-laden hydrogels. Phys Rev E Stat Nonlin Soft Matter Phys 80, 
061901 (Dec, 2009). 
195. Y. Du et al., Surface-directed assembly of cell-laden microgels. Biotechnology 
and bioengineering 105, 655 (Feb 15, 2010). 
196. B. Zamanian et al., Interface-directed self-assembly of cell-laden microgels. 
Small 6, 937 (Apr 23, 2010). 
197. Y. Du et al., Sequential assembly of cell-laden hydrogel constructs to engineer 
vascular-like microchannels. Biotechnology and bioengineering,  (Feb 17, 2011). 
198. D. L. Elbert, Bottom-up tissue engineering. Curr Opin Biotechnol 22, 674 (Oct, 
2011). 
199. M. D. Nichols, E. A. Scott, D. L. Elbert, Factors affecting size and swelling of 
poly(ethylene glycol) microspheres formed in aqueous sodium sulfate solutions 
without surfactants. Biomaterials 30, 5283 (Oct, 2009). 
200. E. A. Scott, M. D. Nichols, R. Kuntz-Willits, D. L. Elbert, Modular scaffolds 
assembled around living cells using poly(ethylene glycol) microspheres with 
macroporation via a non-cytotoxic porogen. Acta Biomater 6, 29 (Jan, 2010). 
201. M. D. Pierschbacher, E. Ruoslahti, Cell attachment activity of fibronectin can be 
duplicated by small synthetic fragments of the molecule. Nature 309, 30 (May 3-9, 
1984). 
202. J. L. Roam, H. Xu, P. K. Nguyen, D. L. Elbert, The formation of protein 
concentration gradients mediated by density differences of poly(ethylene glycol) 
microspheres. Biomaterials,  (Aug 16). 
203. E. Laboureau, J. C. Capiod, C. Dessaint, L. Prin, M. A. Vijayalakshmi, Study of 
human cord blood lymphocytes by immobilized metal ion affinity partitioning. J 
Chromatogr B Biomed Appl 680, 189 (May 17, 1996). 
204. P. Albertsson, Partitioning of Cell Particles and Macromolecules.  (Wiley, New 
York, ed. 3rd, 1986). 
205. J. M. Cabral, Cell partitioning in aqueous two-phase polymer systems. Adv 
Biochem Eng Biotechnol 106, 151 (2007). 
206. K. H. Nam et al., Continuous-flow fractionation of animal cells in microfluidic 
device using aqueous two-phase extraction. Biomed Microdevices 7, 189 (Sep, 
2005). 
 123 
207. H. Tavana et al., Nanolitre liquid patterning in aqueous environments for spatially 
defined reagent delivery to mammalian cells. Nature materials 8, 736 (Sep, 2009). 
208. O. Frannsen, W. E. Hennink, A novel preparation method for polymeric 
microparticles without the use of organic solvents. International Journal of 
Pharmaceutics 168, 1 (1998). 
209. R. J. Stenekes, O. Franssen, E. M. van Bommel, D. J. Crommelin, W. E. Hennink, 
The preparation of dextran microspheres in an all-aqueous system: effect of the 
formulation parameters on particle characteristics. Pharmaceutical research 15, 
557 (Apr, 1998). 
210. R. J. Stenekes, O. Franssen, E. M. van Bommel, D. J. Crommelin, W. E. Hennink, 
The use of aqueous PEG/dextran phase separation for the preparation of dextran 
microspheres. International journal of pharmaceutics 183, 29 (Jun 10, 1999). 
211. S. G. Levesque, R. M. Lim, M. S. Shoichet, Macroporous interconnected dextran 
scaffolds of controlled porosity for tissue-engineering applications. Biomaterials 
26, 7436 (Dec, 2005). 
212. S. G. Levesque, M. S. Shoichet, Synthesis of cell-adhesive dextran hydrogels and 
macroporous scaffolds. Biomaterials 27, 5277 (Oct, 2006). 
213. D. L. Elbert, J. A. Hubbell, Conjugate addition reactions combined with free-
radical cross-linking for the design of materials for tissue engineering. 
Biomacromolecules 2, 430 (Summer, 2001). 
214. B. K. Wacker, E. A. Scott, M. M. Kaneda, S. K. Alford, D. L. Elbert, Delivery of 
sphingosine 1-phosphate from poly(ethylene glycol) hydrogels. 
Biomacromolecules 7, 1335 (Apr, 2006). 
215. W. C. Claycomb et al., HL-1 cells: a cardiac muscle cell line that contracts and 
retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci 
U S A 95, 2979 (Mar 17, 1998). 
216. S. M. White, P. E. Constantin, W. C. Claycomb, Cardiac physiology at the 
cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle 
cell structure and function. Am J Physiol Heart Circ Physiol 286, H823 (Mar, 
2004). 
217. W. C. Claycomb, personal communication. 
218. D. L. Elbert, Liquid-liquid two-phase systems for the production of porous 
hydrogels and hydrogel microspheres for biomedical applications: A tutorial 
review. Acta Biomaterialia 7, 31 (2011). 
219. C. I. Berul et al., Electrophysiological abnormalities and arrhythmias in alpha 
MHC mutant familial hypertrophic cardiomyopathy mice. J Clin Invest 99, 570 
(Feb 15, 1997). 
220. O. Wichterle, D. Lim, Hydrophilic gels for biological use. Nature 185, 117 (1960). 
221. M. Barvic, K. Kliment, M. Zavadil, Biologic properties and possible uses of 
polymer-like sponges. Journal of biomedical materials research 1, 313 (Sep, 
1967). 
222. L. Sprincl, J. Kopecek, D. Lim, Effect of porosity of heterogeneous poly(glycol 
monomethacrylate) gels on the healing-in of test implants. Journal of biomedical 
materials research 5, 447 (Sep, 1971). 
 124 
223. D. Asnaghi, M. Giglio, A. Bossi, P. G. Righetti, Large-scale microsegregation in 
polyacrylamide gels (spinodal gels). The Journal of Chemical Physics 102, 9736 
(1995). 
224. P. D. Dalton, M. S. Shoichet, Creating porous tubes by centrifugal forces for soft 
tissue application. Biomaterials 22, 2661 (2001). 
225. S. G. Lévesque, R. M. Lim, M. S. Shoichet, Macroporous interconnected dextran 
scaffolds of controlled porosity for tissue-engineering applications. Biomaterials 
26, 7436 (2005). 
226. Y. Wang, G. A. Ameer, B. J. Sheppard, R. Langer, A tough biodegradable 
elastomer. Nature biotechnology 20, 602 (Jun, 2002). 
227. G. C. Engelmayr, Jr. et al., Accordion-like honeycombs for tissue engineering of 
cardiac anisotropy. Nature materials 7, 1003 (Dec, 2008). 
228. T. Eschenhagen et al., Three-dimensional reconstitution of embryonic 
cardiomyocytes in a collagen matrix: a new heart muscle model system. FASEB J 
11, 683 (Jul, 1997). 
229. W. H. Zimmermann et al., Tissue engineering of a differentiated cardiac muscle 
construct. Circ Res 90, 223 (Feb 8, 2002). 
230. C. Fink et al., Chronic stretch of engineered heart tissue induces hypertrophy and 
functional improvement. FASEB J 14, 669 (Apr, 2000). 
231. H. Naito et al., Optimizing engineered heart tissue for therapeutic applications as 
surrogate heart muscle. Circulation 114, I72 (Jul 4, 2006). 
232. Y. Yildirim et al., Development of a biological ventricular assist device: 
preliminary data from a small animal model. Circulation 116, I16 (Sep 11, 2007). 
233. D. L. Elbert, J. A. Hubbell, Self-assembly and steric stabilization at 
heterogeneous, biological surfaces using adsorbing block copolymers. Chem Biol 
5, 177 (Mar, 1998). 
234. S. Hsu, A. M. Jamieson, J. Blackwell, Viscoelastic studies of extracellular matrix 
interactions in a model native collagen gel system. Biorheology 31, 21 (Jan-Feb, 
1994). 
235. V. H. Barocas, A. G. Moon, R. T. Tranquillo, The fibroblast-populated collagen 
microsphere assay of cell traction force--Part 2: Measurement of the cell traction 
parameter. J Biomech Eng 117, 161 (May, 1995). 
236. D. Velegol, F. Lanni, Cell traction forces on soft biomaterials. I. Microrheology 
of type I collagen gels. Biophys J 81, 1786 (Sep, 2001). 
237. S. Battista et al., The effect of matrix composition of 3D constructs on embryonic 
stem cell differentiation. Biomaterials 26, 6194 (Nov, 2005). 
238. T. Wakatsuki, M. S. Kolodney, G. I. Zahalak, E. L. Elson, Cell Mechanics 
Studied by a Reconstituted Model Tissue. Biophysical Journal 79, 2353 (2000). 
239. R. Wondergem, B. M. Graves, T. R. Ozment-Skelton, C. Li, D. L. Williams, 
Lipopolysaccharides directly decrease Ca2+ oscillations and the 
hyperpolarization-activated nonselective cation current If in immortalized HL-1 
cardiomyocytes. American journal of physiology. Cell physiology 299, C665 (Sep, 
2010). 
240. S. Ravassa, A. Zudaire, R. D. Carr, J. Diez, Antiapoptotic effects of GLP-1 in 
murine HL-1 cardiomyocytes. American journal of physiology. Heart and 
circulatory physiology 300, H1361 (Apr, 2011). 
 125 
241. A. D. Andersen, K. A. Poulsen, I. H. Lambert, S. F. Pedersen, HL-1 mouse 
cardiomyocyte injury and death after simulated ischemia and reperfusion: roles of 
pH, Ca2+-independent phospholipase A2, and Na+/H+ exchange. American 
journal of physiology. Cell physiology 296, C1227 (May, 2009). 
242. S. Zhang et al., A self-assembly pathway to aligned monodomain gels. Nature 
materials 9, 594 (Jul, 2010). 
243. L. A. Hidalgo-Bastida et al., Cell adhesion and mechanical properties of a flexible 
scaffold for cardiac tissue engineering. Acta biomaterialia 3, 457 (Jul, 2007). 
244. J. D. Fromstein et al., Seeding bioreactor-produced embryonic stem cell-derived 
cardiomyocytes on different porous, degradable, polyurethane scaffolds reveals 
the effect of scaffold architecture on cell morphology. Tissue engineering. Part A 
14, 369 (Mar, 2008). 
245. L. Jongpaiboonkit et al., An adaptable hydrogel array format for 3-dimensional 
cell culture and analysis. Biomaterials 29, 3346 (Aug, 2008). 
246. L. Sartiani, P. Bochet, E. Cerbai, A. Mugelli, R. Fischmeister, Functional 
expression of the hyperpolarization-activated, non-selective cation current I(f) in 
immortalized HL-1 cardiomyocytes. J Physiol 545, 81 (Nov 15, 2002). 
247. M. Radisic et al., Functional assembly of engineered myocardium by electrical 
stimulation of cardiac myocytes cultured on scaffolds. Proceedings of the 
National Academy of Sciences of the United States of America 101, 18129 (Dec 
28, 2004). 
248. J. G. Jacot, A. D. McCulloch, J. H. Omens, Substrate stiffness affects the 
functional maturation of neonatal rat ventricular myocytes. Biophysical journal 95, 
3479 (Oct, 2008). 
249. S. L. Chen et al., Effect on left ventricular function of intracoronary 
transplantation of autologous bone marrow mesenchymal stem cell in patients 
with acute myocardial infarction. The American journal of cardiology 94, 92 (Jul 
1, 2004). 
250. J. M. Hare et al., A randomized, double-blind, placebo-controlled, dose-escalation 
study of intravenous adult human mesenchymal stem cells (prochymal) after acute 
myocardial infarction. Journal of the American College of Cardiology 54, 2277 
(Dec 8, 2009). 
251. T. E. Ludwig et al., Derivation of human embryonic stem cells in defined 
conditions. Nature biotechnology 24, 185 (Feb, 2006). 
252. J. M. Sperger et al., Gene expression patterns in human embryonic stem cells and 
human pluripotent germ cell tumors. Proceedings of the National Academy of 
Sciences of the United States of America 100, 13350 (Nov 11, 2003). 
253. R. P. Koche et al., Reprogramming factor expression initiates widespread targeted 
chromatin remodeling. Cell Stem Cell 8, 96 (Jan 7, 2011). 
254. S. Vukicevic et al., Identification of multiple active growth factors in basement 
membrane Matrigel suggests caution in interpretation of cellular activity related to 
extracellular matrix components. Exp Cell Res 202, 1 (Sep, 1992). 
255. M. Baker, Stem cells in culture: defining the substrate Nat Methods 8, 293 (2011). 
256. F. Grinnell, M. K. Feld, Adsorption characteristics of plasma fibronectin in 
relationship to biological activity. Journal of biomedical materials research 15, 
363 (May, 1981). 
 126 
257. N. T. Kohen, L. E. Little, K. E. Healy, Characterization of Matrigel interfaces 
during defined human embryonic stem cell culture. Biointerphases 4, 69 (Dec, 
2009). 
258. B. G. Keselowsky, D. M. Collard, A. J. Garcia, Surface chemistry modulates 
fibronectin conformation and directs integrin binding and specificity to control 
cell adhesion. J Biomed Mater Res A 66, 247 (Aug 1, 2003). 
259. B. G. Keselowsky, D. M. Collard, A. J. Garcia, Integrin binding specificity 
regulates biomaterial surface chemistry effects on cell differentiation. 
Proceedings of the National Academy of Sciences of the United States of America 
102, 5953 (Apr 26, 2005). 
260. L. Vroman, A. L. Adams, G. C. Fischer, P. C. Munoz, Interaction of high 
molecular weight kininogen, factor XII, and fibrinogen in plasma at interfaces. 
Blood 55, 156 (Jan, 1980). 
261. S. M. Cannizzaro et al., A novel biotinylated degradable polymer for cell-
interactive applications. Biotechnology and bioengineering 58, 529 (Jun 5, 1998). 
262. N. P. Huang, J. Vörös, S. M. De Paul, M. Textor, N. D. Spencer, Biotin-
Derivatized Poly(l-lysine)-g-poly(ethylene glycol):   A Novel Polymeric Interface 
for Bioaffinity Sensing. Langmuir 18, 220 (2002). 
263. B. W. Carey, S. Markoulaki, C. Beard, J. Hanna, R. Jaenisch, Single-gene 
transgenic mouse strains for reprogramming adult somatic cells. Nat Methods 7, 
56 (Jan, 2010). 
264. B. K. Wacker et al., Endothelial cell migration on RGD-peptide-containing PEG 
hydrogels in the presence of sphingosine 1-phosphate. Biophysical journal 94, 
273 (Jan 1, 2008). 
265. H. K. Kleinman et al., Basement membrane complexes with biological activity. 
Biochemistry 25, 312 (Jan 28, 1986). 
266. A. W. Smith et al., Long-term culture of HL-1 cardiomyocytes in modular 
poly(ethylene glycol) microsphere-based scaffolds crosslinked in the phase-
separated state. Acta biomaterialia 8, 31 (Jan, 2012). 
267. S. M. Willerth, T. E. Faxel, D. I. Gottlieb, S. E. Sakiyama-Elbert, The effects of 
soluble growth factors on embryonic stem cell differentiation inside of fibrin 
scaffolds. Stem Cells 25, 2235 (Sep, 2007). 
268. T. D. Schmittgen, K. J. Livak, Analyzing real-time PCR data by the comparative 
C(T) method. Nature protocols 3, 1101 (2008). 
269. A. Behfar et al., Stem cell differentiation requires a paracrine pathway in the heart. 
FASEB journal : official publication of the Federation of American Societies for 
Experimental Biology 16, 1558 (Oct, 2002). 
270. S. Kaichi et al., Cell line-dependent differentiation of induced pluripotent stem 
cells into cardiomyocytes in mice. Cardiovascular research 88, 314 (Nov 1, 
2010). 
271. Y. Ren et al., Small molecule Wnt inhibitors enhance the efficiency of BMP-4-
directed cardiac differentiation of human pluripotent stem cells. Journal of 
molecular and cellular cardiology 51, 280 (Sep, 2011). 
272. K. W. Au et al., Effects of iron oxide nanoparticles on cardiac differentiation of 
embryonic stem cells. Biochemical and biophysical research communications 379, 
898 (Feb 20, 2009). 
 127 
273. B. C. Heng et al., Translating human embryonic stem cells from 2-dimensional to 
3-dimensional cultures in a defined medium on laminin- and vitronectin-coated 
surfaces. Stem Cells Dev 21, 1701 (Jul 1, 2012). 
274. L. G. Villa-Diaz, A. M. Ross, J. Lahann, P. H. Krebsbach, Concise review: The 
evolution of human pluripotent stem cell culture: from feeder cells to synthetic 
coatings. Stem Cells 31, 1 (Jan, 2013). 
275. L. G. Villa-Diaz et al., Synthetic polymer coatings for long-term growth of human 
embryonic stem cells. Nature biotechnology 28, 581 (Jun, 2010). 
276. D. A. Brafman et al., Long-term human pluripotent stem cell self-renewal on 
synthetic polymer surfaces. Biomaterials 31, 9135 (Dec, 2010). 
277. R. Derda et al., Defined substrates for human embryonic stem cell growth 
identified from surface arrays. ACS chemical biology 2, 347 (May 22, 2007). 
278. Y. J. Li, E. H. Chung, R. T. Rodriguez, M. T. Firpo, K. E. Healy, Hydrogels as 
artificial matrices for human embryonic stem cell self-renewal. J Biomed Mater 
Res A 79, 1 (Oct, 2006). 
279. J. R. Klim, L. Li, P. J. Wrighton, M. S. Piekarczyk, L. L. Kiessling, A defined 
glycosaminoglycan-binding substratum for human pluripotent stem cells. Nat 
Methods 7, 989 (Dec, 2010). 
280. T. Miyazaki et al., Recombinant human laminin isoforms can support the 
undifferentiated growth of human embryonic stem cells. Biochemical and 
biophysical research communications 375, 27 (Oct 10, 2008). 
281. M. Nagaoka, K. Si-Tayeb, T. Akaike, S. A. Duncan, Culture of human pluripotent 
stem cells using completely defined conditions on a recombinant E-cadherin 
substratum. BMC developmental biology 10, 60 (2010). 
282. A. Domogatskaya, S. Rodin, A. Boutaud, K. Tryggvason, Laminin-511 but not -
332, -111, or -411 enables mouse embryonic stem cell self-renewal in vitro. Stem 
Cells 26, 2800 (Nov, 2008). 
283. K. Plath, W. E. Lowry, Progress in understanding reprogramming to the induced 
pluripotent state. Nature reviews. Genetics 12, 253 (Apr, 2011). 
284. J. Zhang et al., Extracellular matrix promotes highly efficient cardiac 
differentiation of human pluripotent stem cells: the matrix sandwich method. 
Circulation research 111, 1125 (Oct 12, 2012). 
285. C. L. Bauwens et al., Control of human embryonic stem cell colony and aggregate 
size heterogeneity influences differentiation trajectories. Stem Cells 26, 2300 (Sep, 
2008). 
286. C. Y. Sargent, G. Y. Berguig, T. C. McDevitt, Cardiomyogenic differentiation of 
embryoid bodies is promoted by rotary orbital suspension culture. Tissue 
engineering. Part A 15, 331 (Feb, 2009). 
287. T. C. McDevitt, M. A. Laflamme, C. E. Murry, Proliferation of cardiomyocytes 
derived from human embryonic stem cells is mediated via the IGF/PI 3-
kinase/Akt signaling pathway. Journal of molecular and cellular cardiology 39, 
865 (Dec, 2005). 
288. C. Robertson, D. D. Tran, S. C. George, Concise Review: Maturation Phases of 
Human Pluripotent Stem Cell-Derived Cardiomyocytes. Stem Cells,  (Jan 25, 
2013). 
 128 
289. A. Margariti et al., Direct reprogramming of fibroblasts into endothelial cells 
capable of angiogenesis and reendothelialization in tissue-engineered vessels. 
Proceedings of the National Academy of Sciences of the United States of America 
109, 13793 (Aug 21, 2012). 
290. T. Ma, M. Xie, T. Laurent, S. Ding, Progress in the reprogramming of somatic 
cells. Circulation research 112, 562 (Feb 1, 2013). 
291. J. X. Chen et al., Inefficient reprogramming of fibroblasts into cardiomyocytes 
using Gata4, Mef2c, and Tbx5. Circulation research 111, 50 (Jun 22, 2012). 
292. D. Srivastava, M. Ieda, Critical factors for cardiac reprogramming. Circulation 
research 111, 5 (Jun 22, 2012). 
293. A. J. Ridley, A. Hall, The small GTP-binding protein rho regulates the assembly 
of focal adhesions and actin stress fibers in response to growth factors. Cell 70, 
389 (Aug 7, 1992). 
294. M. D. Schaller et al., pp125FAK a structurally distinctive protein-tyrosine kinase 
associated with focal adhesions. Proceedings of the National Academy of Sciences 
of the United States of America 89, 5192 (Jun 1, 1992). 
295. D. D. Schlaepfer, S. K. Hanks, T. Hunter, P. van der Geer, Integrin-mediated 
signal transduction linked to Ras pathway by GRB2 binding to focal adhesion 
kinase. Nature 372, 786 (Dec 22-29, 1994). 
296. M. A. Wozniak, R. Desai, P. A. Solski, C. J. Der, P. J. Keely, ROCK-generated 
contractility regulates breast epithelial cell differentiation in response to the 
physical properties of a three-dimensional collagen matrix. The Journal of cell 
biology 163, 583 (Nov 10, 2003). 
297. G. F. Weber, M. A. Bjerke, D. W. DeSimone, Integrins and cadherins join forces 
to form adhesive networks. Journal of cell science 124, 1183 (Apr 15, 2011). 
298. C. S. Chen, M. Mrksich, S. Huang, G. M. Whitesides, D. E. Ingber, 
Micropatterned surfaces for control of cell shape, position, and function. 
Biotechnology progress 14, 356 (May-Jun, 1998). 
299. C. S. Chen, J. L. Alonso, E. Ostuni, G. M. Whitesides, D. E. Ingber, Cell shape 
provides global control of focal adhesion assembly. Biochemical and biophysical 
research communications 307, 355 (Jul 25, 2003). 
300. A. W. Smith et al., Direct reprograming of mouse fibroblasts to cardiomyocyte-
like cells using Yamanaka factors on engineered poly(ethylene glycol) (PEG) 
hydrogels. Accepted, Biomaterials: DOI  10.1016/j.biomaterials.2013.05.050,  
(2013). 
301. E. Bell, B. Ivarsson, C. Merrill, Production of a tissue-like structure by 
contraction of collagen lattices by human fibroblasts of different proliferative 
potential in vitro. Proceedings of the National Academy of Sciences of the United 
States of America 76, 1274 (Mar, 1979). 
302. B. Bhattacharya et al., Gene expression in human embryonic stem cell lines: 
unique molecular signature. Blood 103, 2956 (Apr 15, 2004). 
303. A. Woodfin, M. B. Voisin, S. Nourshargh, PECAM-1: a multi-functional 
molecule in inflammation and vascular biology. Arterioscler Thromb Vasc Biol 
27, 2514 (Dec, 2007). 
 129 
304. S. C. Smith, K. R. Reuhl, J. Craig, M. W. McBurney, The role of aggregation in 
embryonal carcinoma cell differentiation. Journal of cellular physiology 131, 74 
(Apr, 1987). 
305. S. Niebruegge et al., Generation of human embryonic stem cell-derived 
mesoderm and cardiac cells using size-specified aggregates in an oxygen-
controlled bioreactor. Biotechnology and bioengineering 102, 493 (Feb 1, 2009). 
306. Y. S. Hwang et al., Microwell-mediated control of embryoid body size regulates 
embryonic stem cell fate via differential expression of WNT5a and WNT11. 
Proceedings of the National Academy of Sciences of the United States of America 
106, 16978 (Oct 6, 2009). 
307. J. C. Mohr et al., The microwell control of embryoid body size in order to 
regulate cardiac differentiation of human embryonic stem cells. Biomaterials 31, 
1885 (Mar, 2010). 
308. F. Grinnell, C. R. Lamke, Reorganization of hydrated collagen lattices by human 
skin fibroblasts. Journal of cell science 66, 51 (Mar, 1984). 
309. B. Nusgens, C. Merrill, C. Lapiere, E. Bell, Collagen biosynthesis by cells in a 
tissue equivalent matrix in vitro. Coll Relat Res 4, 351 (Oct, 1984). 
310. M. Wernig et al., A drug-inducible transgenic system for direct reprogramming of 
multiple somatic cell types. Nature biotechnology 26, 916 (Aug, 2008). 
311. R. A. Scott, D. L. Elbert, R. K. Willits, Modular poly(ethylene glycol) scaffolds 
provide the ability to decouple the effects of stiffness and protein concentration on 
PC12 cells. Acta biomaterialia 7, 3841 (Nov, 2011). 
312. D. Dikovsky, H. Bianco-Peled, D. Seliktar, The effect of structural alterations of 
PEG-fibrinogen hydrogel scaffolds on 3-D cellular morphology and cellular 
migration. Biomaterials 27, 1496 (Mar, 2006). 
313. K. Shapira-Schweitzer, D. Seliktar, Matrix stiffness affects spontaneous 
contraction of cardiomyocytes cultured within a PEGylated fibrinogen biomaterial. 
Acta biomaterialia 3, 33 (Jan, 2007). 
314. C. L. Bauwens et al., Geometric control of cardiomyogenic induction in human 
pluripotent stem cells. Tissue engineering. Part A 17, 1901 (Aug, 2011). 
315. T. Sano, N. Takayama, T. Shimamoto, Directional difference of conduction 
velocity in the cardiac ventricular syncytium studied by microelectrodes. 
Circulation research 7, 262 (Mar, 1959). 
316. I. J. LeGrice et al., Laminar structure of the heart: ventricular myocyte 
arrangement and connective tissue architecture in the dog. Am J Physiol 269, 
H571 (Aug, 1995). 
317. H. Kaji, K. Takoh, M. Nishizawa, T. Matsue, Intracellular Ca2+ imaging for 
micropatterned cardiac myocytes. Biotechnology and bioengineering 81, 748 
(Mar 20, 2003). 
318. T. C. McDevitt et al., In vitro generation of differentiated cardiac myofibers on 
micropatterned laminin surfaces. Journal of biomedical materials research 60, 
472 (Jun 5, 2002). 
319. N. Bursac, K. K. Parker, S. Iravanian, L. Tung, Cardiomyocyte cultures with 
controlled macroscopic anisotropy: a model for functional electrophysiological 
studies of cardiac muscle. Circ Res 91, e45 (Dec 13, 2002). 
 130 
320. X. Zong et al., Electrospun fine-textured scaffolds for heart tissue constructs. 
Biomaterials 26, 5330 (Sep, 2005). 
321. N. Bursac, Y. Loo, K. Leong, L. Tung, Novel anisotropic engineered cardiac 
tissues: studies of electrical propagation. Biochemical and biophysical research 
communications 361, 847 (Oct 5, 2007). 
322. E. A. Gonnerman, D. O. Kelkhoff, L. M. McGregor, B. A. Harley, The promotion 
of HL-1 cardiomyocyte beating using anisotropic collagen-GAG scaffolds. 
Biomaterials 33, 8812 (Dec, 2012). 
323. S. Ravindran et al., Changes of chondrocyte expression profiles in human MSC 
aggregates in the presence of PEG microspheres and TGF-beta3. Biomaterials 32, 
8436 (Nov, 2011). 
324. R. L. Carpenedo et al., Homogeneous and organized differentiation within 
embryoid bodies induced by microsphere-mediated delivery of small molecules. 
Biomaterials 30, 2507 (May, 2009). 
325. J. Blummel et al., Protein repellent properties of covalently attached PEG 
coatings on nanostructured SiO(2)-based interfaces. Biomaterials 28, 4739 (Nov, 
2007). 
326. M. Mrksich, L. E. Dike, J. Tien, D. E. Ingber, G. M. Whitesides, Using 
microcontact printing to pattern the attachment of mammalian cells to self-
assembled monolayers of alkanethiolates on transparent films of gold and silver. 
Exp Cell Res 235, 305 (Sep 15, 1997). 
327. P. A. Sotiropoulou, S. A. Perez, M. Salagianni, C. N. Baxevanis, M. Papamichail, 
Characterization of the optimal culture conditions for clinical scale production of 
human mesenchymal stem cells. Stem Cells 24, 462 (Feb, 2006). 
328. K. Schallmoser et al., Rapid large-scale expansion of functional mesenchymal 
stem cells from unmanipulated bone marrow without animal serum. Tissue Eng 
Part C Methods 14, 185 (Sep, 2008). 
 
 
